STOCK CODE：4157

TaiGen Biopharmaceuticals Holdings Limited

2025 Annual Report

The content of this annual report and the relevant information of the company can be found at the following website：

Taiwan Stock Exchange Market Observation Post System：
http://mops.twse.com.tw/

TaiGen Website：http://www.taigenbiotech.com/

Printed on March 31, 2026

Notice to readers

This English-version annual report is a summary translation of the Chinese version and is not an official document of the shareholders' meeting. If there is any discrepancy between the English and Chinese versions, the Chinese version shall prevail.

I.Spokesperson and Acting Spokesperson：

	Spokesperson	Acting Spokesperson
Name	Kuo-Lung Huang	Richard Lu
Title	Chairman	Financial vice president
Contact Number	+886-2-81777020	+886-2-81777020
Email	ir@taigenbiotech.com	ir@taigenbiotech.com

II.Headquarters, branches, factories：

(I) Headquarters

Name：TaiGen Biopharmaceuticals Holdings Limited

Address：PO Box 309, Ugland House, Grand Cayman, KY1-1104,Cayman Islands

Main operation address：7th Floor, No. 138, Xinming Road, Neihu District, Taipei City, Taiwan, ROC

Tel：+886-2-81777020

(II)Subsidiary

Name：TaiGen Biotechnology Co., Ltd.

Address：7th Floor, No. 138, Xinming Road, Neihu District, Taipei City, Taiwan, ROC

Tel：+886-2-81777020

Name：TAIGEN BIOMEDICAL FOOD CORPORATION

Address：4F., No. 51, Sec. 2, Chongqing S. Rd., Zhongzheng Dist., Taipei City, Taiwan, ROC

Tel：+886-2-81777020

Name：TaiGen Biotechnology Holdings Limited

Address：PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands

Tel：+886-2-81777020

Name：TaiGen Biopharmaceuticals Co. (Beijing), Ltd.

Address：Room 2502, Building A, Fenglian Plaza, No. 18, Chaoyangmenwai Street, Chaoyang District, Beijing, People's Republic of China

Tel：+86-10-65885166

III.Stock transfer agent：

Name：SinoPac Securities - Share Registration Services Department

Address：3rd Floor, No. 17, Boai Road, Taipei City

Website：https://www.sinotrade.com.tw/

Tel：+886-2-2381-6288

IV.CPA who attested the most recent year’s financial statements：

Name：Hsieh-Chang Li、Hui-Min Huang

Office：Deloitte & Touche

Address：20th Floor, No. 100, Songren Road, Xinyi District, Taipei City

Website：http://www.deloitte.com.tw/

Tel：+886-2-2725-9988

V.Stock exchange(s) on which the stock is traded overseas and ways to obtain relevant information：N/A

VI.Website：http://www.taigenbiotech.com/

VII.(I) List of Board Directors：

Title	Name	Nattionality	Education and work experience
Chairman	Kao Hsiang Investment Co., Ltd Representative： Kuo-Lung Huang	R.O.C	• University of South Australia EMBA • The Taiwan branch of Merck & Co., Inc. • The Taiwan branch of Sandoz • Haio International Co., Ltd • Takeda Pharmaceutical Company Limited • Senior vice president for TaiGen Biopharmaceuticals Holdings Limited and TaiGen Biopharmaceutical Co.(Beijing) Ltd • CMO of Asia Area of TaiGen Biopharmaceuticals Holdings Limited
Director	YFY Investment Holding Co.,Ltd. Representative： Weng-Foung Huang	R.O.C.	• Ph.D., Social and Administrative Pharmacy, University of Minnesota • Associate Professor, Director and Professor, Institute of health and Welfare policy, National Yang-Ming University • Deputy Director, Director of Food and Drug Administration, MOHW • Director General of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan • Chairman of Instruction Drug Review and Advisory Committee • Chairman of Pharmaceutical Society of Taiwan • Associate Professor, Professor, Institute of Health Policy and Management, National Taiwan University
Director	Kao Hsiang Investment Co., Ltd Representative： Hong-Jen Chang	R.O.C.	• M.S.,Health Policy and Management,Harvard School of Public Health • Deputy Minister, Department of Health • President and CEO, Bureau of National Health Insurance • Director General, Center for Disease Control
Director	Kao Hsiang Investment Co., Ltd Representative： Peter Wu	R.O.C.	• CEO of Jia Chen International Pharmaceuticals Group • Chairman of the Board Directors of Twi Biotechnology Inc. • CEO of AmCad BioMed Co. • CEO of HOLLING BIO-PHARMA. CORP. • Dirctor and CEO of MSD China • Chairman of the Board Directors and CEO of SCHERING-PLOUGH Ltd. • President for PHARMACIA China/Taiwan • President for Pharmacia＆Upjoh Taiwan • Indepent director of iXensor Co., Ltd. • Consultant of Biogen Inc. US
Director	National Development Fund, Executive Yuan Representative： Hsun-Yuan Tsou	R.O.C.	• Deputy Director-General, Department of Regulatory Assessment, National Development Council • Chief of Department of Community Medicine of Kaohsiung Medical University • Director, Sing Da Marine Structure Corporation
Director	Taiwan Sugar Corporation Representative： I-Jen Huang	R.O.C.	• Ph.D., Department of Biology, Utah State University, USA • Director of Taiwan Sugar Corporation Research Institute • Convener of Taiwan Sugar Corporation Enzyme Company Preparatory Group • Deputy CEO of Taiwan Sugar Corporation Biotechnology Business Division • Department head of Applied Bioscience of Taiwan Sugar Corporation Research Institute
Independent Director	Mei-Li Su	R.O.C.	• Bachelor of Accounting, Tamkang University • Senior Manager, Deloitte & Touche Taiwan • Member of the Taxation Committee, Certified Public Accountants Association (R.O.C)
Independent Director	Eric, Yi-Chun Huang	R.O.C.	• Ph.D., Molecular and Medical Parasitology, New York University • General Manager and Chief Scientific Officer (CSO), Moderna Cenomics • Deputy Director, Director of Food and Drug Administration, MOHW • Director, Business Development of Seaside Therapeutics • Associate Director, Business Development of Stromedix • Manager, Business Development of Domantis
Independent Director	Chen-Wu, Chang	R.O.C.	• Independent Director, ANNJI PHARMACEUTICAL CO., LTD. • Independent Director, TAIRX, Inc. • Director, ANBOGEN THERAPEUTICS, INC. • Director, WELLGEN MEDICAL CO., LTD • Remuneration Committee Member, OBIGEN PHARMA, INC.

(II) R.O.C. domestic designated agent：

Name：Kuo-Lung Huang　　Title：Chairman
Tel：+886-2-81777020　　E-mail：ir@taigenbiotech.com

TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED

CONTENTS

Chapter 1、Letter to Shareholders

The Company's operating performance in 2025 was primarily driven by the continued commercialization progress of TG-1000, an anti-influenza therapeutic. Following the successful completion of Phase III clinical trials in Mainland China and achievement of the primary efficacy endpoints, TG-1000 obtained marketing authorization for use in adults and adolescents aged 12 years and above on December 11, 2025. The product has been commercialized under the brand name Yilikan®. In addition, in the fourth quarter, TG-1000 was successfully licensed to a multinational pharmaceutical company in India, which will be responsible for further development and regulatory filings for marketing authorization in the local market.

Meanwhile, the Company's internally developed DPP1 inhibitor TG-4318 for the treatment of bronchiectasis completed the preclinical candidate (PCC) development stage and was successfully out-licensed for the Greater China region to YR Pharma (Health Biotech). In addition, the Company's novel antibiotic, Nemonoxacin, entered into a new licensing partnership in Vietnam, further strengthening its presence in the Southeast Asian market. Together with its broader adoption in medical institutions in Taiwan, Nemonoxacin continued to generate steady and growing revenue contributions.

The following is a report to shareholders on the Company's overall operating performance for the year 2025:

I、2025 Business Performance

(I) Implementation of Business Plans

The Company's consolidated revenue for 2025 increased compared to 2024, primarily due to higher recognition of milestone payments from the licensing agreement with HEC Pharm Co., Ltd. The scope of the license covers the development, manufacturing, and sales of the antiviral drug Pixavir marboxil (TG-1000) in Mainland China, Hong Kong, and the Macau Special Administrative Region. The increase in revenue was also attributable to licensing income recognized in 2025 from a multinational pharmaceutical company in India, with respect to the development, manufacturing, regulatory filing, and sales of Pixavir marboxil (TG-1000) in the Indian market.

For the year ended 2025, the Company's consolidated revenue amounted to NT$259,474 thousand, with consolidated net profit after tax of NT$45,178 thousand, and earnings per share of NT$0.06. Research and development expenses amounted to NT$96,884 thousand, representing 56% of total operating expenses of NT$171,905 thousand. Non-operating items mainly included a net foreign exchange loss of NT$33,402 thousand and interest income of NT$18,468 thousand..

(II)Financial Performance and profitability analysis

Apart from ongoing investments in R&D, TaiGen actively seeks commercialization opportunities for its pipeline products. The development of new drugs does not always require the approval of drug certificates to realize its commercial value. Each stage of the R&D process has inherent commercial value, and introducing strategic partners to co-develop at various stages can often result in greater benefits.

The following is the financial performance and profitability analysis details：

Unit：NTD thousand；%

Item		2024	2025
Financial balance	Operating Revenue	150,651	259,474
	Operating Expenses	256,617	171,905
	Non-Operating Income and Expenses	89,213	(11,954)
	Comprehensive Income	(69,053)	61,456
Profitability analysis	Return on Assets	(3.21%)	3.86%
	Return on Equity	(3.51%)	4.19%
	Net Profit Margin	(25.61%)	17.41%
	Earnings Per Share	(0.05)	0.06

(III) Research & Development and Operational Status

Key achievements and drug development progress in 2025 include：

1. The new anti-bacterial drug, Taigexyn®(Nemonoxacin), Taiwan
   (1) As of December 2025, 125 hospitals (23 medical centers &102 non-medical centers) and 13 pharmacies/clinics have purchased Taigexyn Capsule.
   (2) As of December 2025, 72hospitals (20 medical centers & 52 non-medical centers) have purchased Taigexyn Infusion Solution.
   (3) The sales revenue for Taigexyn® (capsules and infusion) in 2025 grew by 2.3%, showing strong growth momentum.
2. In October 2025, the Company entered into licensing agreements with Fideschem Inc. and Newsun Pharmaceutical JSC. in Vietnam, further expanding its pharmaceutical market presence in Southeast Asia.
3. The new anti-influenza virus drug（Pixavir marboxil/TG-1000）
   (1)) In December 2025, Pixavir marboxil successfully obtained marketing authorization for a new drug in Mainland China under the brand name Yilikan®. Subsequently, the Company recognized milestone payments upon the successful achievement of this regulatory approval..
   (2) In March 2025, the Company submitted an IND application for the pediatric granule formulation of Pixavir marboxil to the National Medical Products Administration (NMPA) in Mainland China. The application was approved in June 2025, and a Phase III clinical trial for pediatric patients (under 12 years of age) was initiated in Mainland China in October 2025.
   (3) In 2025, the Company submitted a pre-NDA review application (non-formal review) for Pixavir marboxil to the Center for Drug Evaluation (CDE) in Taiwan, with the aim of making this domestically developed antiviral influenza drug available to patients in Taiwan..
   (4) Patent portfolio: The Company has completed the global patent strategy for Pixavir marboxil / TG-1000, covering composition-of-matter, process, and formulation patents. Among these, the composition-of-matter patent has been granted in 24 countries, including Mainland China, Taiwan, and the United States, with protection extending through 2039. In addition, 12 process and formulation patents have been granted. Based on the Company's patent strategy, the overall patent protection for Pixavir marboxil / TG-1000 may be extended up to 2043.

4. NCFBE New Drug（TG-4318）

   TG-4318 is an internally developed novel small-molecule inhibitor targeting dipeptidyl

peptidase 1 (DPP1). Its intended indication is non-cystic fibrosis bronchiectasis (NCFBE). Preclinical studies have demonstrated that TG-4318 exhibits excellent biochemical activity and high selectivity, showing potential to become a best-in-class therapy within its class.

(1) Development stage: TG-4318 is currently in the pre-clinical candidate (PCC) evaluation stage. In December 2025, the Company out-licensed the development and commercialization rights of TG-4318 in Mainland China, Hong Kong, and Macau to HEC Pharm Co., Ltd., which will be responsible for subsequent preclinical development and further advancement of the program..

(2) Patent portfolio: In September 2025, the Company filed a U.S. provisional patent application for Taigen. The Company plans to complete Patent Cooperation Treaty (PCT), Mainland China (CN), and Taiwan (TW) filings by September 2026 to further strengthen its global patent portfolio.

5.CKD Novel Anemia Drug（ISM4808）

Anemia associated with chronic kidney disease (CKD) is caused by insufficient secretion of erythropoietin (EPO) from the kidneys, leading to reduced red blood cell production. It represents a significant global medical need that remains inadequately addressed. Current treatment options are mainly symptomatic, and there is still a lack of more effective and safe long-term therapeutic solutions.

ISM4808 is a potential best-in-class prolyl hydroxylase domain (PHD) inhibitor. It acts by activating the hypoxia-inducible factor alpha (HIF-α) signaling pathway, thereby increasing erythropoietin (EPO) production and improving iron utilization to promote erythropoiesis, and consequently providing a therapeutic approach for anemia associated with chronic kidney disease (CKD)

(1) Licensing and rights: In December 2025, the Company entered into licensing agreements with Insilico Medicine Ltd. (Shanghai) and INSILICO MEDICINE IP LIMITED, obtaining exclusive rights for the development, commercialization, and sublicensing of ISM4808 in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan.

(2) Clinical development plan: The Company has selected Xiangya Hospital, Central South University, as the Phase I clinical trial site. Upon obtaining Institutional Review Board (IRB) approval in January 2026, subject enrollment for the Phase I clinical trial is expected to commence immediately.

II、Business plan for 2026

The main operating policies and strategies of the company in 2026 include:

(I) The Company will accelerate the in-licensing of external drug candidates, advancing them directly into IND-enabling studies and clinical development. This strategy aims to fully leverage the Company’s core drug discovery and development capabilities, enabling candidate compounds to realize their commercial potential in a timely manner. In addition, through the introduction of external assets, the Company seeks to expand into new therapeutic areas and further enhance the breadth and capabilities of its drug development portfolio.

(II) In 2025, the Company in-licensed ISM-4808, a hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor for the treatment of anemia associated with chronic kidney disease. A Phase I clinical trial in Mainland China is planned for 2026, and the development program is currently progressing in line with schedul.

(III) With respect to the anti-influenza antiviral drug Pixavir marboxil (TG-1000), the Company obtained marketing authorization for adults and adolescents aged 12 years and above in Mainland China in 2025. In 2026, the clinical development of the pediatric formulation

continues to progress actively. Upon approval, the product is expected to cover a broader age population.

(IV) Pixavir marboxil (TG-1000) has been demonstrated in clinical trials to effectively shorten the duration of influenza symptom relief, with a single-dose regimen covering the full treatment course. It is effective against both influenza A and B viruses. In addition to having obtained marketing authorization in Mainland China, the Company is actively engaging a potential partner in Taiwan and preparing for the submission of a marketing authorization application, with the aim of making this domestically developed antiviral influenza therapy available to patients in Taiwan. Furthermore, the Company is actively expanding its global presence and is in ongoing licensing discussions in major markets, including Europe, the United States, Japan, and South Korea.

(V) Based on the Company's proprietary R&D technology platform, the development scope has been expanded to include dietary supplements and health foods, with the aim of developing products that truly support human health. The Company has developed health food products such as Taigan Cheng (for liver protection and lipid reduction) and Taijie Tang (for blood glucose control), thereby enhancing the Company's operating momentum.

III、Future company development strategy

(I) Build on core R&D capabilities, integrate external products, and seek commercialization opportunities at various development stages with partners.

(II) Leverage Taiwan's R&D and business development capabilities, using the Mainland China platform to expand operations in Greater China and globally.

(III) Leveraging its extensive experience in new drug research and development, the Company has expanded its product development scope into dietary supplements and health foods, further strengthening and deepening its operational foundation.

IV、Affected by the external competitive environment, regulatory environment and overall business environment

(I) Following the second inauguration of the U.S. Trump administration in January 2025, reciprocal tariffs have been imposed on countries worldwide, with varying tariff rates applied to exports to the United States depending on the outcomes of bilateral negotiations. Combined with ongoing geopolitical tensions, these developments have significantly reshaped the globalization trend that has prevailed since 2000. At the same time, major breakthroughs in artificial intelligence (AI) have introduced rapid and profound changes to the global economic and business environment, resulting in heightened uncertainty for enterprises worldwide, which in turn necessitates the formulation of respective strategic responses..

(II) Following the three-year COVID-19 pandemic, many regions worldwide have experienced a resurgence of other viral infections. Influenza outbreaks re-emerged in 2024 and 2025 across Taiwan, Japan, South Korea, the United States, and Mainland China, underscoring that influenza continues to pose a significant public health burden comparable to that of the pandemic. This also highlights that the demand for anti-infective therapeutics has not diminished with the easing of COVID-19. Building on its foundation in anti-infective drug development, the Company will continue to strengthen and expand its presence in this therapeutic area.

In light of the above, the Company will continue to uphold its core drug discovery and development technology platform while accelerating the in-licensing of external drug candidates. At the same time, the Company is actively pursuing a broader range of collaboration models and no longer limits its strategy to in-house development through to commercialization, with the aim

of achieving the most favorable outcomes for the Company. The Company also sincerely hopes for the continued support of its shareholders. Finally, we would like to express our appreciation for shareholders' attendance at this Annual General Meeting and wish everyone good health and success.

TaiGen Biopharmaceuticals Holdings Limited

Chairman：Kuo-Lung Huang

Chapter 2、Company Introduction

I、Company and Group Profile

(I) Date of Establishment：September 15, 2005

(II) Group Profile：

TaiGen Biopharmaceuticals Holdings Limited (hereinafter referred to as "the company" or "TaiGen Holdings") was established on September 15, 2005 in British Cayman Islands, the group is primarily engaged in new drug research and development, dedicated to the development of New Chemical Entities(NCE) related to infectious diseases, cancer and diabetes complications.

The companies in which our company holds direct or indirect equity stake include TaiGen Biotechnology Co., Ltd.（hereinafter referred to as" TaiGen Taiwan"）、TaiGen Biotechnology Holdings Limited（ hereinafter referred to as" TaiGen Cayman" ） and TaiGen Biopharmaceuticals Co.(Beijing),Ltd.（hereinafter referred to as" TaiGen Beijing"）.

(III) Group Structure：



(IV) Risk Factors: Please refer to Chapter 6: Review of Financial Conditions, Operating Results, and Risk Management.

Chapter 3、Corporate Governance Report

I、Profiles of Directors, Supervisors and Management Teams

(I) Directors

1. Profiles of Directors

March 25, 2026；Unit：thousand share；%

Title	Nationality/ Place of Incorporation	Name	Gender	Date Elected	Term	Date First Elected	Shareholding when Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Experience（Education）	Other Position	Executives, Directors or Supervisors Who are Spouses or within Two Degrees of Kinship			Remark
							Shares	%	Shares	%	Shares	%	Shares	%			Title	Name	Relation	
Chairman	R.O.C	Kao Hsiang Investment Co., Ltd	-	2025.5.23	III	2019.6.12	65	0.01	65	0.01	0	0	0	0	◆ University of South Australia EMBA ◆ The Taiwan branch of Merck & Co., Inc. ◆ The Taiwan branch of Sandoz ◆ Haio International Co., Ltd ◆ Takeda Pharmaceutical Company Limited ◆ Senior vice president for TaiGen Biopharmaceuticals Holdings Limited and TaiGen Biopharmaceutical Co.(Beijing) Ltd ◆ CMO of Asia Area of TaiGen Biopharmaceuticals Holdings Limited	◆ Chairman & President & CEO, TaiGen Holdings ◆ Chairman, TaiGen Taiwan ◆ Chairman, TaiGen Cayman ◆ Chairman, TaiGen Beijing ◆ Chairman, TaiGen Biomedical	-	-	-	-
	R.O.C	Representative：Kuo-Lung Huang	Male 61~70 years				1,061	0.15	1,061	0.15	0	0	0	0			-	-	-	-

Director	R.O.C	YFY Inc.	-	2025.5.23	III	2020.6.28	97,503	13.58	97,503	13.70	-	-	0	0	• Ph.D., Social and Administrative Pharmacy, University of Minnesota • Associate Professor, Director and Professor, Institute of health and Welfare policy, National Yang-Ming University • Deputy Director, Director of Food and Drug Administration, MOHW • Director General of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan • Chairman of Instruction Drug Review and Advisory Committee • Chairman of Pharmaceutical Society of Taiwan • Associate Professor, Professor, Institute of Health Policy and Management, National Taiwan University	• Adjunct Professor, Institute of health and Welfare policy, National Yang-Ming University • Director, Development Center for Biotechnology • Independent Director, Eusol Biotech Co., Ltd. • Independent Director, Amcad Biomed Corporation • Director, Orient Pharma Co., Ltd. • Director, Panion & Bf Biotech Inc. • Director, Bowlin Holding Co., Ltd. Seychelles • Director, Bowlin Holding Co., Ltd. Cayman • Director, Cheng Fong Chemical Co., Ltd. • Director, Formosa Pharmaceuticals Inc. • Senior Consultant of YFY Biotech Management Co., Ltd. • Invest Consultant of Formosa Laboratories, Inc. • Member of the Investor Advisory Committee, Hercules Bioventure II, L.P. • Director, Caravel Oculus INC.	-	-	-	-
	R.O.C	Weng-Foung Huang	Male 71~80 years				0	0	0	0	0	0	0	0			-	-	-	-
Director	R.O.C	National Development Fund, Executive Yuan	-	2025.5.23	III	2007.12.31	103,007	14.35	103,007	14.47	-	-	0	0	• MPA, Department of Public Administration, National Chengchi University • Secretary of the Executive Yuan Premier's Office • Director, the Office of the Secretary-General, Executive Yuan • Director, the Office of the Chairperson, National Development Council • Deputy Director, Department of Evaluation and Control, National Development Council	• Deputy Director, Office of Disaster Management, Executive Yuan • Director of TaiGen Biotechnology Co., Ltd.	-	-	-	-
	R.O.C	Representative：Hsun-Yuan Tsou	Male 51~60 years				0	0	0	0	0	0	0	0			-	-	-	-
Director	R.O.C	Kao Hsiang Investment Co., Ltd		2025.5.23	III	2016.6.17	65	0.01	65	0.01	-	-	0	0	• Bachelor, Department of Pharmacy, Chia Nan University of Pharmacy • CEO of Jia Chen International Pharmaceuticals Group	• Director of TaiGen Biotechnology Co., Ltd. • Independent Director of Pharmosa Biopharma Inc.	-	-	-	-

	R.O.C	Peter Wu	Male 61~0 years				0	0	0	0	0	0	0	0	♦ Chairman of the Board Directors of Twi Biotechnology Inc. ♦ CEO of AmCad BioMed Co. ♦ CEO of HOLLING BIO-PHARMA. CORP. ♦ Dirctor and CEO of MSD China ♦ Chairman of the Board Directors and CEO of SCHERING-PLOUGH Ltd. ♦ President for PHARMACIA China/Taiwan ♦ President for Pharmacia & Upjoh Taiwan ♦ Independent Director of iXensor Co. Ltd. ♦ Consultant of Biogen Inc. US	♦ Comissioner of the investment review committee of Taiwania Capital ♦ Honorary Chairman of Taiwan Pharmaceutical Marketing and Management Association	-	-	-	-
Director	R.O.C	Kao Hsiang Investment Co., Ltd	-	2025.5.23	III	2016.6.17	65	0.01	65	0.01	-	-	0	0	♦ M.S.,Health Policy and Management,Harvard School of Public Health ♦ Deputy Minister, Department of Health ♦ President and CEO, Bureau of National Health Insurance ♦ Director General, Center for Disease Control	♦ Director , TaiGen Biotechnology Co., Ltd. ♦ Director, Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA) ♦ Adjunct Professor, Institute of Public health, National Yang-Ming Chiao-Tung University ♦ Chairman and CEO, YFY Biotech Management Co., Ltd. ♦ Chairma, Eusol Biotech Co., LTD. ♦ Chairman, Micareo Taiwan Co., Ltd ♦ Chairman, Micareo, Inc ♦ Director, Taiwania Capital Biotechnology Corporation ♦ Chairman, A2+ Bioteh Consulting Co., Ltd. ♦ Independent Director, Maywufa Company Ltd. ♦ Director, TCCD Angels Investment Co., Ltd. ♦ Director, Universal Vision Biotechnology Co., Ltd. ♦ Director, Shih-Hung Consulting Co., Ltd. ♦ Director, Shih-Hung Biotechnology Co., Ltd.	-	-	-	-
	R.O.C	Representative：Hong-Jen Chang	Male 61~70 years				0	0	0	0	0	0	0	0			-	-	-	-

Director	R.O.C	Taiwan Sugar Corporation	-	2025.5.23	III	2009.3.3	43,883	6.11	37,669	5.00	0	0	0	0	♦ Ph.D., Department of Biology, Utah State University, USA ♦ Director of Taiwan Sugar Corporation Research Institute ♦ Convener of Taiwan Sugar Corporation Enzyme Company Preparatory Group ♦ Deputy CEO of Taiwan Sugar Corporation Biotechnology Business Division ♦ Department head of Applied Bioscience of Taiwan Sugar Corporation Research Institute.	♦ Director , TaiGen Biotechnology Co., Ltd. ♦ Director, Taiwan Sugar Corporation Research Institute ♦ Director, TEC BioWorks Co., Ltd.	-	-	-	-
	R.O.C	Representative：I-Jen Huang	Male 61~70 years				0	0	0	0	0	0	0	0			-	-	-	-
Independent Director	R.O.C	Mei-Li Su	Female 51-60 years	2025.5.23	III	2025.5.23	0	0	0	0	0	0	0	0	♦ Bachelor of Science in Accounting, Department of Accounting, Tamkang University ♦ Senior Manager, Deloitte & Touche Taiwan ♦ Member of the Taxation Committee, Certified Public Accountants Association (R.O.C)	♦ Partner, C&S Certified Public Accountant Firm ♦ Independent director, Alar Pharmaceuticals Inc. ♦ Independent director, Yuen Foong Yu Consumer Prosucts Co., Ltd. ♦ Independent director, Youngqin International Co., Ltd.	-	-	-	-
Independent Director	P.R.C	Eric, Yi-Chun Huang	Male 51~60 years	2025.5.23	III	2025.5.23	0	0	0	0	0	0	0	0	♦ PhD., Molecular and Medical Parasitology, New York University ♦ General Manager and Chief Scientific Officer (CSO), Moderna Cenomics	♦ Partner, Delos Capital ♦ Director, TRex Bio, Inc. ♦ Board observer, Averna Therapeutics, Inc.	-	-	-	-
Independent Director	R.O.C	Chang, Chen-Wu	Male 61~70 years	2025.9.15	III	2025.5.23	0	0	0	0	0	0	0	0	♦ MBA, Graduate School of Business Finance, The University of Chicago. ♦ Ferring Pharmaceutical Senior Vice President ♦ Novartis General Manager,Taiwan and Head, Asia Cluster ♦ Johnson & Johnson Managing Director, Taiwan	♦ Independent Director, ANNJI PHARMACEUTICAL CO., LTD. ♦ Independent Director, TAIRX, Inc. ♦ Director, WELLGEN MEDICAL CO., LTD ♦ Remuneration Committee Member, OBIGEN PHARMA, INC.	-	-	-	-

2. Major shareholders of corporate shareholders

December 31, 2025

Name of corporate shareholders	Major shareholders of corporate shareholders	Shareholding ratio
National Development Fund, Executive Yuan	「According to Article 29 of the Statute for Industrial Innovation, the Executive Yuan has established the National Development Fund and set up a management committee to handle matters related to the fund's income, expenditure, custody, and utilization. The management committee consists of 11 to 13 members appointed by the Executive Yuan, and is currently convened by LIN, TSU-CHIA, the Chairperson of the National Development Council」	—
YFY Inc.	He-Tse-Yi Enterprise Co., Ltd.	9.92%
	Hsin-Yi Foundation	5.66%
	Hsin-Yi Enterprise Co., Ltd.	4.69%
	Hsinex International Corp.	4.52%
	HO,CHENG-TING	2.92%
	The Labor Retirement Reserve Supervisory Committee of YFY Inc.	2.79%
	Chen-Yu Co., Ltd.	2.76%
	Lui Co., Ltd.	2.69%
	HO,MEI-YU	2.65%
	HO,I-TA	2.14%
Taiwan Sugar Corporation	Ministry of Economic Affairs	86.15%
	Northern Region Branch, National Administration,MOF	9.92%
	First Commercial Bank, Ltd.	0.75%
	Chang Hwa Commercial Bank, Ltd.	0.41%
	Bank of Taiwan	0.36%
	Taiwan Business Bank, Ltd.	0.30%
	Hua Nan Commercial Bank, Ltd.	0.14%
	Central Investment Co., Ltd.	0.14%
	Mega Internaitonal Commercial Bank, Ltd.	0.13%
	Land Bank of Taiwan	0.08%
	Taiwan Cooperative Bank	0.08%
Kao Hsiang Investment Co., Ltd	YANG,LIEN-TSAI	33.33%
	HUANG,CHIA-YING	33.33%
	CHAN,SHUN-HSIANG	33.33%

3. The major shareholder in the above table is a legal person

December 31, 2025

Name of corporate shareholders	Major shareholders of corporate shareholders	Shareholding ratio
He-Tse-Yi Enterprise Co., Ltd.	He-Tse-Chia Investment Co., Lts.	100.00%
Hsin-Yi Enterprise Co., Ltd.	Show-Chung Ho	27.84%
	Jucheng Investment Co., Ltd.	12.50%
	BRILLIANT PRIDE LIMITED	12.50%
	Gundam Global Limited	12.50%
	HO,MEI-YU	12.50%
	Crown Honor Investment Co., Ltd.	5.91%
	Yu Hai Investment Corp.	2.48%
	HO,HSING-HUI	2.18%
	Jinjie Investment Co., Ltd.	1.52%
	Hoss Educational Foundation	1.48%
	Hoss Cultural Foundation	1.48%
First Commercial Bank, Ltd.	First Financial Holding Company	100.00%
Chang Hwa Commercial Bank, Ltd.	Ministry of Finance	12.19%
	Chunghwa Post Co., Ltd.	7.50%
	Naional Development Fund, Executive Yuan	5.42%
	First Commercial Bank, Ltd.	4.09%
	TS Financial Holding Co., Ltd.	2.68%
	EXCEL CHEMICAL CORPORATION	2.53%
	Taiwan Cooperative Bank	2.39%
	Bank of Taiwan	1.81%
	Land Bank of Taiwan	1.80%
	Hua Nan Commercial Bank, Ltd.	1.79%
Bank of Taiwan	Taiwan Financial Holdings Company	100.00%
Taiwan Business Bank, Ltd.	Bank of Taiwan	16.21%
	Naional Development Fund, Executive Yuan	5.87%
	Land Bank of Taiwan	2.29%
	Ministry of Finance	2.08%
	Taiwan Business Bank Employee Stock Ownership Trust Account of Taiwan Business Bank	1.08%
	Vanguard Total International Stock Index Fund， a series of Vanguard Star Funds	1.04%
	Vanguard Emerging Markets Stock Index Fund, A Series Of Vanguard International Equity Index Funds	0.96%
	New Labor Pension Fund	0.86%
	Deutsche Bank Taipei Branch Custody iShares Core MSCI Emerging Markets ETF Investment Account	0.76%
	Norges Bank	0.72%
Hua Nan Commercial Bank, Ltd.	Hua Nan Financial Holding Company	100.00%
Central Investment Co., Ltd.	Kuomintang Offical	100.00%

Name of corporate shareholders	Major shareholders of corporate shareholders	Shareholding ratio
Mega Internaitonal Commercial Bank, Ltd.	Mega Financial Holding Company	100.00%
Land Bank of Taiwan	Ministry of Finance	100.00%
Taiwan Cooperative Bank	Taiwan Cooperative Holding Company	100.00%
Hsinex International Corp.	Show-Chung Ho	27.13%
	Chang, Hsin-Ju	26.00%
	Ho,I-Chia	24.48%
	Ho,I-Ta	22.28%
	Chen-Yu Co., Ltd.	0.11%
Lui Co., Ltd.	Show-Chung Ho	76.0%
	HO,I-CHIA	24.0%
Chen-Yu Co., Ltd.	Show-Chung Ho	40.75%
	Chang, Hsin-Ju	30.00%
	Ho,I-Chia	22.92%
	Ho,I-Ta	6.33%
Hsin-Yi Foundation	Established in the year 1971, the main donors were HO, CHUAN (deceased), HO, SHOU-SHAN (deceased), Show-Chung Ho, HO, LIN-FU-HSIANG (deceased), SUN, YEH (deceased), YFY Inc. (donated before going public), and Hsin-Yi Enterprise Co., Ltd.	

4.Director and Supervisor qualifications and information disclosure on the independence of independent directors

Qualification / Name	Professional qualification and experience	Status of independence	Number of concurrent posts at other listed companies as independent director
Chairman：Kao Hsiang Investment Co., Ltd Representative：Kuo-Lung Huang	With more than five years of business experience, and rich experience in the pharmaceutical industry, Gender is Male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law.	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	0
Director：YFY Investment Holding Co.,Ltd Representative：Weng-Foung Huang	With a mechanical educational background; has more than five years of business and manufacturing, financial, and chemical industry experience; Gender is Male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	2
Director：Kao Hsiang Investment Co., Ltd Representative： Hong-Jen Chang	With a medical policy and management education and practical background; as well as biotechnology industry, health and disease control experience; Gender is Male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	1
Director：Kao Hsiang Investment Co., Ltd Representative：Peter Wu	With a pharmaceutical education and practical background; as well as more than five years of business and biotechnology industry experience; Gender is Male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	1
Director：National Development Fund, Executive Yuan Representative：Hsun-Yuan Tsou	With an academic background and practical experience in public administration and management. Gender is male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	0

Director：Taiwan Sugar Corporation Representative： I-Jen Huang	With a background in biology and chemistry as well as practical experience: and business and biotechnology industry experience.. Gender is male. Nationality R.O.C.. No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	0
Independence Director： Mei-Li Su	With an academic background and practical experience in accounting and finance, as well as business experience. Gender is female, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	3
Independence Director：Eric, Yi-Chun Huang	The individual has five years or more of experience in the international pharmaceutical industry. Gender is male, Nationality China.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	0
Independence Director： Chen-Wu, Chang	The individual has five years or more of experience in the international pharmaceutical industry. Gender is male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	2

5. Board Diversity and Independence：

(1) Board Diversity：

Nationality: Composed of R.O.C. and U.S.A.
Industry: Across business, biochemistry, public administration and academia
Education background: including R.O.C. and American doctorate and master degree
Age: Age distribution covers 51~79 years old

In light of the Company's primary business being new drug research and development, which involves a high degree of specialization and a unique business model, the Company has established diversity policy objectives for its Board of Directors. Specifically, more than half of the board seats should be held by individuals with experience in the biotechnology and pharmaceutical industry, and at least one director should be of a different gender.

At present, among the Company's nine directors, five have previously held positions in the biotechnology and pharmaceutical industry, and one director is female. The composition of the current Board of Directors is therefore in compliance with the Company's board diversity policy objectives.

(2) Board Independence: There are 3 independent directors now, which make up one-third of the board members. There are no circumstances as specified in Article 26, Paragraph 3 and 4 of the Securities and Exchange Act between the directors. That is, more than half of the seats among the directors do not have a spouse or close relatives within the second degree of kinship. The independent directors also do not have a spouse or close relatives within the second degree of kinship with the other directors.

(II) The president, vice president, assistant vice president, heads of various departments and branches

March 31, 2025；Unit：thousand shares；%

Title	Nationality	Name	Gender	Date Effective	Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Experience（Education）	Other Position	Managers who are Spouses or Within Two Degrees of Kinship			Remark(s)
					Share	%	Share	%	Shares	%			Title	Name	Relation	
Chairman of The Cmpany & General Manager, TaiGen Beijing	R.O.C.	Kuo-Lung Huang	Male	2004.7	1,061	0.15	0	0	0	0	• University of South Australia EMBA • Takeda Pharmaceutical Company Limited	• TaiGen Taiwan Chairman • TaiGen Cayman Chairman • TaiGen Beijing Chairman	-	-	-	(Note1)
General Manager	R.O.C.	Li-Wen Chang	Female	2019.3	196	0.03	0	0	0	0	• National Cheng Kung University Master of Biochemistry and Molecular Biology	• TaiGen Beijing Director • TaiGen Taiwan General Manager	-	-	-	-
Finance and Administration Division Vice President	R.O.C.	Richard Lu	Male	2016.4	88	0.01	0	0	0	0	• Rutgers U. Master of Financial Management • Chien Kuo Construction Co.,Ltd. Financial Vice President • Taiwan Prosperity Chemical Co.,Ltd. Financial Vice President • Director of Operations and Management Division Hon Hai Precision Industry Co., Ltd. • Zyxel Communications Co.,Ltd. Senior Manager • ProMOS Technologies INC. Manager	• Vice President of Finance and Administration Department of TaiGen Taiwan • TeiGen Beijing Superviosr	-	-	-	-
Preclinical Research DivisionVice President	R.O.C.	Cheng-Yuan Tsai	Male	2020.4	502	0.07	0	0	0	0	• Ph.D. in Analytical Chemistry, National Taiwan University • Head of Preclinical Pharmacokinetics and Metabolism Group, Biotechnology Development Center, Foundation • Intellectual Property Office Patent Examination Committee • Adjunct Assistant Professor, Department of Chemistry, Soochow University	None	-	-	-	-

Accounting Department Director	R.O.C.	Mark Kao	Male	2019.12	0	0	0	0	0	0	♦ Institute of Accountancy, National Taiwan University ♦ Kaisheng Holdings Co., Ltd. Accounting Supervisor	TaiGen Taiwan Accounting Department Supervisor	-	-	-	-

(III) Remuneration paid to directors, president and vice president in the most recent year

1. Remuneration of directors (including independent directors)（2025）

Unit：NT$ thousand

Title	Name	Remuneration								Amount and Ratio of Total Remuneration (A+B+C+D) to Net Income (%)		Relevant Remuneration Received by Directors Who are Also Employees								Amount and Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		Base Compensation (A)		Severance Pay (B)		Directors Compensation (C)		Allowances (D)				Salary, Bonuses, and Allowances €		Severance Pay (F)		Employee Compensation (G)						
																The company		Companies in the consolidated financial statements				
		The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	Cash	Stock	Cash	Stock	The company	Companies in the consolidated financial statements	
Chairman	Kao Hsiang Investment Co., Ltd. .(Note 1) Representative：Kuo-Lung Huang	0	4649	0	0	0	0	27	27	27 0.0598	4676 10.3503	0	4608	0	0	0	0	0	0	27 0.0598	9,284 20.5501	None
Director	Kao Hsiang Investment Co., Ltd Representative：Hong-Jen Chang	120	120	0	0	0	0	27	27	147 0.3254	147 0.3254	0	0	0	0	0	0	0	0	147 0.3254	147 0.3254	None
Director	Kao Hsiang Investment Co., Ltd Representative：Peter Wu	120	120	0	0	0	0	24	24	144 0.3187	144 0.3187	0	0	0	0	0	0	0	0	144 0.3187	144 0.3187	None
Director	YFY Investment Co., Ltd.(Note 2) Representative：Show-Chung Ho Representative：Weng-Foung Huang	120	120	0	0	0	0	27	27	147 0.3254	147 0.3254	0	0	0	0	0	0	0	0	147 0.3254	147 0.3254	None
Director	National Development Fund, Executive Yuan.(Note 2) Representative：Chi-Kung Ho Representative：Hsun-Yuan Tsou	120	120	0	0	0	0	18	18	138 0.3055	138 0.3055	0	0	0	0	0	0	0	0	138 0.3055	138 0.3055	None
Director	Taiwan Sugar Corporation Representative：I-Jen Huang	120	120	0	0	0	0	27	27	147 0.3254	147 0.3254	0	0	0	0	0	0	0	0	147 0.3254	147 0.3254	None
Independent Director	Weng-Foung Huang.(Note 4)	392	392	0	0	0	0	30	30	422 0.9341	422 0.9341	0	0	0	0	0	0	0	0	422 0.9341	422 0.9341	None
Independent Director	Ye-Hong Zhang.(Note 3)	750	750	0	0	0	0	70	70	820 1.8151	820 1.8151	0	0	0	0	0	0	0	0	820 1.8151	820 1.8151	None
Independent Director	Shen-Fu Yu.(Note 4)	392	392	0	0	0	0	40	40	432 0.9562	432 0.9562	0	0	0	0	0	0	0	0	432 0.9562	432 0.9562	None
Independent Director	Mei-Li Su.(Note 5)	608	608	0	0	0	0	56	56	664 1.4697	664 1.4697	0	0	0	0	0	0	0	0	664 1.4697	664 1.4697	None
Independent Director	Eric, Yi-Chun Huang.(Note 5)	608	608	0	0	0	0	60	60	668 1.4786	668 1.4786	0	0	0	0	0	0	0	0	668 1.4786	668 1.4786	None
Independent Director	Chen-Wu, Chang.(Note 6)	294	294	0	0	0	0	43	43	337 0.7459	337 0.7459	0	0	0	0	0	0	0	0	337 0.7459	337 0.7459	None

* The content of the bonus revealed in this table is different from the concept of income in the Income Tax Law, so the purpose of this table is for informational disclosure and not for tax purposes.

Note 1：After the board re-election on May 23, 2025, Kuo-Lung Huang no longer concurrently serves as CEO

Note 2：After the board re-election on May 23, 2025, the corporate directors reassigned their representatives: the representative of YFY Investment Co., Ltd.(was changed from Show-Chung Ho to Weng-Foung Huang, and the representative of National Development Fund, Executive Yuan was changed from Chi-Kung Ho to Hsun-Yuan Tsou.

Note 3：Resigned on October 1, 2025.

Note 4：Stepped down following the board re-election on May 23, 2025.

Note 5：Assumed office following the board re-election on May 23, 2025.

Note 6：Assumed office following election at the extraordinary shareholders' meeting on September 15, 2025.

Note 7：The policy, system, standards, and structure of independent director compensation, and the relationship between the amount of compensation paid and factors such as responsibilities, risks, and time invested：The Company's director compensation is considered by the compensation committee based on market benchmarks for the industry, and the reasonableness of the relationship between individual performance, company performance, and future risks, and then submitted to the board of directors for resolution. The compensation of the company's directors consists of a fixed amount and business expenses. The compensation of independent directors may be reasonably different from that of general director. According to the company's article of coporation, if there is pre-tax profit in a given year, up to 2% of pre-tax profit should be set aside for director compensation, and approved by more than half of the directors present and more than two-thirds of the board of directors present.

Note 8：After-tax net profit refers to the after-tax net profit of the 2025 consolidated financial report. (The company is a KY company and only needs to issue a consolidated financial report)

Note 9：In addition to the disclosure in the above table, the remuneration received by the directors for providing services to all companies in the financial statements (such as serving as consultants who are not employees, etc.) in the most recent year: None.

Remuneration Range Table

Range of Remuneration	Name of Directors			
	Total of (A+B+C+D)		Total of (A+B+C+D+E+F+G)	
	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements
Under NT$ 1,000,000	General director：National Development Fund, Executive Yuan Representative：Chi-KungHo、Hsun-Yuan Tsou /YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho、Hong-Jen Chang /Taiwan Sugar CorporationRepresentative：Yi-Zen Huang /Kao Hsiang Investment Co., Ltd.Representative：Kuo-Lung Huang、Hong-Jen Chang、Peter Wu Independent director： Shen-Fu Yu、Ye-Hong Zhang、Mei-Li Su、Eric, Yi-Chun Huang、Chen-Wu, Chang	General director：National Development Fund, Executive Yuan Representative：Chi-KungHo、Hsun-Yuan Tsou /YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho、Hong-Jen Chang /Taiwan Sugar CorporationRepresentative：Yi-Zen Huang /Kao Hsiang Investment Co., Ltd.Representative：Kuo-Lung Huang、Hong-Jen Chang、Peter Wu Independent director： Shen-Fu Yu、Ye-Hong Zhang、Mei-Li Su、Eric, Yi-Chun Huang、Chen-Wu, Chang	General director：National Development Fund, Executive Yuan Representative：Chi-KungHo、Hsun-Yuan Tsou /YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho、Hong-Jen Chang /Taiwan Sugar CorporationRepresentative：Yi-Zen Huang /Kao Hsiang Investment Co., Ltd.Representative：Kuo-Lung Huang、Hong-Jen Chang、Peter Wu Independent director： Shen-Fu Yu、Ye-Hong Zhang、Mei-Li Su、Eric, Yi-Chun Huang、Chen-Wu, Chang	General director：National Development Fund, Executive Yuan Representative：Chi-KungHo、Hsun-Yuan Tsou /YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho、Hong-Jen Chang /Taiwan Sugar CorporationRepresentative：Yi-Zen Huang /Kao Hsiang Investment Co., Ltd.Representative：Hong-Jen Chang、Peter Wu Independent director： Shen-Fu Yu、Ye-Hong Zhang、Mei-Li Su、Eric, Yi-Chun Huang、Chen-Wu, Chang
NT$1,000,000（inclusive）～ NT$2,000,000（exclusive）				
NT$2,000,000（inclusive）～ NT$3,500,000（exclusive）	-	-	-	-
NT$3,500,000（inclusive）～ NT$5,000,000（exclusive）	-	General director：Kao Hsiang Investment Co., Ltd.Representative：Kuo-Lung Huang-	-	-
NT$5,000,000（inclusive）～ NT$10,000,000（exclusive）	-	-	-	- General director：Kao Hsiang Investment Co., Ltd.Representative：Kuo-Lung Huang
NT$10,000,000（inclusive）～ NT$15,000,000（exclusive）	-	-	-	-
NT$15,000,000（inclusive）～ NT$30,000,000（exclusive）	-	-	-	-
NT$30,000,000（inclusive）～ NT$50,000,000（exclusive）	-	-	-	-
NT$50,000,000（inclusive）～ NT$100,000,000（exclusive）	-	-	-	-
NT$100,000,000（inclusive） or more	-	-	-	-
Total	13	13	13	13

2. Remuneration for president and vice president（2025）

Unit：NT$ thousand

Title	Name	Salary(A)		Severance Pay (B)		Bonuses and Allowances (C)		Employee Compensation (D)				Amount and Ratio of total compensation (A+B+C+D) to net income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company		Companies in the consolidated financial statements		The company	Companies in the consolidated financial statements	
								Cash	Stock	Cash	Stock			
Chairman of The Cmpany & General Manager, TaiGen Beijing	Kuo-Lung Huang	0	3,533	0	0	0	1,075	0	0	0	0	0	4,608 (10.20)	none
General Manager	Li-Wen Chang (Note 1)	0	4,754	0	0	0	605	0	0	0	0	0	5,359 (11.86)	none
Finanical Administration Division Vice President	Richard Lu	0	5,000	0	0	0	672	0	0	0	0	0	5,672 (12.55)	none
Preclinical Research Division Vice President	Cheng-Yuan Tsai	0	3,220	0	0	0	168	0	0	0	0	0	3,388 (7.50)	none

Note 1：Includes salary for the position of Vice President of Clinical Development from January to May 2025.

Remuneration of the Top 5 Executives

Title	Name	Salary(A)		Severance Pay (B)		Bonuses and Allowances (C)		Employee Compensation (D)				Amount and Ratio of total compensation (A+B+C+D) to net income (%)		Remuneration from ventures other than subsidiaries or from the parent company
		The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company	Companies in the consolidated financial statements	The company		Companies in the consolidated financial statements		The company	Companies in the consolidated financial statements	
								Cash	Stock	Cash	Stock			
CEO	Kuo-Lung Huang	0	3,533	0	0	0	1,075	0	0	0	0	0	4,608 (10.20)	none
General Manager	Li-Wen Chang	0	4,754	0	0	0	605	0	0	0	0	0	5,359 (11.86)	none
Finanical Administration Division Vice President	Richard Lu	0	5,000	0	0	0	672	0	0	0	0	0	5,672 (12.55)	none
Preclinical Research Division Vice President	Cheng-Yuan Tsai	0	3,220	0	0	0	168	0	0	0	0	0	3,388 (7.50)	none
Accounting Department Director	Mark Kao	0	1,800	0	0	0	27	0	0	0	0	0	1,827 (4.04)	none

(IV) Comparison of Remuneration for Directors, Supervisors, President and Vice Presidents in the Most Recent Two Fiscal Years and Remuneration Policy for Directors, Supervisors, President and Vice Presidents

1. The ratio of total remuneration paid by the Company and by all companies included in the consolidated financial statements for the two most recent fiscal years to directors, supervisors, president and vice presidents of the Company, to the net income.

Unit：NT$ thousands

Title	Amount and Ratio of total remuneration to net income (%)			
	2024		2025	
	Amount	%	Amount	%
Directors	3,843	(9.96)	8,742	19.35%
President and vice presidents	28,032	(72.65)	16,507	36.54%

Note 1：The company held a shareholders' meeting on May 23, 2025 to elect the 8th board of directors and on the same day, the board of directors passed the resolution to establish the 4th audit committee, so there is no remuneration for supervisors.

2. The policies, standards, and portfolios for the payment of remuneration, the procedures for determining remuneration, and the correlation with risks and business performance.：

(1) The Company’s director compensation is considered by the compensation committee based on market benchmarks for the industry, and the reasonableness of the relationship between individual performance, company performance, and future risks, and then submitted to the board of directors for resolution. The compensation of the company's directors consists of a fixed amount and business expenses. The compensation of independent directors may be reasonably different from that of general director. According to the company's article of coporation, if there is pre-tax profit in a given year, up to 2% of pre-tax profit should be set aside for director compensation, and approved by more than half of the directors present and more than two-thirds of the board of directors present. As the company is in the new drug development stage and considering future funding needs, no directors' remuneration will be allocated in 2025.

(2) The appointment of the company's President and Vice President is mainly through professional recruitment agencies, targeting international senior managers with relevant experience and who agree with the company's business philosophy. Their remuneration is based on their position, the degree and contribution to the company's operations (considering factors such as target achievement rate, profit rate, operational efficiency etc.), and consider the futre risk. Then handled in accordance with the company's personnel regulations and is discussed by the salary and remuneration committee and then passed by resolution of the board of directors.

II、Implementation of Corporate Governance

(I) Operation of the board of directors

In 2025，and and as of the date of printing the annual report, the 7th session of the board of directors held 3 meetings (A). The attendance of directors is as follows：

Title	Name	Actual Attendance (B)	Proxy Attendance	Actual attendance (%)【B/A】	Remark
Chairman	Kao Hsiang Investment Co., Ltd. Representative：Kuo-Lung Huang	3	0	100.00	Re-elected on May 30, 2022
Director	YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho	3	0	100.00	Re-elected on May 30, 2022
Director	Kao Hsiang Investment Co., Ltd. Representative：Hong-Jen Chang	3	0	100.00	Re-elected on May 30, 2022
Director	National Development Fund, Executive Yuan Representative：Chi-Kung Ho	3	0	100.00	New-elected on May 30, 2022
Director	Kao Hsiang Investment Co., Ltd Representative：Peter Wu	3	0	100.00	New-elected on May 30, 2022
Director	Taiwan Sugar Corporation Representative：I-Jen Huang	3	0	100.00	Re-elected on May 30, 2022
Independent director	Weng-Foung Huang	3	0	100.00	Re-elected on May 30, 2022
Independent director	Ye-Hong Zhang	3	0	100.00	Re-elected on May 30, 2022
Independent director	Shen-Fu Yu	3	0	100.00	Re-elected on May 30, 2022
In 2025 and as of the date of printing the annual report, the 8th Board of Directors had 8 meetings (A). The attendance of the directors was as follows：					
Chairman	Kao Hsiang Investment Co., Ltd. Representative：Kuo-Lung Huang	8	0	100.00	Re-elected on May 23, 2025
Director	YFY Investment Holding Co., Ltd. Representative：Weng-Foung Huang	8	0	100.00	New-elected on May 23, 2025
Director	Kao Hsiang Investment Co., Ltd. Representative：Hong-Jen Chang	8	0	100.00	Re-elected on May 23, 2025
Director	Kao Hsiang Investment Co., Ltd Representative：Peter Wu	7	1	87.50	Re-elected on May 23, 2025
Director	National Development Fund, Executive Yuan Representative：Hsun-Yuan Tsou	5	3	62.50	New-elected on May 23, 2025
Director	Taiwan Sugar Corporation Representative：I-Jen Huang	8	0	100.00	Re-elected on May 23, 2025
Independent director	Ye-Hong Zhang	2	0	66.67	Re-elected on May 23, 2025 Resigned on October 1, 2025
Independent director	Mei-Li Su	7	1	87.50	New-elected on May 23, 2025
Independent director	Eric, Yi-Chun Huang	2	5	25.00	New-elected on May 23, 2025
Independent director	Chen-Wu, Chang	5	0	100.00	New-elected on Sep 15, 2025

※In the recent fiscal year and as of the date of printing the annual report, at least one independent director personally attended each meeting of the Board of Directors.

Other items that should be recorded：

I、If the operation of the Board of Directors has any of the following circumstances, the date, period, content of the resolution, opinions of all independent directors, and the company's handling of independent directors' opinions should be specified：

(I) Items listed in Article 14-3 of the Securities Exchange Law: All proposals were passed without objection by the Independent director. For details, please refer to important resolutions of the shareholders' meeting and the board of directors on pages 42 to 45.

(II) In addition to the above-mentioned matters, other resolutions of the board of directors that have been opposed or reserved by the Independent director and have records or written statements: None.

II、The implementation of directors' recusal of interest-related proposals shall state the director's name, content of the proposal, reasons for recusal of interests, and participation in voting:

Meeting Date	Name	Content	Reasons for recusal of interests and voting situation
2025/3/4	Kuo-Lung Huang	**1.** Agreed to the roster of eligible stock option holders meeting the exercisable conditions on the first expiry date for Type I stock options under the "2023 Employee Stock Option Issuance and Subscription Plan." **2.** Approved the issuance of employee stock options in accordance with the "2023 Employee Stock Option Issuance and Subscription Plan."	Reasons for recusal of interests: Director Kuo-Lung Huang also serves as the CEO and is an interested party in this case. Voting Details: The two proposals were passed unanimously by a show of hands from all attending directors with voting rights, following consultation by the acting chairman.
2025/08/19	Kuo-Lung Huang	Discussed the proposed compensation package for the Company's Chairman.	Reasons for recusal of interests: Director Kuo-Lung Huang also serves as the CEO and is an interested party in this case. Voting Details: The proposal was passed unanimously by a show of hands from all attending directors with voting rights, following consultation by the acting chairman.
2025/11/13	Kuo-Lung Huang	Approved the roster of eligible stock option holders who meet the exercisable conditions on the first expiry	Reasons for recusal of interests: Director Kuo-Lung Huang also serves as the CEO and is an interested party in this

		date for Type II stock options under the "2023 Employee Stock Option Issuance and Subscription Plan."	case. Voting Details: The proposal was passed unanimously by a show of hands from all attending directors with voting rights, following consultation by the acting chairman.
2025/12/11	Kuo-Lung Huang	Approved the roster of eligible stock option holders meeting the exercisable conditions on the first expiry date for Type II stock options under the "2023 Employee Stock Option Issuance and Subscription Plan."	Reasons for recusal of interests: Director Kuo-Lung Huang also serves as the CEO and is an interested party in this case. Voting Details: The proposal was passed unanimously by a show of hands from all attending directors with voting rights, following consultation by the acting chairman.

III、Listed companies should disclose information on the assessment period, scope, method, and Content of Board Self-Evaluation (or Peer Evaluation) ：

Evaluation cycle	period	Scope	Method	Assessment content
Once a year	2025/1/1~ 2025/12/31	Individual Directors, Board of Directors, Functional Committees	Board member self-assessment	(1)Board Performance Evaluation: Includes involvement in company operations, quality of board decisions, board composition and structure, director selection and continuing education, internal control, etc 2)Individual Director Performance Evaluation: Includes understanding of company goals and objectives, perception of director responsibilities, involvement in company operations, management of internal relationships and communication, professional development and continuing education, internal control, etc. (3)Committee Performance Evaluation: Includes involvement in company operations, perception of committee responsibilities, quality of committee decisions, committee composition and member selection, internal control, etc.

IV、Assessment of the year and recent years' goals for enhancing board functions (e.g. establishing an audit committee, improving transparency) and the implementation situation：

(I) The company has designated personnel responsible for collecting and disclosing company information, and can promptly and properly disclose all information required by law to improve transparency.

(II)The company has a " Rules and Procedures of Board of Directors Meetings " and regularly announces attendance of directors at board meetings, disclosing material decisions of the board on Market Observation Post System

(III)Our company established the Salary and Remuneration Committee on May 7th, 2013, through the 4th 2nd board meeting, and formulated the "Organizational Regulations of the Salary and Remuneration Committee" to strengthen corporate governance and the functions of the board of directors. In 2025, the Salary and Remuneration Committee held 5 meetings in the latest fiscal year up to the date of printing the annual report, to discuss the salary and remuneration methods for directors and executives of the company and its subsidiaries, and related proposals

(IV)Our company's shareholders' meeting resolved to pass the amendment of the company's articles of incorporation on June 17, 2016, setting up an Audit Committee.

(V)The company established the head of corporate governance on April 28th, 2021, to handle matters related to the board of directors, assist directors in training, carry out business requirements, and comply with relevant regulations.

(VI) All members of the current board of directors of our company have participated in corporate governance-related courses held by the designated institutions specified by the "Directions for the Implementation of Continuing Education for Directors and Supervisors of TWSE Listed and TPEx Listed Companies " during their term of office

(VII)To implement corporate governance and enhance the function of the board of directors, establish performance targets and improve the efficiency of board operations, the company has completed the establishment of the board of directors' performance evaluation method on November 6, 2019. The situation of the 2025 board of directors evaluation has been reported to the board of directors on March 9, 2026.

(II) Operation of the Audit Committee

The company conducted a comprehensive election of directors on May 23, 2025, resulting in the 8th term of the board of directors. The first meeting of the board was held on the same day, and the list of the 4th term of the audit committee was announced. The audit committee of the company consists of 3 members, with a term from May 23, 2025 to May 22, 2028.

The 3rd term of the audit committee held 3 meetings(A) in 2025 and until the printing date of the annual report, and the attendance of the audit committee members is as follows：

Title	Name	Actual Attendance (B)	Proxy Attendance	Actual attendance (%) 【B/A】	Remark
Independent director (Convener)	Weng-Foung Huang	3	0	100	Re-elected on May 5, 2022
Independent director	Ye-Hong Zhang	3	0	100	Re-elected on May 5, 2022
Independent director	Shen-Fu Yu	3	0	100	Re-elected on May 5, 2022

The 4th term of the Audit Committee held 5 meetings(A) in 2025 and until the end of the

year-endreport, and the attendance of the Audit Committee members is as follows：

Independent director (Convener)	Ye-Hong Zhang	2	0	100	Re-elected on May 23, 2025 Resigned on October 1, 2025
Independent director (Convener)	Mei-Li Su	4	1	80	New-elected on May 23, 2025
Independent director	Eric, Yi-Chun Huang	3	2	60	New-elected on May 23, 2025
Independent director	Chen-Wu, Chang	4	0	100	New-elected on Sep 15, 2025

Other matters to be disclosed：

I、The matters mainly considered by the audit committee include the following：

●Financial statements ●Audit and accounting policies and procedures ●Internal control systems and related policies and procedures ●Significant asset or derivative transactions ●Significant loaning of funds and guarantees or endorsements/guarantees ●Offering and Issuance of securities ●Derivative financial instruments and cash investments ●Compliance with regulations ●Related-party transactions and potential conflicts of interest by management and directors ●Complaint reports ●Antifraud plans and investigation reports ●Information security ●Company risk management ●Appointment, dismissal, or compensation of auditors ●Appointment or removal of financial, accounting, or internal auditor●Performance evaluation of the Audit Committee and self-assessment questionnaire, etc.

II、Summary of Audit Committee's 2025 Work Focus

1. Review financial reports

The board of directors has prepared the company's 2025 annual business report, financial statements, and loss compensation proposals, among others. The financial statements have been audited by KPMG and a review report has been issued. The above operating report, financial statements, and loss compensation proposals have been reviewed by the audit committee and are considered to be in compliance.

2. Assess the effectiveness of the internal control system

The Audit Committee evaluates the effectiveness of the company's policies and procedures for its internal control system (including financial, operational, risk management, information security, outsourcing, compliance, and other control measures) and reviews the reports from the company's audit department and auditors, as well as regular reports from management, including risk management and compliance. Based on the 2013 Internal Control – Integrated Framework issued by The Committee of Sponsoring Organizations of the Treadway Commission (COSO), the Audit Committee considers the company's risk management and internal control system to be effective and that the necessary control mechanisms have been put in place to monitor and correct any violations

3. Communicate with the auditing accountant to discuss key audit matters regarding the annual financial report

In accordance with the " Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies," to improve the implementation of internal control systems, a communication mechanism between the Independent Director and the auditing accountant

has been established. The key audit matters (KAM) and the financial reporting audit relating matters were communicated during an independent meeting with the auditing accountant and the head of internal audit on December 24, 2025.

III、2025 annual Audit Committee meeting dates, session, agenda content, Audit Committee resolutions and the company's handling of Audit Committee opinions：

Meeting Date	Session	Agenda Content	Article 14-5 of Securities and Exchange Act	Resolution Results	The company's handling of the Audit Committee's comments
2025/3/4	3rd term, 15th meeting	2024Internal Control System Statement.	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
		2024Financial Statements and Business Report	V		
		2024 Earning Distribution Proposal.	V		
		Proposal of Securities Investment	V		
		The 2025 general meeting of shareholders elects the 6 directors and the 3 Independent directors for the sixth session	V		
		Approval of 2023Employee Stock Option Certificate the terms and conditions " First Expiration Date Eligible Exercise Stock Option List.	V		
		Agreement to the roster of eligible exercising of stock options in accordance with the "2023 Employee Stock Option Certificate Issuance and Stock Option Plan	V		
2025/4/9	3rd term, 16th meeting	Proposal to remove the restriction on the new director and their representative from engaging in competitive business	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
2025/5/14	3rd term, 17th	2025 1st quarter consolidated financial report	V	This proposal was passed with no	Implement

	meeting	Resolved to approve the amendments to the Company's "Rules of Procedure for Board of Directors Meetings	V	objections after consultation with all attending members, and will be submitted to the board for discussion	according to the resolution result
		Approved the amendments to the Company's "Audit Committee Charter."			
2025/7/30	4rd term, 1th meeting	The Company plans to elect one additional Independent Director for the 8th term at the 2025 Extraordinary Shareholders' Meeting.	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
		Proposal of Securities Investment	V		
2025/8/19	4rd term, 2th meeting	Proposal for the Share Repurchase Program to Buy Back a Portion of the Company's Shares	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
		Proposal for the Adoption of the "Procedures for the Repurchase of Treasury Shares"	V		
		Authorization for TaiGen Taiwan to lend funds to TaiGen Biopharmaceuticals	V		
		2025 2rd quarter consolidated financial report	V		
		Proposal to remove the restriction on the new director and their representative from engaging in competitive business	V		
		Approved the amendment to the proposal description for the election of Independent Directors at the Company's Extraordinary Shareholders' Meeting on September 15, 2025.	V		
2025/11/13	4rd term, 3th meeting	Proposal for the Formulation of the Company's 2026 Internal Audit Plan	V	This proposal was passed with no objections after consultation with all attending	Implement according to the resolution
		2025 3rd quarter consolidated financial report	V		

		Approved the cash capital reduction of TaiGen Taiwan	V	members, and will be submitted to the board for discussion	result
		Proposal for the Capital Reduction through Cancellation of Treasury Shares	V		
		Proposal for the Capital Reduction through Cancellation of Restricted Shares Previously Reclaimed from Employees	V		
		Authorization for TaiGen Taiwan to lend funds to TaiGen Beijing	V		
		Proposal for the Approval of the Remuneration of the Certified Public Accountant for the Fiscal Years 2026–2027	V		
		Agreement to the roster of eligible exercising of stock options in accordance with the "2023 Employee Stock Option Certificate Issuance and Stock Option Plan" on the first expiration date	V		
2025/12/11	4rd term, 4th meeting	Agreement to the roster of eligible exercising of stock options in accordance with the "2023 Employee Stock Option Certificate Issuance and Stock Option Plan" on the first expiration date	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
		Proposal to Authorize the Company's Representative on the Board of Company TaiGen Beijing to Approve the Appointment of the Chief Financial Officer of Company TaiGen Beijing	V		
2026/3/9	4rd term, 5th meeting	2025Internal Control System Statement.	V	This proposal was passed with no objections after consultation with all attending members, and will be submitted to the board for discussion	Implement according to the resolution result
		2025Financial Statements and Business Report	V		
		2025 Earning Distribution Proposal.	V		
		Proposal for the Amendments to Certain Provisions of the Company's "Procedures for the Acquisition or Disposal of Assets"	V		
		Proposal to Approve the Amendments to Certain Provisions of the Company's "Procedures for Lending Funds to Others"	V		

		Proposal for the Amendments to Certain Provisions of the Company's "Procedures for Endorsements and Guarantees"	**V**		
		Proposal for the Amendments to Certain Provisions of the Company's "Procedures and Guidelines for Integrity Management"	**V**		
		Proposal of Securities Investment	V		
		Proposal to Approve the Evaluation of the Competence and Independence of the Certified Public Accountant	V		

IV、The prior matter whether there are resolutions passed by a two-thirds majority of all directors without the approval of the Audit Committee：None

V、The independent director's implementation of the recusal of the stakeholder proposal shall state the name of the independent director, the content of the proposal, the reasons for the refusal of interests, and the status of participation in voting.：None

VI、Communication between the Independent director and the internal audit supervisor and accountants (such as the matters, methods and results of communication on the company's financial and business conditions, etc.)：

(I) The internal audit supervisor of the company regularly communicates the results of the audit report with the members of the Audit Committee, and makes an internal audit report at the quarterly Audit Committee meeting. In case of special circumstances, a separate report will be made to the committee members immediately or before the Audit Committee meeting.

(II) The company's CPA reports the results of their review or audit of the financial statements for each quarter and any related legal requirements to the Audit Committee in each quarterly meeting. In case of special circumstances, a separate report will be made to the committee members immediately or before the Audit Committee meeting.

(III) The communication between the independent directors, internal audit management, and accountants as of the end of the most recent fiscal year and the date of publication of the annual report is as follow：

Date	Way	Communication parties	Matters of communication	Results
2025/3/04	Audit Committee	The head of the audit department	The audit report for the fourth quarter of 2024	Inquire
			The 2024 annual internal control system statement	The proposal was passed without objection and will be presented to the board of directors for resolution.
		Accountants	2024 consolidated financial statements	The proposal was passed without objection and will be presented to the board of directors for resolution.
2025/5/14	Audit Committ	The head of the audit department	The audit report for the 1st quarter of 2025	Inquire

		Accountants	The consolidated financial statements for the 1st quarter of 2025	The proposal was passed without objection and will be presented to the board of directors for resolution.
2025/8/19	Audit Committee	The head of the audit department	The audit report for the2nd quarter of 2025	Inquire
		Accountants	Proposal for the consolidated financial statements for the 2nd quarter of 2025	The proposal was passed without objection and will be presented to the board of directors for resolution.
2025/11/13	Audit Committee	The head of the audit department	The audit report for the 3rd quarter of 2025	Inquire
			Internal audit plan for the year 2026	The proposal was passed without objection and will be presented to the board of directors for resolution.
		Accountants	The audit report for the 3rd quarter of 2025	The proposal was passed without objection and will be presented to the board of directors for resolution.
2024/12/24	Independent Meeting	The head of the audit department & Accountants	Explanation for 2025 Financial Report and Internal Control Audit	Inquire
			Key Audit Matters and Significant Risk	Inquire
			Explanation of Key Audit Points and Methods for Identifying Management Override of Controls	Inquire
			Potential Impacts of Regulatory Updates on the Company and Corresponding Measures	Inquire
2026/3/9	Audit Committee	The head of the audit department	The audit report for the fourth quarter of 2025	Inquire
			The 2025 annual internal control system statement	The proposal was passed without objection and will be presented to the board of directors for resolution.
		Accountants	2025 consolidated financial statements	The proposal was passed without objection and will be presented to the board of directors for resolution.

(III)The operation of the company governance, as well as any differences from Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies and the reasons for such differences

Evaluation items	Operation situation			Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies
	Yes	No	Summary description	
I、Has the company established and disclosed its corporate governance practice guidelines based on the 'Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies'?	✓		The company adopted the "Corporate Governance Practices Guidelines" at the Board of Directors meeting on November 10, 2017, and it can be accessed via the company's website and Market Observation Post System. The guidelines will be amended as necessary in the future based on the company's business conditions and regulatory requirements.	Compliant
II、The Company's shareholding structure and shareholders' rights and interests (I) Does the Company have in place an internal operating procedure for handling shareholders'suggestions, questions, disputes, or litigation and abide by it? (II) Does the Company possess a list of major shareholders and a list of ultimate owners of those major shareholders? (III) Whether the company has established, implemented and related enterprise risk control and firewall mechanisms (IV)Whether the company has established internal regulations to prohibit company insiders from using unpublished information on the market to buy and sell securities?	✓ ✓ ✓ ✓		(I)The company has designated spokesperson, proxy spokesperson and stock transfer agent, responsible for handling shareholder suggestions and communication channels. Information regarding investor contact channels is also set up on the company's website to handle and respond to shareholder suggestions, doubts and disputes. During shareholder meetings, communication is conducted with shareholders in accordance with the " Rules of Procedure for Shareholders Meetings. (II)The company has a Board of Directors and a unit responsible for stock affairs, managing related information and grasping the list of major shareholders and ultimate controllers of major shareholders through the shareholder register provided by the appointed stock transfer agent. (III)The company has established "AD-11 Group Enterprise, Specific Company, and Affiliate Transactions Management Operations" with related companies to regulate the management of personnel, assets, and finances, effectively assess risks, and establish appropriate firewall measures. (IV)The company has established "AD15- Internal Major Information Processing and Prevention of Insider Trading Management Operations Procedure" to regulate and prohibit company insiders from using non-public information for profit that is not obtainable in the market.	Compliant
III、Composition and Responsibilities of the Board of Directors				Compliant

<table>
<tr><th rowspan="2">Evaluation items</th><th colspan="3">Operation situation</th><th rowspan="2">Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary description</th></tr>
<tr><td>(I) Does the board of directors formulate diversity policies, specific management objectives and implement them?</td><td>✓</td><td></td><td>(I)
<table>
<tr><th>Diversified core projects
Name</th><th>Gender</th><th>Operational Judgment</th><th>Financial Accounting</th><th>Management</th><th>Inustry Knowledge</th><th>Decision Making Ability</th><th>Leadership</th><th>Internaitonal Market Outlook</th></tr>
<tr><td>Chairman：Kao Hsiang Investment Co., Ltd.
Representative：Kuo-Lung Huang</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Director：YFY Investment Holding Co., Ltd.
Representative：Weng-Foung Huang</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Director：National Development Fund, Executive Yuan
Representative：Hsun-Yuan Tsou</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Director：Taiwan Sugar Corporation
Representative：I-Jen Huang</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Director：Kao Hsiang Investment Co., Ltd.
Representative：
Hong-Jen Chang</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Director：Kao Hsiang Investment Co., Ltd.
Representative：Peter Wu</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Independent director：
Mei-Li Su</td><td>Female</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Independent director：
Eric, Yi-Chun Huang</td><td>Male</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr>
<tr><td>Independent director：
Chen-Wu, Chang</td><td>Male</td><td>V</td><td></td><td>V</td><td></td><td>V</td><td></td><td>V</td></tr>
</table>
The company's 8th Board of Directors consists of 9 directors in total. Of the 9 current directors, approximately 11% are employees, approximately 33% are independent directors,</td><td></td></tr>
</table>

Evaluation items	Operation situation			Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies
	Yes	No	Summary description	
			In the board, approximately 56% of the directors have backgrounds in the biotechnology and pharmaceutical industry, about 22% have backgrounds in biotechnology and pharmaceutical academia, and approximately 11% each have backgrounds in other industries and financial accounting expertise. In view of the Company's primary focus on new drug research and development, which involves a high degree of professional expertise and a unique business model, the Company has established diversity policy objectives for the Board of Directors requiring that more than half of the board seats be held by individuals with experience in the biotechnology and pharmaceutical industry, and that at least one director be of a different gender. Currently, among the Company's nine directors, five have experience serving in the biotechnology and pharmaceutical industry, and one is a female director. The composition of the current Board therefore complies with the Company's board diversity policy objectives.	
(II) In addition to setting up the Salary and Remuneration Committee and Audit Committee according to the law, whether the company has voluntarily set up other various functional committees ?		✓	(II)The company set up the Salary and Remuneration Committee and Audit Committee, and will establish various types of functional committees at an appropriate time, based on the operational scale and regulatory requirements.	
(III) Does the company formulate the performance evaluation method and evaluation method of the board of directors, conduct performance evaluation every year and regularly, and report the results of the performance evaluation to the board of directors, and use it as a reference for the salary of individual directors and nomination for renewal ?	✓		(III)The company has established the Board of Directors Performance Evaluation Policy on November 6, 2019. Pursuant to the policy, an internal board performance evaluation shall be conducted at least once annually, with the evaluation results submitted to the Board. The internal evaluation shall be conducted at the end of each year, following the designated evaluation procedures and indicators. Additionally, at least once every three years, the evaluation shall be performed by an external professional independent institution or a team of external experts and scholars. The results of the 2025 Board of Directors performance evaluation have been submitted to the Board meeting held on March 9, 2026.	
(IV) Does the company regularly assess the independence of accountants ?	✓		(IV) The Audit Committee of the Company conducts an annual assessment of the independence and competency of the engaged certified public accountants (CPAs). In addition to requiring the CPAs to provide a "Declaration of Independence" and an	

Evaluation items	Operation situation			Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies
	Yes	No	Summary description	
			"Audit Quality Report," the Committee also prepares an Evaluation Form for CPA Independence and Competency based on the Audit Quality Indicators (AQIs). This form outlines relevant assessment items to evaluate the CPAs' independence. The assessment confirms that, apart from audit and tax-related service fees, there are no other financial interests or business relationships between the CPAs and the Company, and that the CPAs' family members do not violate independence requirements. The evaluation results are submitted to the Board of Directors for resolution. The most recent annual assessment was reviewed and approved by the Audit Committee on March 9, 2026, and subsequently approved by the Board of Directors on the same date.	
IV、Listed and over-the-counter companies should appoint appropriate number of corporate governance personnel, and designate a person in charge of corporate governance to be responsible for related matters, including but not limited to providing necessary information for directors and supervisors to carry out their duties, assisting directors and supervisors in following laws and regulations, handling related matters of board of directors and shareholders meetings, producing minutes of board of directors and shareholders meetings, etc.	✓		The finance department of the company has been designated as a concurrent corporate governance unit, and a person in charge of corporate governance was established and approved by the board of directors on April 28, 2021. The responsibilities of the person in charge of corporate governance include the following： (I) Handling director appointments and annual training, and assisting directors with necessary information for carrying out their duties. (II) Assisting directors in following relevant laws and regulations, and planning appropriate company systems and organizational structure to promote the independence of the board of directors and the transparency of the company. (III) Preparing and setting the agenda for the board of directors meetings and providing it to all directors seven days prior to the meeting to allow them to understand the content of relevant proposals; if there are any conflicts of interest related to the proposals, they will be reminded to appropriately avoid them. (IV) Register the annual shareholders' meeting date according to the legal deadline, prepare and announce the meeting notice, annual report, meeting manual, and minutes before the deadline. After the revision of the company's articles of association or the election of new directors, the relevant information should be reported to the competent authority. (V) Review if the qualifications of the independent director meet the relevant laws and regulations during the nomination, election, and tenure period, and report to the board of directors.	Compliant
V、Has the company established a communication channel with stakeholders and set up a stakeholders' area on the company's website, and	✓		The company considers its stakeholders, including banks and other creditors, employees, suppliers, customers, and others with a relevant interest, to be important, and it has established communication channels for them. The company discloses information in the Market Observation Post System in accordance with relevant laws and regulations to provide stakeholders with sufficient information to make informed decisions in order to protect their	Compliant

Evaluation items	Operation situation			Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies
	Yes	No	Summary description	
appropriately responded to important corporate social responsibility issues that stakeholders are concerned about?			interests. The company also has a relevant link on its website.	
VI、Does the company appoint a professional stock affairs agency to handle the affairs of the shareholder meetings？	✓		The company appointed the Stock Affairs Agency Department of SinoPac Securities Co., Ltd. to handle the affairs of the company's shareholders' meeting	Compliant
VII、Information Disclosure (I) Does the company have a website that discloses financial business and corporate governance information？ (II) Does the company adopt other methods of information disclosure (such as setting up an English website, designated personnel responsible for collecting and disclosing company information, implementing a spokesperson system, placing the process of legal person conference on the company's website, etc.)? (III)Does the company announce and declare its annual financial report within two months after the end of the fiscal year, and announce and declare its Q1, Q2, Q3 financial reports and operational situation of each month in advance of the prescribed deadline?	✓ ✓	 ✓	(I) The company has a website (http://www.taigenbiotech.com.tw) and in accordance with relevant laws and regulations, regularly and irregularly reports and discloses various business and financial information on the Market Observation Post System. (II) Our company has both Chinese and English websites, and there are dedicated personnel responsible for relevant tasks based on their job responsibilities. They are responsible for collecting and disclosing relevant information. We have a spokesperson and a spokesperson agent to handle relevant matters as the corresponding window. The presentation materials for investor conference are disclosed on the company's website (III) Although the Company has not announced and filed its annual financial report within two months after the end of the fiscal year, all financial statements and operational information have been duly disclosed within the prescribed deadlines on the Market Observation Post System and published on the Company’s website.	Compliant

Evaluation items	Operation situation			Differences and reasons between the company's governance operation and the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies
	Yes	No	Summary description	
VIII、Are there any other important information that can help understand the company's governance and operational situation (including but not limited to employee rights, employee care, investor relations, supplier relations, rights of stakeholders, training of directors and supervisors, implementation of risk management policies and risk measurement standards, implementation of customer policies, situation of the company purchasing liability insurance for directors and supervisors, etc.)?	✓		(I) Regarding employee rights and employee care, our company has established a staff welfare committee, implemented a pension system, held employee education and training courses and group insurance for employees, and arranged for regular health check-ups and other benefits, in order to promote a harmonious relationship between labor and management.. (II) Our company publicly discloses company information in accordance with legal regulations to protect the rights and interests of investors and stakeholders, and to fulfill its responsibility to shareholders. (III) The directors of our company follow the provisions of the articles of incorporation when dealing with matters that may have conflicts of interest, and avoid participating in discussions and voting in such cases. (IV) Our company has smooth communication channels with clients and suppliers and maintains good relationships with them. (V) The company is always aware of continuing education courses and informs its directors and supervisors, who may attend such courses based on their needs, and must comply with the training hours set out in the "Directions for the Implementation of Continuing Education for Directors and Supervisors of TWSE Listed and TPEx Listed Companies". (VI)The company implements risk management policies and standards, following relevant regulations, its internal control system, and regulations governing the acquisition and disposal of assets, and conduct various risk assessments (VII) The company regularly purchases liability insurance for its directors, supervisors, and managers.	Compliant
IX、Please explain the improved situation in regards to the recent annual corporate governance evaluation results published by the Corporate Governance Center of Taiwan Stock Exchange Corporation, and prioritize the improvement measures for the areas yet to be improved. Improvement and Implementation： Our company has reviewed the deficiencies identified in the corporate governance evaluation results and has implemented improvement measures in accordance with the internal Corporate Governance Code to effectively enhance corporate governance.				

(IV) The company should disclose the composition, responsibilities, and operation of the Salary and Compensation Committee if one is established.

The Company established the Remuneration Committee on May 7, 2013, pursuant to a resolution of the Board of Directors and adopted the “Remuneration Committee Charter”.

Due to the re-election of directors on May 23, 2025, the new members of the Committee are Independent Director Mei-Li Su、Eric, Yi-Chun Huang 、Chen-Wu, Chang. The responsibilities of the Committee are to establish and maintain a sound remuneration system for the Company’s directors and managerial officers.

Information on the Committee members and its operation is provided as follows:

1.Salary and Compensation Committee member profile

Condition / Identity	Name	Professional qualifications and experience	Independence situation	The number of independent directors serving as members of Salary and Compensation Committee in other publicly traded companies.
Independent director (convener)	Mei-Li Su	With an academic background and practical experience in accounting and finance, as well as business experience. Gender is female, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	3
Independent director	Eric, Yi-Chun Huang	The individual has five years or more of experience in the international pharmaceutical industry. Gender is male, Nationality China.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	0
Independent director	Chen-Wu, Chang	The individual has five years or more of experience in the international pharmaceutical industry. Gender is male, Nationality R.O.C.; No circumstances specified in Article 30 of the Company Law	No spouse or second degree relatives relationship between directors, independent directors, or between directors and independent directors.	2

2.Salary and Compensation Committee operational information

The Company conducted a full re-election of directors on May 23, 2025. Following the re-election, the Eighth Board of Directors was formed, and the first Board meeting was convened on the same day, at which the members of the Fifth Remuneration Committee were announced.

The Company’s Remuneration Committee consists of three members. The term of the Fifth Committee is from May 23, 2025 to May 22, 2028. On October 1, 2025, Independent Director

Ye-Hong Zhang resigned due to a heavy workload. On the same day, the Board of Directors resolved to appoint Independent Director Chen-Wu, Chang as a member of the Remuneration Committee.

The 4th Salary and Compensation Committee in 2025 had held once (A). The attendance of the Salary and Compensation Committee is as follows:

Title	Name	Actual Attendance (B)	Proxy Attendance	Actual attendance (%) 【B/A】	Remark
Independent director (convener)	Shen-Fu Yu	1	0	100	Term ended on May 23, 2025
Independent director	Weng-Foung Huang	1	0	100%	Term ended on May 23, 2025
Independent director	Ye-Hong Zhang	1	0	100%	Re-elected on May 23, 2025 Resigned on October 1, 2025

In 2025 and up to the date of publication of this annual report, the 5th Audit Committee held a total of four meetings. The attendance of the committee members is as follows:

Independent director (convener)	Ye-Hong Zhan	1	1	100%	Re-elected on May 23, 2025 Resigned on October 1, 2025
Independent director (convener)	Mei-Li Su	3	1	75%	New-elected on May 23, 2025
Independent director	Eric, Yi-Chun Huang	3	1	75%	New-elected on May 23, 2025
Independent director	Chen-Wu, Chang	3	0	100%	New-elected on May 23, 2025

Other matters to be recorded：

I、The operation of the Salary and Compensation Committee is as follows：

Date	Term	Content	Resolution	The company's handling of the opinions of the Salary and Compensation Committee
2025/3/3	4th term 7th meeting	Discuss the number of shares allocated under the 2023 Employee Stock Options and, based on the achievement of key project performance targets, calculate the actual number of shares that employees can exercise under Employee Stock Option Certificate Type I	All members of the committee agreed to adopt	Implement according to the resolution result
2025/8/1	5th term 1th meeting	Discussion of the proposed amendments to the Compensation Policy for Directors, Supervisors, and Managers of the Company and its Subsidiaries	All members of the committee agreed to adopt	Implement according to the resolution result
		Discussion of the proposed		

		compensation package for the Chairman, Kuo-Lung Huang, of the Company.		
		Discussion of the proposed subsidy for National Health Insurance premiums for the Chairman, Kuo-Lung Huang, of the Company.		
		Discussion of the proposed compensation package for the Chairman, Li-Wen Chang , of the Company.		
2025/11/11	5th term 2th meeting	Discussion of the number of shares allocated under the Company's 2023 Employee Stock Options and, based on the achievement of key project performance targets, determination of the actual number of shares exercisable by employees under Employee Stock Option Certificate Type II	All members of the committee agreed to adopt	Implement according to the resolution result
		Propose to discuss the 2026 salary compensation for the directors, supervisors, and managers of the company.	All members of the committee agreed to adopt	Implement according to the resolution result
2025/12/11	5th term 3th meeting	Discussion of the number of shares allocated under the Company's 2023 Employee Stock Options and, based on the achievement of key project performance targets, determination of the actual number of shares exercisable by employees under Employee Stock Option Certificate Type II	All members of the committee agreed to adopt	Implement according to the resolution result
2026/03/6	5th term 4th meeting	Discussion on Performance Bonuses for Company Executi	All members of the committee agreed to adopt	Implement according to the resolution result

II、If the board of directors does not adopt or revise the proposal of the Salary and Compensation Committee, it shall state the date, period, content of the proposal, the result of the resolution of the board of directors, and the company's handling of the opinions of the Salary and Compensation Committee (for example, the salary approved by the board of directors is better than that of the Salary and Compensation Committee. The recommendations of the Committee shall describe the differences and reasons)：None

III、For resolutions of the Salary and Compensation Committee, if members have objections or reservations and there are records or written statements, the Salary and Compensation Committee date, period, content of the proposal, all members' opinions, and the handling of members' opinions

should be stated: None

IV、Regular salary review: The function of the company's Salary and Compensation Committee is to evaluate the company's directors and managers' salary policies and systems in a professional and objective position, and hold meetings at least twice a year, and may hold meetings at any time as needed , to make recommendations to the board of directors for reference in its decision-making,

1. Responsibilities of the Salary and Compensation Committee of the company
   (1) Formulate and regularly review the policies, systems, standards and structure of the company's directors, supervisors and managers' performance and salary remuneration.
   (2) Regularly evaluate the remuneration of the company's directors, supervisors and managers.
2. When the Salary and Compensation Committee performs its duties, it shall follow the following standards
   (1) The performance evaluation and remuneration of directors, supervisors and managers should refer to the normal payment situation of the industry, and consider the rationality of the relationship with individual performance, company operating performance and future risks.
   (2) Directors and managers should not be guided to engage in behaviors that exceed the company's risk appetite in pursuit of compensation.
   (3) The ratio of dividends for short-term performance of directors and senior managers and the timing of payment of partial variable remuneration should be determined by taking into account the characteristics of the industry and the nature of the company's business.

(V) Promoting the Implementation Status of Sustainable Development and Differences and Reasons between it and the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies

Promote the project	Execution situation			Deviation from the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies and reasons thereof
	Yes	No	Summary description	
I、Has the company established a governance structure for promoting sustainable development, set up a dedicated unit for promoting sustainable development, and authorized the senior management to handle it under the supervision of the board of directors?	✓		The company has the CEO's office as the unit responsible for promoting sustainable development. Cross-departmental work meetings are held Irregularly to gather and collate information from various departments. The Chairman, Mr. Kuo-Lung Huang, continues to oversee the situation of sustainable development. The annual relevant implementation results be disclosured in the ESG report and submitted to the board every year. The board approved the ESG report for year 2024 on August 19, 2025.	No major differences yet
II、Does the company assess the risks	✓		The company has conducted assessments of material issues based on the principle of materiality. As a holding	No major differences

related to environmental, social and governance issues that are relevant to its operations based on the principle of materiality, and establish relevant risk management policies or strategies?			company, the main information disclosed for relevant operations includes the business activities of its subsidiary, TaiGen Biotechnology Co., Ltd. in Taiwan and TaiGen Biopharmaceuticals Co.(Beijing),Ltd. in China, which are mainly involved in clinical and regulatory-related operations. The company has strict internal control systems for each material issue and the audit department regularly and irregularly checks and reports to the board of directors." The company categorizes the related risks of sustainable issues into the following 6 items.： 1. Financial risk Risks related to management and operational activities, including interest rate risks, exchange rate risks, and inflationary factors ☞ Countermeasures Identify, evaluate and mitigate market uncertainties to reduce the potential adverse impact of market changes on the company's financial performance. ● Interest Rate Risk ＊The company maintains good long-term relationships with banks and obtains reasonable bank financing amounts and interest rate conditions, but there is currently no need to use them. ＊Constantly monitor interest rate changes, comprehensively evaluate the available funding sources and their cost-benefit, and secure funding with optimal efficiency. ● Currency risk ＊Closely monitor exchange rate fluctuations and purchase foreign currency deposits when exchange rates are favorable, to pay for foreign currency expenses. ＊When signing authorization contracts, try to set favorable exchange rate conditions for the group, allocate funds in the same currency as expense payments to avoid exchange rate risks. ● Inflation ＊Maintaining good interactions with suppliers and monitoring market price fluctuations. ● Capital risk ＊The financial policy adheres to the principle of conservatism, avoiding high-risk, highly leveraged investments, and derivatives trading activities. ＊The company has established "Procedures for Acquisition or Disposal of Assets", "Procedures for Endorsement & Guarantee", "Procedures for Financial Derivatives Transactions", and "Procedures for Lending Funds to Other Parties" and follows legal requirements for public disclosure and filing.	yet

			2. R & D risk Risk of drugs not being able to pass clinical trials or successfully obtain new drug approval due to safety or efficacy concerns. ☞ Countermeasures ● Pooling resources to find the most suitable academic or medical experts for collaboration. ● Develop a comprehensive new drug R&D team by attracting and training relevant personnel, including experts in design, synthesis, pharmacology, pharmacokinetics, pharmacochemistry, toxicology, and other technical fields, as well as cross-disciplinary experts in patent, regulation, and market, to integrate various resources and collaborate with the best suitable academic or medical specialists.	
			3. Market industry risk Innovations in biotechnology, changes in industry trends, and market competition from the development of similar drugs can all potentially impact the terms and conditions of external licensing negotiations. ● Closely monitor the R&D activities of competitors who are developing similar drugs to take timely measures in response. ● Regularly assess industry research trends and own R&D strategies, invite experts for discussions and meetings to keep track of drug development trends, and adjust R&D plans accordingly. ● After completing the proof-of-concept trial for the new drug, it will be authorized to an international pharmaceutical company to accelerate subsequent clinical trials, drug registration, and market launch. ● Accelerate the market launch of new drugs in Mainland China and across the Taiwan Strait using the established 1.1 class new drug research and development platform and expand the market value of new drugs by combining external professional sales teams.	
			4. Supply chain risk The risk that the supplier cannot provide raw materials or services, resulting in the company being unable to provide customers with products or services. ● There are long-term contract specifications with manufacturers. ● Continue to expand overseas authorization to reduce the risk of concentrated sales.	
			5. Compliance Risk Risks of legal compliance, integrity management and intellectual property rights management ●There are《Best Practice Principles of Corporate Governance》、《Procedures for Ethical	

			Management and Guidelines for Conduct》、《Code of Ethics》、《Rules for Internal Material Information and Prevention of Insider Trading》 ● Established internal control and internal audit management system and internal audit personnel appointment and dismissal measures ● Business ethics and integrity management standards in the commercialization stage from research and development to clinical trials must comply with relevant external regulations. ●There are《Intellectual Property Management Policy》and《Intellectual Property Management Policy》	
			6. Information Security Risk Risks of network attacks and information leakage which could impact the protection of intellectual property and customer information, resulting in serious financial losses and legal issues ● Strengthen multi-layered information security protection for both software and hardware, including complex password authentication, anti-virus for hosts and clients, internet behavior management, protection against malicious websites, firewall blocking, host data backup, encryption, etc. to ensure information security and establish clear and strict internal control systems.	
III、Environmental issues （I）Has the company established an appropriate environmental management system in accordance with its industrial characteristics？	✓		The company formulated the "Safety and Health Management Operation Measures" to ensure the implementation of personnel and environmental management Due to the characteristics of the biotech industry in the development of new drugs, the research and development process must involve experimentation using live animals, cell lines, bacteria, viruses, and other infectious materials. The Biological Safety Committee was established in 2008 to regularly carry out related environmental tests. Waste disposal is coordinated with external professional contractors for weekly regular collection. Toxic chemicals and precursor chemicals are listed and reported to the competent authority on a regular basis to maintain a safe working environment.	No major differences yet
（II）Is the company committed to improving energy efficiency and using renewable materials that have a lower impact on the environment？	✓		The Company is committed to enhancing resource utilization efficiency to minimize our environmental impact. To implement energy-saving and carbon reduction measures, we are progressively replacing energy-intensive fluorescent lighting and improving the control of air conditioning temperatures, operating hours, and boiler schedules. Furthermore, we are optimizing and consolidating office spaces to reduce the consumption of electricity and fuel oil.	No major differences yet
（III）Has the company assessed the potential risks and opportunities posed by climate change to	✓		The potential risks and increased operational costs posed by climate change have prompted the company to consider and adopt measures to reduce cost. Starting from the aspect of electricity conservation, dedicated to reducing energy consumption and waste reduction measures.	No major differences yet

<table>
<tr><td>the business both now and in the future, and taken appropriate response measures？</td><td></td><td></td><td></td><td></td></tr>
<tr><td>（IV）Has the company kept track of its greenhouse gas emissions, water usage and total waste weight in the past two years, and set policies for reducing greenhouse gas emissions, reducing water usage, or managing other waste?</td><td>✓</td><td></td><td>1. Greenhouse gases
The company mainly surveys three types of greenhouse gases: carbon dioxide (CO2), methane (CH4), and nitrous oxide (N2O). Changing past electricity consumption habits by promoting various energy-saving and carbon-reduction activities and measures, the company effectively manages energy efficiency and continuously implements and improves it.
The data listed in the table are all collected from the self-inquiry and have not been verified by the third party：<table><tr><th>Item</th><th>2025</th><th>2024</th></tr><tr><td>Category I (ton CO_2e)</td><td>31.061</td><td>31.7921</td></tr><tr><td>Category II (ton CO_2e)</td><td>474.5999</td><td>777.2847</td></tr><tr><td>Category III (ton CO_2e)</td><td>164.502</td><td>492.4821</td></tr><tr><td>total emissions</td><td>670.1629</td><td>769.4</td></tr><tr><td>carbon intensity(tons CO_2e /m2)</td><td>2.5828</td><td>0.1157</td></tr></table>
2. Water consumption
Our company's water usage is entirely from Taiwan Water Corporation and does not have any impact on the water source. Additionally, our company does not have any production factories and therefore does not require a large amount of water resources. The water fee is included in the building management fee, so the water usage cannot be calculated
3.Waste
The company is committed to environmental conservation and entrusts all waste, whether hazardous or non-hazardous, to legally registered haulers or final disposal companies for off-site handling. The total waste in 2023 was 7.20 tons, and in 2024 it was 9.19 tons.</td><td>No major differences yet</td></tr>
<tr><td>IV、Social issues
（I）Does the company have management policies and procedures in place in accordance with relevant laws and regulations and international human rights conventions?</td><td>✓</td><td></td><td>Our company follows internationally recognized human rights standards such as the International Covenant on Civil and Political Rights, the International Labor Organization's Core Labor Standards, and the United Nations Global Compact's Ten Principles, and has established policies for the dignified treatment and respect of employees. These policies have been made available on our company's official website.</td><td>No major differences yet</td></tr>
<tr><td>（II）Does the company have reasonable</td><td>✓</td><td></td><td>The company cares about the well-being and mental health of its employees, plans multiple employee</td><td>No major differences</td></tr>
</table>

employee benefits in place (including salary, vacation, and other benefits), and are their performance or results reflected appropriately in their pay？			welfare activities, and enhances job satisfaction. In addition to handling the regulations stipulated by the Labor Standards Act, group insurance and health checks are also provided. The employee welfare committee is responsible for planning, promoting, and implementing various welfare activities, while the company's performance is also reflected in the employees' salaries.	yet
（III）The company is concerned about providing employees with a safe and healthy working environment and conducts regular safety and health education for employees？	✓		In addition to providing a safe and healthy working environment for our employees, our company has also established the "Safety and Health Management Procedures" and is responsible for the following matters.： 1. Hold regular employee health checks 2.Irregularly hold a series of lectures on employee health care 3. Support the government's smoke-free workplace policy 4. Insure employees for accident and medical insurance to increase employee protection 5. Special workplace health services with medical clinics The company irregularly promote occupational safety and health knowledge and slogans, carry out daily self-inspections, and improve and prevent hazards and risks. At the same time, it plans and reviews various risk prevention plans each year to reduce the frequency of occupational accidents.	No major differences yet
（IV）Does the company establish an effective career development training plan for employees? ？	✓		To enhance employees' professional capabilities and managerial competencies, while supporting the Company’s operational goals and sustainable development, our Employee Training and Development Plan covers the following areas: 1.New Hire Orientation 2.Professional On-the-Job Training (OJT) 3.Management Competency Training 4.Statutory Environment, Health, and Safety (EHS) Training In 2025, various training sessions were conducted according to the development plan. For management training, courses were designed based on the competency development of mid-to-senior level executives, totaling 4 participants and 27 hours to improve operational performance. Professional training, encompassing both internal and external programs, recorded 25 participants and 200 hours, leveraging diverse learning methods to bolster employees' expertise and practical skills. The Company provides paid training leave and tuition subsidies to encourage active participation and ensure the effective utilization of resources. We remain committed to strengthening employee expertise and leadership, integrating training outcomes into annual performance appraisals and career development	No major differences yet

			planning. This demonstrates our commitment to continuous education and the long-term growth of our workforce.	
（V）Regarding issues of customer health and safety, customer privacy, marketing and labeling for products and services, does the company comply with relevant laws and regulations and international standards, and formulate policies and complaint procedures to protect the rights and interests of consumers or customers？	✓		The company cooperates with suppliers who have been checked and approved by the national drug certification unit to ensure compliance with environmental protection, safety, and health regulations. The packaging and brochures of Taigexyn® and 太甘澄, the dietary supplement products, sold in Taiwan comply with relevant laws and regulations in the R.O.C. We established th policy to protect the rights and interests of consumers or other stakeholders, and have product liability insurance to prevent direct or indirect harm to the rights and interests, health, and safety of consumers or other stakeholders from products or services.	No major differences yet
（VI）Does the company have a supplier management policy that requires suppliers to comply with relevant regulations in areas such as the environment, occupational health and safety, and workers' rights, and their implementation status?	✓		The company has established a supplier management policy and strictly adheres to labor policies related to the Labor Standards Act. The company actively implements these policies and is committed to enhancing corporate social responsibility.	No major differences yet
V、Does the company refer to internationally recognized reporting guidelines or guidelines to prepare sustainability reports and other reports disclosing non-financial information? Have the previous sustainability reports obtained a positive		✓	The company’s ESG report for year 2024 has approved by the board on August 6, 2025 and disclosed it publicly afterwards. The report was compiled in accordance with the Global Reporting Initiative (GRI Standards) and the Sustainability Accounting Standards Board (SASB), however, at this stage, it has not yet undergone verification or assurance by a third-party verification unit。	The company will conduct third-party verification based on circumstances in the future.

assurance or assurance opinion from a third-party verification unit?				
VI、If the company has its own sustainable development principles based on the "Sustainable Development and Differences and Reasons between it and the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies", please explain the differences in its operation compared to the established principles.：The company has not yet established its own sustainable development principles, but its operations follow the company's articles of corporation and relevant laws and regulations in terms of corporate governance, which encompasses the main governance principles.				
VII、Other important information that helps understand the implementation of sustainable development： (I) The company is primarily a pharmaceutical R&D company and belongs to the medical biotech industry. The company is committed to implementing environmental protection work and actively promotes energy saving and carbon reduction measures to its employees. (II) At present, the waste generated by the research and development of the company's laboratory is in accordance with laws and regulations and entrusted to a professional waste disposal organization to ensure the safety, sanitation and environmental protection of internal employees and the external environment. (III)The company has established safety and health management measures to ensure the health and safety of employees.				

(VI) implementation status of climate-related information

Item	Implementation situation
1. Describe the board of directors' and management's oversight and governance of climate-related risks and opportunities	In response to the high uncertainty of climate change and the rapid shifts in policies and markets, and to effectively monitor and estimate the potential impacts of climate change, the company's management team, along with senior executives from each department, will identify significant climate risks and opportunities. They will also further assess risks related to flooding, droughts, typhoons, and high temperatures. This approach aims to comprehensively consider the overall operational strategy and planning. Depending on the nature of the planning content, relevant matters will be included in the board reports and resolutions.
2. Describe how the identified climate risks and opportunities affect the company's operations, strategy, and finances (short-term, medium-term, long-term)	The consolidated company defines short-term as within 3 years, mid-term as 3 to 5 years, and long-term as over 5 years, and evaluates the potential operational and financial impacts of related climate risks and opportunities. Short-term climate risks focus on the impact of extreme weather on product transportation. Mid-term climate risks are related to the profit impacts from measures such as carbon pricing. Long-term climate risks are centered on the increased costs associated with aligning with

	national net-zero emission measures. Regarding opportunities, the company emphasizes actively utilizing the loans and subsidies obtained through the promotion of low-carbon technology transformation to address past deficiencies.
3. Describe the financial impact of extreme climate events and transition actions."	To mitigate the impact of extreme weather on product transportation, which may increase shipping costs or disrupt raw material supply, the consolidated company will actively review supply chain security and explore the possibility of establishing a secondary supply chain. By implementing energy-saving and carbon-reduction projects, the consolidated company aims to minimize the impact on the climate by reducing energy consumption, water usage, and waste in operations and the supply chain. Specific measures, such as reducing air conditioning usage, will be taken to decrease energy consumption and support the transformation efforts. However, these projects will require capital investment from the company and may slightly increase operational costs.
4. Describe how the processes of identifying, assessing, and managing climate risks are integrated into the overall risk management system	Each department is responsible for developing response strategies, integrating, and managing risks that may impact operations and profitability. Regular reports are submitted to the management team, which oversees and tracks the implementation of risk management activities to strengthen the overall resilience of the company.
5. If scenario analysis is used to assess resilience to climate change risks, it should describe the scenarios used, parameters, assumptions, analysis factors, and main financial impacts.	Not applicable
6. If there is a transition plan for managing climate-related risks, describe the content of the plan, and the indicators and targets used to identify and manage physical risks and transition risks	In order to achieve net-zero emissions, the consolidated company has developed a low-carbon transformation plan that will focus on reducing emissions from direct operational activities (Scope 1), indirect emissions from energy use (Scope 2), and indirect emissions from the value chain (Scope 3). The implementation plan includes the following actions: 1. Actively eliminate excess refrigeration equipment and prioritize the purchase of environmentally friendly refrigerant products. 2. Accelerate the replacement of

	energy-efficient lighting and electrical appliances, while continuously optimizing the use of air conditioning and lighting. 3. Design a reasonable and low-carbon business travel mechanism to reduce the total carbon emissions from travel. 4. By optimizing and consolidating office spaces to reduce the use of air conditioning and electricity, the Company has achieved tangible results in reducing both fugitive emission sources and indirect greenhouse gas emissions.
7. If internal carbon pricing is used as a planning tool, the basis for setting the price should be described."	Not applicable
8. "If climate-related targets are set, the description should include the activities covered, the scopes of greenhouse gas emissions, the planning period, and annual progress towards achievement. If carbon offsets or Renewable Energy Certificates (RECs) are used to meet these targets, the source and amount of the carbon reduction or the number of RECs should be detailed	Please refer to Section 1-2
9. Greenhouse gas inventory and assurance status, along with reduction targets, strategies, and specific action plans (to be filled in Sections 1-1 and 1-2).	Please refer to Section 1-1 and 1-2

1-1 Recent Two-Year Company Greenhouse Gas Inventory and Confirmation Status 1-1-1 Greenhouse Gas Inventory Information

Describe the greenhouse gas emissions (in metric tons CO2e), intensity (metric tons CO2e per million dollars), and scope of data coverage for the past two years.

Item / Year	2025	2024	20
Scope 1(tons CO_2e)	31.061	31.7921	31.
Scope 2(tons CO_2e)	474.5599	777.2847	777.
Scope 3(tons CO_2e)	164.502	492.4821	492.
Total Release Volume	670.1229	1301.5589	1301
Release Carbon Density (tons CO_2e/million (NTD))	2.5826	0.1157	0.1

The consolidated company follows the guidelines of CNS14064-1:2021 to account for seven major greenhouse gases: carbon dioxide (CO2), methane (CH4), nitrous oxide (N2O), hydrofluorocarbons (HFCs), perfluorocarbons (PFCs), sulfur hexafluoride (SF6), and nitrogen trifluoride (NF3). The data in the table are based on self-reported inventories and have not been verified by a third party. For the year 2024, due to the consolidation of subsidiary companies, gases such as hydrofluorocarbons are now included in the inventory scope, and the company has voluntarily disclosed Scope 3 greenhouse gas emissions. Therefore, compared to 2023, when only CO2, CH4, and N2O were accounted for and Scope 3 emissions were not disclosed, the total greenhouse gas emissions have significantly increased. The company has set 2024 as the baseline year and established greenhouse gas reduction targets.

Note 1: Direct emissions (Scope 1, emissions directly from sources owned or controlled by the company), energy indirect emissions (Scope 2, emissions from purchased electricity, heat, or steam), and other indirect emissions (Scope 3, emissions from company activities not included in Scope 2 but from sources owned or controlled by other companies).

Note 2: The scope of data coverage for direct emissions and energy indirect emissions shall comply with the schedule set forth in Article 10, Paragraph 2 of these regulations, while information on other indirect emissions may be voluntarily disclosed.

Note 3: Greenhouse gas inventory standards: Greenhouse Gas Protocol (GHG Protocol) or ISO 14064-1 published by the International Organization for Standardization (ISO).

Note 4: The intensity of greenhouse gas emissions may be calculated per unit of product/service or revenue, but data calculated based on revenue (in millions of New Taiwan Dollars) should be disclosed at least.

1-1-2 Greenhouse Gas Assurance Information

Provide an explanation of the assurance status for the most recent two fiscal years up to the printing date of the annual report, including the scope of assurance, assurance provider, assurance criteria, and assurance opinion
Not applicable

1-2 Greenhouse Gas Reduction Targets, Strategies, and Specific Action Plans

Outline the baseline year and data for greenhouse gas reduction, reduction targets, strategies, specific action plans, and the achievement of reduction targets
In order to integrate carbon management into the business strategy, the consolidated company has designated 2024 as the baseline year and set a greenhouse gas reduction management goal to reduce total emissions by more than 1‰ within three years, starting from 2025. This aims to achieve higher carbon reduction results. The specific measures for implementation are as follows: 1. Regarding fugitive emissions: Consolidated company will review the use of refrigerants in various devices and carry out reasonable disposal operations to reduce greenhouse gas emissions caused by refrigerant leaks. 2. Regarding indirect emissions (Scope 2): Consolidated company will continue to replace lighting with energy-efficient options and and optimize office space utilization. These efforts aim to eliminate unnecessary lighting, conserve electricity, and reduce indirect greenhouse gas emissions. 3. Regarding indirect emissions (Scope 3): Consolidated company will also incorporate carbon emissions into the cost-benefit analysis of business trip policies, aiming to strike a balance between revenue generation and carbon emissions reduction. 4. Total greenhouse gas emissions in 2025 decreased by 48.51% compared to 2024.

Note 1: Compliance should be carried out according to the schedule specified in Article 10, Paragraph 2 of these regulations.

Note 2: The baseline year should be the year in which the greenhouse gas inventory is completed within the boundary of the merged financial reports. For example, according to the provisions specified in Article 10, Paragraph 2 of these regulations, companies with a capital of over 10 billion NT dollars should complete the inventory of the merged financial reports for the year 2024 in the year 2025. Hence, the baseline year is 2024. If the company has completed the inventory of merged

financial reports earlier, the earlier year may be used as the baseline year. Additionally, the data for the baseline year may be calculated as a single-year value or as an average over several years.

Note 3: The disclosure content can refer to the best practice examples on the Corporate Governance Center website of the Taiwan Stock Exchange.

(VII) The situation of fulfillment of integrity management and the reasons and situations of differences with Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies.

Evaluation items	Operating situation			The reasons and situations of differences with Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies
	Yes	No	Summary description	
I、Formulate integrity management policies and plans				Compliant
(I) Whether the company has formulated a policy of integrity management approved by the board of directors, and clearly stated the policy and practices of integrity management in regulations and external documents, as well as the commitment of the board of directors and senior management to actively implement the operation policy ?	✓		(I)The company has 「Procedures for Ethical Management and Guidelines for Conduct」, The directors, supervisors, managers and employees of the company actively implement this policy of integrity management.	
(II) Does the company establish an evaluation mechanism for assessing the risk of unethical behavior, regularly analyze and evaluate business activities with higher risk of unethical behavior within its business scope, and formulate measures to prevent unethical behavior based on the analysis, at least covering the prevention measures of the behaviors specified in Article 7, Section 2, of the "Ethical Corporate Management Best Practice	✓		(II) Our company has a " Procedures for Ethical Management and Guidelines for Conduct " which governs all related regulations. To mitigate the risk of unethical conduct, our company has established the "Ethical Business Operations Procedures and Code of Conduct" as a behavioral guideline for directors, independent directors, senior executives, and all employees. This includes regulations addressing various forms of unethical behavior and corresponding preventive measures as stipulated in Article 7, Paragraph 2 of the "Code of Ethical Business Operations for Listed Companies."	

Evaluation items	Operating situation			The reasons and situations of differences with Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies
	Yes	No	Summary description	
Principles for TWSE/GTSM Listed Companies"?				
(III) Does the company's plan to prevent unethical behavior include clearly defined procedures, guidelines for behavior, sanctions for violations, and a complaint system, and is it implemented and regularly reviewed and revised?	✓		(III) Our company has clearly defined the scope of unethical conduct and the corresponding disciplinary system within the "Ethical Business Operations Procedures and Code of Conduct" and has established a dedicated unit to oversee and prevent such conduct.	
II、Implement integrity management				Compliant
(I) Whether the company evaluates the integrity record of the counterparty, and clearly stipulates the integrity behavior clause in the contract signed with the counterparty？	✓		(I) The company assesses the legality of the counterpart before establishing business relations, and checks for records of unethical behavior, in order to ensure that their business operations are fair, transparent, and free from bribery. The contracts signed with customers also include provisions for compliance with the ethical business policy, and the right to terminate or terminate the contract at any time if the counterpart engages in unethical behavior	
(II) Has the company set up a unit responsible for promoting ethical business operations that is subordinate to the board of directors, and regularly (at least once a year) report its policies on ethical business operations and measures to prevent unethical behavior, as well as the implementation situation, to the board of directors?	✓		(II)To promote ethical business practices, the company will conduct internal audits (at least once a year) by the internal audit unit to report any violations of this policy to the board of directors. The Administrative Division promote the education of all employees in 2025. They compiled the ethical business practices and internal guidelines for handling important information, and educate employees on relevant considerations during the course of their work	
(III) Has the company			(III) The director of the company should	

Evaluation items	Operating situation			The reasons and situations of differences with Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies
	Yes	No	Summary description	
established a policy to prevent conflicts of interest and provided appropriate disclosure channels, and implemented it effectively ?	✓		maintain high self-discipline and should not participate in discussion and voting on resolutions of the board of directors if there is a conflict of interest with the company or its representative legal person that is harmful to the interests of the company. In such cases, the director should recuse themselves during discussion and voting.	
(IV) Does the company have effective accounting and internal control systems in place for the purpose of implementing honest business practices and has the internal audit unit formulated audit plans based on the assessment of risks of unethical behavior and conducted audits or commissioned accountants to carry out the audits to ensure the compliance of the plans to prevent unethical behavior? ?	✓		(IV) To ensure the implementation of ethical business practices, the company has established effective internal control systems, relevant management regulations and accounting systems, as well as an auditing unit to periodically review compliance by various units within the company.	
(V) Does the company regularly conduct internal and external training on ethical business practices?	✓		(V)The company has established "Ethical Business Operations Procedures and Code of Conduct" and regularly holds related training once a year	
III、The operation of the company whistleblowing system				Compliant
(I) Whether the company has established a specific whistleblowing and reward system, established channels to facilitate whistleblowing, and assigned appropriate specialists for handling whistleblowers ?	✓		(I) The company has whistleblowing mailboxes and Tel, and a dedicated unit handles whistleblowing incidents.	
(II) Whether the company has formulated standard	✓		(II) The relevant personnel of the company handling the whistleblowing situation	

Evaluation items	Operating situation			The reasons and situations of differences with Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies
	Yes	No	Summary description	
operating procedures for the investigation of whistleblowing matter, the follow-up measures to be taken after the investigation is completed, and related confidentiality mechanisms？			all make a written statement to keep the identity of the whistleblower and the content of the whistleblower confidential.	
(III) Does the company take measures to protect whistleblowers from being improperly dealt with due to whistleblowing?	✓		(III) The company keeps full confidentiality and protection for the whistleblower, and strictly prohibits any form of improper treatment of the whistleblower.	
IV 、Strengthening information disclosure (I) Does the company disclose the content and effectiveness of its established code of ethics and integrity on its website and Market Observation Post System	✓		(I) In addition to disclosing it on the company website, the company also discloses it in the annual report of the company's shareholders' meeting and public prospectus.	Compliant
V、Please specify if the company has its own code of conduct in accordance with the "Ethical Corporate Management Best Practice Principles for TWSE/GTSM Listed Companies" and describe any differences in its operation and the established code of conduct.：The company has established "Ethical Business Operations Procedures and Code of Conduct" and the company's directors, supervisors, managers, and employees actively implement this policy of ethical management.				
VI、Other important information that helps to understand the company's honest business operation (such as the company's review and correction of its established integrity business rules, etc.)： (I)The company's 'Board of Directors Meeting Rules' includes a system for avoiding conflicts of interest by directors. In regards to the agenda items listed by the board of directors, if they have a conflict of interest with their own or their representative legal entities that could harm the interests of the company, they may state their opinions and answer questions, but may not participate in discussions and voting, and must avoid participating during discussions and voting, and may not act as proxies for other directors in exercising their voting rights. (II)Education and training for directors, executives, and employees are held to fully understand the company's commitment to ethical management practices and the consequences of unethical behavior. The policy of honest business practices is combined with employee performance evaluations and a reward and punishment system is established.				

(VIII) Important information that is sufficient to enhance understanding of the company's

governance and operation situation must also be disclosed.

1. Director training situation for the 2025 fiscal year

Title	Name	Date		Course Name	Hour	Exam Administrator
		From	To			
Institutional director Representative	Kuo-Lung Huang	2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative AI Applications and Risk Management	3	Taiwan Corporate Governance Association
Institutional director Representative	Weng-Foun g Huang	2025/8/22	2025/8/22	2025 Taishin Shin Kong Net-Zero Summit Forum	3	Chinese National Association of Industry and Commerce
		2025/11/17	2025/11/17	The New Role of Environmental Economics – Corporate TCFD/TNFD and Biodiversity & Nature-Related Financial Disclosures	3	Chinese Corporate Governance Association
		2025/11/17	2025/11/17	The Corporate AI Brain – Navigation and Mapping in the Age of AI	3	Chinese Corporate Governance Association
		2025/12/18	2025/12/18	Taiwan in a Rapidly Changing World	3	Importers and Exporters Association of Taipei
		2025/12/18	2025/12/18	Challenges and Opportunities of Sustainability Risks in the Biopharmaceutical Industry	3	Importers and Exporters Association of Taipei
Institutional director Representative	Hong-Jen Chang	2025/3/13	2025/3/13	The Great Wafer War of the Century: Key Technologies and Business Opportunities Behind TSMC's Global Leadership	3	Securities & Futures Institute
		2025/3/25	2025/3/25	Industry Analysis and Corporate Diagnosis	3	International Project Management Association
Institutional director Representative	Peter Wu	2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/12/16	2025/12/16	Dual-Track Transformation for Strengthening Organizational Resilience – AI Governance and Sustainability Governance	3	Chinese Corporate Governance Association
Institutional director Representative	Hsun-Yuan Tsou	2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative AI	3	Taiwan

				Applications and Risk Management		Corporate Governance Association
Institutional director Representative	I-Jen Huang	2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative AI Applications and Risk Management	3	Taiwan Corporate Governance Association
Independent director	Mei-Li Su	2025/6/19	2025/6/19	Practical Case Analysis of Short-Term Trading and Insider Trading	3	Taiwan Corporate Governance Association
		2025/8/12	2025/8/12	The Next Evolution of Artificial Intelligence: How ChatGPT is Transforming Industry Trends	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
Independent director	Chen-Wu, Chang	2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative AI Applications and Risk Management	3	Taiwan Corporate Governance Association
Independent director	Eric, Yi-Chun Huang	2025/12/16	2025/12/16	Stablecoin “Legalization”: Triggering Global Currency Competition	3	The Greater China Financial Development Association

2. Manager training situation for the 2025 fiscal year

Title	Name	Date		Course Name	Hour	Exam Administrator
		From	To			
Chairman	Kuo-Lung Huang	2025/11/18	2025/11/18	Analysis of Mergers and Acquisitions Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative Applications of AI and Risk Management	3	Taiwan Corporate Governance Association
The head of Corporate Governance	Richard Lu	2025/11/17	2025/11/17	The New Role of Environmental Economics – Corporate TCFD/TNFD and Biodiversity & Nature-Related Financial Disclosures	3	Taiwan Corporate Governance Association

Title	Name	Date		Course Name	Hour	Exam Administrator
		From	To			
		2025/11/17	2025/11/17	Corporate AI Brain: Strategic Navigation and Mapping in the AI Era	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Analysis of M&A Trends in the Biotechnology Industry	3	Taiwan Corporate Governance Association
		2025/11/18	2025/11/18	Technology Trends – Innovative AI Applications and Risk Management	3	Taiwan Corporate Governance Association

(IX) Implementation of the internal control system

1. The Company's 2025 Internal Control Statement was disclosured on the Market Observation Post System (https://mops.twse.com.tw/mops/#/web/home) on March 17, 2026 and can be found on the above website.

2.If CPA Was Engaged to Conduct a Special Audit of Internal Control System, Provide Its Audit Report：None.

(X) Important resolutions of the shareholders' meeting and the board of directors in the latest year and as of the date of publication of the annual report.

1. Important Resolutions of the Board of Directors：

Date	Summary of Important Resolutions	Matters listed in §14-3 or §14-5 of the Securities and Exchange Act	Independent director's opinions and the company's handling of opinions	Results of Audit Committee Resolutions
2025/3/4	1. Approve the declaration of the internal control system for the fiscal year 2024 of the company. 2. Approve the 2024 financial statements and business report of the Company and Taigen Taiwan, and authorize the Company’s representatives on the boards of subsidiaries to approve their respective 2024 financial statements and business reports. 3. Acknowledge the 2024 profit distribution plan of the Company, and authorize the boards of Taigen Taiwan and its subsidiaries to acknowledge their 2024 loss appropriation plans. 4. Approve the amendment to certain provisions of the Company’s Articles of Incorporation. 5. Approve the evaluation of the suitability and independence of the certifying accountant. 6. Authorize the Company’s representative on the Board of Directors of Taigen	V V V V V	passed without objection	passed without objection

	Taiwan to approve Taigen Taiwan's application for the renewal of short-term loan credit facilities with banks, and authorize Chairman Mr. Huang Kuo-Lung of Taigen Taiwan to sign all related contracts, documents, and handle all relevant matters on behalf of Taigen Taiwan. 7. Approve the election of nine directors for the 8th Board of Directors, including six directors and three independent directors, at the 2025 Annual General Shareholders' Meeting. 8. Approve the convening of the 2025 Annual General Shareholders' Meeting on May 23, 2025, and designate the period from March 25, 2025, to May 23, 2025, as the share transfer suspension period. 9. Approve the list of exercisable stock option conditions for Type I stock option certificates under the "2023 Employee Stock Option Issuance and Subscription Rules" on the first maturity date. 10. Approve the issuance of employee stock option certificates in accordance with the "2023 Employee Stock Option Issuance and Subscription Rules."	V V V		
2025/4/9	1. Review of the Nominated Board of Directors (Including Independent Directors) Candidates 2. Approval of the Company's Newly Appointed Directors and Their Representatives, Including Proposal to Lift Non-Compete Restrictions	V	passed without objection	passed without objection
2025/5/14	1. Approve the consolidated financial statements for the first quarter of 2025. 2. Approval of the Company's Amendment to the "Rules of Procedure for the Board of Directors" 3. Approval of the Company's Amendment to the "Audit Committee Charter" 4. Authorized the Company's representative on the board of TaiGen Taiwan to approve the execution of an exclusive distribution agreement.	V V V V	passed without objection	passed without objection
2025/5/23	1. Approval of the Appointment of the Company's New General Manager, and Authorization for the Company's Board Representative to Approve the Appointment of TaiGen Taiwan's General Manager 2. Approval of Adjustments to the Company Group's Organizational Structure 3. Approval of the Amendment to the Company's "Authority and Approval Matrix"	V V	passed without objection	passed without objection

	4. Appointment of TaiGen Taiwan's 10th Term Directors and Supervisor's 5. Authorization for the Company's Board Representative at TaiGen Taiwan to Approve the Waiver of Non-Compete Restrictions for Newly Appointed Directors 6. Authorization for the Company's Board Representative at TaiGen Taiwan to Approve the Reappointment of One Director to TaiGen Taiwan, and Empowerment to Approve the Reappointment of One Director to TaiGen Beijing on TaiGen Biotechnology's Board 7. Approval of the Appointment of Members of the 5th Compensation Committee 8. Approval of the Appointment of Mr. Show-Chung Ho and Dr. Ming-Chu Hsu as Senior Advisors and Advisors to the Company's Board of Directors 9. Approval of the Appointment of Members to the Company's 7th Management Committee, and Authorization for the Company's Representative on TaiGen Taiwan's Board to Appoint Members to TaiGen Taiwan's 9th Management Committee	V V		
2025/07/30	1. Approval of the Company's Election to Add One Independent Director to the 8th Term at the 2025 Extraordinary General Meeting of Shareholders 2. Approval of Amendments to Certain Articles of the Company's Articles of Incorporation 3. Approval to Convene the 2025 Extraordinary General Meeting of Shareholders on September 15, 2025, and to Set the Share Transfer Suspension Period from August 17, 2025, to September 15, 2025	V V	passed without objection	passed without objection
2025/08/19	1. Approval of the Company's Implementation of a Treasury Stock Program to Repurchase a Portion of Its Shares 2. Approval of the Addition of the "Treasury Stock Repurchase Procedures" 3. Approval to Authorize the Company's Representative on the Board of TAIJING Taiwan to Consent to the Loan of Funds from TaiGen Taiwan to TaiGen Gayman, and Authorization for the Company's Chairman, Mr. Kuo-Lung Huang, to Represent the Company, and Supervisor of TaiGen Taiwa, to Sign All Related Contracts, Documents, and Handle All	V V V	passed without objection	passed without objection

	Related Matters 4. Approve the consolidated financial statements for the second quarter of 2025 5. Approve the 2025 ESG Report. 6. Authorize the Company's representative on the Board of Directors of Taigen Taiwan to approve Taigen Taiwan's application for the renewal of short-term loan credit facilities with banks, and authorize Chairman Mr. Huang Kuo-Lung of Taigen Taiwan to sign all related contracts, documents, and handle all relevant matters on behalf of Taigen Taiwan. 7. Approval of the Board's Review of the Nominated Independent Director Candidates 8. Approval of the Proposal to Lift Non-Compete Restrictions for the Company's Independent Directors, and Submission for Resolution at the Extraordinary General Meeting of Shareholders 9. Approval of the Amendment to the Proposal Description for the Independent Director Election at the Company's 2025 Extraordinary General Meeting of Shareholders on September 15, 2025 10. Discussion on the Proposed Amendments to the Remuneration Policies for Directors, Supervisors, and Managers of the Company and Its Subsidiaries 11. Discussion on the Proposed Remuneration for the Company Chairman, Mr. Huang Kuo-Lung 12. Discussion of the proposed compensation package for the Chairman, Li-Wen Chang , of the Company.	V V V V V		
2025/10/01	1. Approval to Authorize the Company's Representative on Taigen Taiwan's Board to Consent to the Execution of the CC Tripartite Authorization Agreement, and Authorization for Taigen Taiwan's Chairman to Sign the Agreement on Behalf of Taigen Taiwan 2. Approval to Authorize the Company's Representative on Taigen Taiwan's Board to Consent to the Execution of the TG-1000 Authorization Agreement, and Authorization for Taigen Taiwan's Chairman to Sign the Agreement on Behalf of Taigen Taiwan 3. Approval to Authorize the Company's Representative on BB's Board to Consent to Grant TG-4318 the Rights	V V V	passed without objection	passed without objection

	for Research, Development, and Commercialization, and Authorization for the Chairmen of TaiGen Beijing and Taigen Taiwan to Execute the Tripartite Agreement			
	4. Approved the appointment of members to the Fifth Remuneration Committee.	V		
2025/11/13	1. Approval of the Register of Exercisable Stock Options on the First Expiration Date, in Compliance with Type II Terms under the 2023 Employee Stock Option Issuance and Exercise Guidelines	V	passed without objection	passed without objection
	2. Approval to Establish the Company's 2026 Internal Audit Plan, and Authorization for the Company's Representative on Taigen Taiwan's Board to Approve the Establishment of Taigen Taiwan's 2026 Internal Audit Plan	V		
	3. Approval of the Company's Consolidated Financial Statements for the Third Quarter of 2025	V		
	4. Approval of the Company's 2026 Operating and Capital Expenditure Budget, and Authorization for the Company's Representative on Taigen Taiwan's Board to Approve the 2026 Operating and Capital Expenditure Budgets for Taigen Taiwan and Its Subsidiaries	V		
	5. Approval to Authorize the Company's Representative on Taigen Taiwan's Board to Consent to Taigen Taiwan's Cash Capital Reduction	V		
	6. Approval for the Company to Conduct a Capital Reduction through the Cancellation of Treasury Shares, and Authorization for Chairman Mr. Kuo-Lung Huang to Handle All Related Matters	V		
	7. Approval for the Company to Conduct a Capital Reduction through the Cancellation of Reclaimed Restricted Employee Shares, and Authorization for Chairman Mr. Kuo-Lung Huang to Handle All Related Matters	V		
	8. Approval to Authorize the Company's Representatives on the Boards of Taigen Taiwan and BB to Consent to the Execution of the ISM4808 Exclusive License Agreement, and Authorization for the Chairmen of Taigen Taiwan and Taigen Beijing to Sign the Agreement	V		
	9. Approval to Authorize the Company's Representative on Taigen Taiwan's Board to Consent to the Execution of the TG-1000 License Agreement, and Authorization for AA's Chairman to Sign	V		

	the Agreement on Behalf of Taigen Taiwan 10. Authorization for the Company's Representative on Taigen Taiwan's Board to Approve the Loan of Funds from Taigen Taiwan to Taigen Beijing 11. Authorization for the Company's Representative on Taigen Taiwan's Board to Approve Taigen Taiwan's Renewal of Its Spot Foreign Exchange Trading Limit 12. Authorization for the Company's Representative on Taigen Taiwan's Board to Approve Taigen Taiwan's Application for Short-Term Loan Credit Facilities 13. Approval of the Engagement and Fee Review for the Company's, Taigen Taiwan's, and Taigen Biomedical Food's Auditors for Fiscal Years 2026–2027	V V V		
2025/12/11	1. Approval of the Register of Exercisable Stock Options on the First Expiration Date, in Compliance with Type II Terms under the 2023 Employee Stock Option Issuance and Exercise Guidelines 2. Approval to Authorize the Company's Representatives on the Boards of Taigen Taiwan and TaiGen Beijing to Consent to the Execution of the ISM4808 Exclusive License Agreement for the Greater China Region, and Authorization for the Chairmen of Taigen Taiwan and TaiGen Beijing to Sign the Agreement 3. Authorization for the Company's Representative on TaiGen Beijing's Board to Approve the Appointment of TaiGen Beijing's Chief Financial Officer	V V V	passed without objection	passed without objection
2026/01/26	1. Authorization for the Company's Representative on Taigen Taiwan's Board to Approve the Execution of the TG-1000 License Agreement with Boryung Biopharma Co.	V	passed without objection	passed without objection
2026/03/09	1. Approve the declaration of the internal control system for the fiscal year 2025 of the company. 2. Approve the 2025 financial statements and business report of the Company and Taigen Taiwan, and authorize the Company's representatives on the boards of subsidiaries to approve their respective 2025 financial statements and business reports. 3. Acknowledge the 2025 profit distribution plan of the Company, and authorize the boards of Taigen Taiwan and its subsidiaries to acknowledge their 2025 loss appropriation plans. 4. Discussion on the 2025 Employee and	V V V V	passed without objection	passed without objection

	Director Remuneration Allocation, and Authorization for the Company's Representative on Taigen Taiwan's Board to Discuss the 2025 Employee Remuneration Allocation for Taigen Taiwan			
	5. Approval of the Partial Amendments to the Company's "Procedures for Acquisition or Disposal of Assets," and Authorization for the Representatives on the Boards of Taigen Taiwan and Its Subsidiaries to Approve Corresponding Partial Amendments to Their Procedures	V		
	6. Approval of the Partial Amendments to the Company's "Procedures for Lending Funds to Others," and Authorization for the Representatives on the Boards of Taigen Taiwan and Its Subsidiaries to Approve Corresponding Partial Amendments to Their Procedures	V		
	7. Approval of the Partial Amendments to the Company's "Procedures for Endorsements and Guarantees," and Authorization for the Representatives on the Boards of Taigen Taiwan and Its Subsidiaries to Approve Corresponding Partial Amendments to Their Procedures	V		
	8. Approval of the Partial Amendments to the Company's "Procedures and Guidelines for Integrity Management"	V		
	9. Approve the amendment to certain provisions of the Company's Articles of Incorporation.	V		
	10. Approve the evaluation of the suitability and independence of the certifying accountant.			
	11. Approval to Convene the 2026 Annual General Meeting of Shareholders on May 28, 2026, and to Set the Share Transfer Suspension Period from March 30, 2026, to May 28, 2026			
	12. Authorization for the Company's Representatives on the Boards of Taigen Taiwan and Taigen Beijing to Approve the Execution of the ISM4808 Joint Development and Profit-Sharing Agreement			
	13. Approval of the Performance Bonus Proposal for the Company's Managers	V		

2. Important resolutions of the shareholders' meeting：

Date	Summary of important resolutions
2025/5/23	1. Acknowledgment of the Company's 2024 Financial Statements and Business Report. 2. Approval of the Company's 2024 Earnings Distribution Proposal. 3. Adoption of the Election of Six Directors and Three Independent Directors for the Company's Eighth Board Term 4. Approval of the Release of Non-Compete Restrictions for Newly Appointed Independent Director 5. Adoption of Partial Amendments to the Company's Articles of Incorporation
2025/09/15	1. Adoption of the By-Election to Add One Independent Director to the Company's Eighth Board Term. 2. Approval of the Release of Non-Compete Restrictions for Newly Appointed Independent Directors. 3. Adoption of Partial Amendments to the Company's Articles of Incorporation.

3. Review of the implementation status of the resolutions passed at the shareholders' meeting：

Date	Resolutions		Implementation status
2025/5/23	Acknowledgments	the financial statements and business report of our company for the year 2024.	The necessary filings and announcements have been made to the competent authority in accordance with regulations.
		the earning distribution plan of our company for the year 2024.	The resolution has been implemented
	Matters for Discussion and Election	By-election to fill one independent director position for the 8th term	On the same day, May 23, the first meeting of the 8th Board of Directors was held to elect the Chairman, appoint members of the Compensation Committee, and designate members of the Management Committee, and the list of the Audit Committee was announced
		Amendments to certain provisions of the Company's Articles of Incorporation	The resolution has been implemented
2025/9/15	Discussion and	Proposal for a by-election to add one independent director for the 8th term	The resolution has been implemented

Date	Resolutions		Implementation status
		Proposal to lift the non-competition restrictions for the newly appointed independent director	The resolution has been implemented
		Amendments to certain provisions of the Company's Articles of Incorporation	The resolution has been implemented

(XI) In the latest year and as of the date of publication of the annual report， Chairman、president，if any directors or audit committee members have expressed a dissenting opinion on any significant resolutions passed by the Board of Directors and recorded or made a written statement, the main contents of such opinions shall be provided：None.

III、Information on the professional fees of the attesting CPAs

2025 Accountant Aptitude and Independence Evaluation Form

1	Whether the appointed accountant has any direct or indirect significant financial interests with the company.	□Yes ■No
2	Whether the appointed accountant has a close business relationship or potential employment relationship with the company.	□Yes ■No
3	Has the appointed auditor acted as legal counsel for the Company or represented the Company in resolving conflicts with third parties?	□Yes ■No
4	Does the appointed accountant and his/her spouse or dependents have any financing or guarantee arrangements with the company or the directors/supervisors of the company?	□Yes ■No
5	Has the appointed accountant, his/her spouse or dependent relatives served as a director, supervisor, officer, or any positions that may have significant impact on the audit cases of the Company in the current or past two years? Will they serve in any of the above-mentioned positions during the audit period in the future?	□Yes ■No
6	Does the appointed accountant or their spouse or dependents have any family relationship with personnel who hold significant positions related to the audit cases, such as directors, supervisors, or managers, of the Company?	□Yes ■No
7	Has the appointed accountant acted as an intermediary for the issuance of stocks or other securities of the Company?	□Yes ■No
8	Does the appointed auditor provide non-audit services to the Company that may have a direct impact on the audit work?	□Yes ■No
9	Does the appointed auditor engage in any other businesses that may compromise their independence?	□Yes ■No
10	Does the appointed accountant receive any commission related to the company's business?	□Yes ■No
11	Has the appointed accountant received any significant gifts or presents (with a value exceeding normal social etiquette standards) from the company, its directors, or managers?	□Yes ■No

12	Has the appointed accountant violated any regulations that affect independence, such as the rotation of accountants, delegation of accounting duties to others, or other non-compliant events stipulated by regulatory agencies	□Yes ■No
13	Are there any other inappropriate relationships between the appointed accountant and the company beyond those mentioned above?	□Yes ■No
14	The appointed accountant should ensure that their assistants adhere to honesty, fairness, and independence.	■Yes □No

(I) Disclose the amounts of the audit fees and non-audit fees paid to the attesting certified public accountants and to the accounting firm to which they belong and to any affiliated enterprises as well as the details of non-audit services

Unit：NT$ thousand

CPA firm	Name of accountant（Note 1、2）	Audit period	Audit fee	Non-audit fee（Note 1）	Total	Remark
Deloitte & Touche	Li Hsieh-Chang Huang Hui-Min	2025/01/01 ~ 2025/12/31	2,360	390	2,750	-

Note 1：The cost of the 2025 internal control project review report was NT$ 350 thousand, and the cost of the capital reduction agreement procedure was NT$ 40 thousand.

(II) Information regarding the replacement of an accounting firm where the audit fees for the replacement year decreased from those of the previous year, thereby requiring disclosure of the reason and the audit fees before and after the replacement：N/A

(III) Information regarding auditing fees that decreased 10% or more from those of the previous year, thereby requiring disclosure of the reduction amount, percentage, and reason：N/A

IV、Information on Replacement of CPA：N/A

V、The Company’s chairman、president、manager in charge of financial or accounting affairs, who have worked in the firm of the audit accountant or its affiliated companies within the last one year, the name, title and period of employment of the audit accountant's firm or its affiliated enterprises shall be disclosed：None

VI、In the latest year and as of the date of publication of the annual report, changes in equity transfer and equity pledge of directors, supervisors, managers and shareholders with a shareholding ratio of more than 10%

(I)Changes in equity transfer and equity pledge of directors, supervisors, managers and shareholders with a shareholding ratio of more than 10%

Unit：thousand share

Title	Name	2025		2026 until March 31	
		Number of shares held increased (decreased)	Number of pledged shares increased (decreased)	Number of shares held increased (decreased)	Number of pledged shares increased (decreased)
Chairman	Kao Hsiang Investment Co., Ltd.	0	0	0	0
	Representative：Kuo-Lung Huang	(96)	0	96	0

Title	Name	2025		2026 until March 31	
		Number of shares held increased (decreased)	Number of pledged shares increased (decreased)	Number of shares held increased (decreased)	Number of pledged shares increased (decreased)
Director	YFY Investment Holding Co., Ltd. Representative：Show-Chung Ho	0 0	0 0	0 0	0 0
Director	National Development Fund, Executive Yuan Representative：Chi-Kung Ho	0 0	0 0	0 0	0 0
Director	Kao Hsiang Investment Co., Ltd. Representative：Hong-Jen Chang、Peter Wu	0 0 0	0 0 0	0 0 0	0 0 0
Director	Taiwan Sugar Corporation Representative：I-Jen Huang	0 0	0 0	(3,384) 0	0 0
Independent director	Mei-Li Su	0	0	0	0
Independent director	Eric, Yi-Chun Huang	0	0	0	0
Independent director	Chen-Wu, Chang	0	0	0	0
CEO	Kuo-Lung Huang	96	0	0	0
Finance and Administration Division Vice President	Richard Lu	(52)	0	(35)	0
Preclinical Research Division Vice President	Cheng-Yuan Tsai	15	0	0	0
Clinical Development Division Vice President	Li-Wen Chang	54	0	0	0
Accounting Department Director	Mark Kao	(0.6)	0	0	0

(II) Equity transfer information (transaction counterparty is a related person)：None

(III) Equity pledge information (transaction counterparty is a related person)：None

VII、Information about Spouses, Kinship within Second Degree, and Relationships between Any of the Top Ten Shareholders:

March 30, 2026；Unit：Share；%

NAME	Shares held by the shareholder		Share held by spouse and minor children		Total shares held in the name of others		Top 10 shareholders who among themselves, are related person or spouse, second degree relative, their name and relationship		Mark
	Shares	ratio	shares	ratio	shares	ratio	Name	relation	
National Development Fund, Executive Yuan	103,007,259	14.47	0	0	0	0	1. Yaohua 2. Taiwan Sugar	The Ministry of the Executive	

NAME	Shares held by the shareholder		Share held by spouse and minor children		Total shares held in the name of others		Top 10 shareholders who among themselves, are related person or spouse, second degree relative, their name and relationship		Mark
	Shares	ratio	shares	ratio	shares	ratio	Name	relation	
							Corporation	Yuan will have the largest share	
Representative：Chi-Kung Ho	0	0	0	0	0	0	None	None	
YFY Investment Holding Co., Ltd.	97,502,590	13.70	0	0	0	0	1. YFY Paradigm 2. Chung Hwa Pulp 3. Hsin-Yi Enterprise Co., Ltd.	1. Investing using the equity method 2. Investing using the equity method 3. Director of YFY	
Representative：Weng-Foung Huang	0	0	0	0	0	0	None	None	
Taiwan Sugar Corporation	35,911,058	5.04	0	0	0	0	1. Yaohua 2. National Development Fund, Executive Yuan	The Ministry of the Executive Yuan will have the largest share	
Representative：I-Jen Huang	0	0	0	0	0	0	None	None	
Chung Hwa Pulp Corporation	17,829,132	2.50	0	0	0	0	1. YFY 2. YFY Paradigm	Investing using the equity method	
YFY Paradigm Investment Co., Ltd.	17,654,353	2.48	0	0	0	0	1. YFY 2. Chung Hwa Pulp	Investing using the equity method	
Ming-Chu Hsu	16,624,325	2.34	0	0	0	0	None	None	
SinoPac Venture Capital Co., Ltd.	14,289,154	2.01	0	0	0	0	None	None	
Hsin-Yi Enterprise Co., Ltd.	12,993,083	1.83	0	0	0	0	YFY Investment Holding Co., Ltd.	Director of YFY	
Yaohua Glass Co., Ltd. Management Committee	9,858,529	1.38	0	0	0	0	1. National Development Fund, Executive Yuan 2. Taiwan	The Ministry of the Executive Yuan will have the largest share	

NAME	Shares held by the shareholder		Share held by spouse and minor children		Total shares held in the name of others		Top 10 shareholders who among themselves, are related person or spouse, second degree relative, their name and relationship		Mark
	Shares	ratio	shares	ratio	shares	ratio	Name	relation	
							Sugar		
Shang-ming Tzen	5,524,000	0.78	0	0	0	0	None	None	

VIII、Shares and total shareholding ratios in a business held by the Company; directors, supervisors, and managers of the Company; and businesses controlled directly or indirectly by the Company：

Unit：Share；%

Investee business（Note 1）	Company investment		Directors, supervisors, and managers of the Company and businesses directly or indirectly controlled by the Company		Comprehensive investment	
	Shares	Shareholding ratio	Shares	Shareholding ratio	Shares	Shareholding ratio
TaiGen Biotechnology Co., Ltd.	231,151	100%	-	-	231,151	100%
TaiGen Biotechnology Holdings Limited	169,000	100%	-	-	169,000	100%
TaiGen Biopharmaceuticals Co. (Beijing), Ltd.	Note 2	100%	-	-	註 2	100%
Taigen Biomedical Corporation	300	100%	-	-	300	100%

Note 1：The following list comprises the investee companies of the Company accounted for using the equity method.

Note 2：Since Taigen Beijing is a limited liability company without shares, its capital amounts to RMB 194,559 thousand and is a great-grandchild company wholly owned (100%) by the Company through indirect investment.

Chapter 4、Capital Overview

I、Capital and shares

(I) Capital sources

Our company was established in the Cayman Islands in September 2005 with 10 common shares issued at a par value of USD 0.001 per share. On April 8, 2008, the company completed a restructuring and issued new shares, with an authorized capital of USD 481,783.254, divided into 254,481,627 common shares, 143,855,000 Class A preferred shares, and 83,446,627 Class B preferred shares. The actual number of shares issued was 1,000,000 common shares, 143,855,000 Class A preferred shares, and 83,446,627 Class B preferred shares. As the preferred shares have a redemption feature, they are treated as financial liabilities in the financial statements according to accounting principles. Therefore, the issued and paid-up capital is only calculated based on the common shares, which is USD 1,000.

On January 12th, 2010, our company completed the issuance of Class C preferred shares, with an authorized capital of USD 1,122,514.16, divided into 624,624,297 common shares, 143,855,000 Class A preferred shares, 83,446,627 Class B preferred shares, and 270,588,236 Class C preferred shares. The actual number of shares issued was 1,000,000 common shares, 143,855,000 Class A preferred shares, 83,446,627 Class B preferred shares, and 235,294,117 Class C preferred shares. As the preferred shares have a redemption feature, they are treated as financial liabilities in the financial statements according to accounting principles. Therefore, the issued and paid-up capital is only calculated based on the common shares, which is USD 1,000. Restricted common shares were also issued to employees and consultants during this period, and common shares were issued in response to the exercise of employee stock options (these common shares cannot be transferred before the company's stock is listed).

On June 11, 2011, the Company's shareholders resolved to convert all preferred shares into common shares as of the conversion date of June 30, 2011. The conversion ratio was 1:1.28 for A series preferred shares, 1:1.44 for B series preferred shares, and 1:1 for C series preferred shares. During the period, common shares were issued in response to the exercise of shareholder and employee stock options (such common shares could not be transferred before the listing of the Company's stock). As of December 31, 2011, the number of outstanding shares in circulation was 571,898,234, with a capital of USD 571,898.23 (converted to NTD at the exchange rate between NTD and USD on each issuance date, the capital amounted to NTD 16,535 thousand).

On August 8, 2012, the company’s board resolved to issued 58,823,530 common shares, with a record date of September 27, 2012. The company also issued additional common shares due to the exercise of shareholder and employee stock options. In 2014, the company issued 22,000,000 new shares in a cash capital increase due to IPO, and in 2015, the company's board approved the issuance of 20,000,000 additional common shares, which were completed on February 24, 2016.

The Company resolved at the shareholders’ meeting on May 26, 2023, to issue 3,000,000 restricted employee shares, which was approved by the Financial Supervisory Commission on October 20, 2023. On December 13, 2023, the Company issued 1,000,000 restricted employee shares free of charge, with a fair value of NT$15.3 per share. On November 13, 2024, the Board of Directors resolved to cancel 2,700 restricted employee shares that had lapsed and to execute a capital reduction of US$2.7, with the capital reduction base date set for November 15, 2024. As of the publication date of the 2025 annual report, the number of outstanding shares is 717,841,475, with a share capital of US$717,841.48 (equivalent to NT$20,942 thousand).

On August 19, 2025, the Board of Directors approved a share buyback program to repurchase a portion of the Company's outstanding shares as treasury stock. The record date for the capital reduction through the retirement of treasury shares was November 14, 2025. A total of 6,007,000 shares were retired, representing a capital reduction of USD 6,007.

Prior to the capital reduction, the Company's paid-in capital amounted to USD 717,841.475 (equivalent to NT$20,941,823 thousand), with 717,841,475 shares outstanding. Following the capital reduction, the paid-in capital decreased to USD 711,834.475 (equivalent to NT$20,766,579 thousand), with 711,834,475 shares outstanding.

On November 14, 2025, the Board of Directors further resolved to cancel 900 restricted employee shares that had become void, resulting in an additional capital reduction of USD 0.9. The record date for this capital reduction was November 20, 2025.

As of the date of publication of the 2026 annual report, the number of outstanding shares was 711,833,575, and the paid-in capital was USD 711,833.575 (equivalent to NT$20,766,000 thousand).

1.Capital formation process：

Unit：Share；US dollar

Month, year	Issue price (US$)	Authorized capital		Paid-in capital		Notes		
		Shares	Amount	Shares	Amount	Capital source	Using property other than cash to offset the share capital	Other
Common shares：								
2005.9	0.001	50,000,000	US$50,000	10	US$0.01	Share capital at the time of establishment	None	
2008.1	0.001	481,783,254	US$481,783.254	999,990	US$999.99	(Note1)	None	
2009.3	0.001	1,122,514,160	US$1,122,514.16	10,321,775	US$10,321.775	Issue of restricted common stock	None	
preferred shares：								
2008.1~4	0.308	143,855,000	US$143,855	143,855,000	(Note 1)	Organizational reorganization and issuance of Series A special shares	A total of 11,550 thousand shares including technical price	
2008.1~4	0.462	83,446,627	US$83,446.627	83,446,627	(Note 1)	Organizational reorganization and issuance of Series B special shares	None	

Month, year	Issue price (US$)	Authorized capital		Paid-in capital		Notes		
		Shares	Amount	Shares	Amount	Capital source	Using property other than cash to offset the share capital	Other
2009.1 2009.4 2010.2	0.17	270,588,236	US$270,588.236	235,294,117	(註 2)	Organizational reorganization and issuance of Series C special shares	None	
Common shares：								
2010.2	0.001	1,122,514,160	US$1,122,514.16	7,350,000	US$7,350	Issue of restricted common stock	None	
	0.0308			586,111	US$586.111	Exercise of employee stock options		
	0.0462			1,162,500	US$1,162.5			
	0.308			9,475	US$9.475			
2010.6	0.001	1,122,514,160	US$1,122,514.16	246,474	US$246.474	Issue of restricted common stock	None	
2010.11	0.001	1,122,514,160	US$1,122,514.16	7,500,000	US$7,500	Issue of restricted common stock	None	
	0.0462			790,000	US$790	Exercise of employee stock options	None	
2011.5	0.308	1,122,514,160	US$1,122,514.16	5,400	US$5.4	Exercise of employee stock options	None	
	0.462			4,325	US$4.325			
2011.6		1,122,514,160	US$1,122,514.16	539,591,660	US$539,591.66	Special shares A, B, C are converted into common shares and new shares are issued	Including technology price amount US$14,784	
2011.7	0.017	1,122,514,160	US$1,122,514.16	200,000	US$200	Exercise of employee stock options	None	
2011.9	0.17	1,122,514,160	US$1,122,514.16	1,911,764	US$1,911.764	exercise of shareholder stock options	None	
2011.12	0.017	1,122,514,160	US$1,122,514.16	100,000	US$100	Exercise of employee stock options	None	
	0.0462			1,118,750	US$1,118.75			
2012.3	0.0462	1,122,514,160	US$1,122,514.16	67,000	US$67	Exercise of employee stock options	None	
	0.0308			150,000	US$150			
	0.17			19,500	US$19.5	exercise of shareholder stock options		
2012.5	0.017	1,122,514,160	US$1,122,514.16	175,000	US$175	Exercise of employee stock options	None	

Month, year	Issue price (US$)	Authorized capital		Paid-in capital		Notes		
		Shares	Amount	Shares	Amount	Capital source	Using property other than cash to offset the share capital	Other
	0.17			24,411	US$24.411	exercise of shareholder stock options		
2012.6	0.17	1,122,514,160	US$1,122,514.16	1,081,952	US$1,081.952	exercise of shareholder stock options	None	
2012.8	0.17	1,122,514,160	US$1,122,514.16	146,139	US$146.139	exercise of shareholder stock options	None	
2012.9	0.17	1,122,514,160	US$1,122,514.16	93,000	US$93	exercise of shareholder stock options	None	
				58,823,530	US$58,823.53	Cash capital increase to issue new shares	None	
2012.12	0.017	1,122,514,160	US$1,122,514.16	150,000	US$150	Exercise of employee stock options	None	
	0.17			25,147	US$25.147	exercise of shareholder stock options		
2013.3	0.017	1,122,514,160	US$1,122,514.16	850,000	US$850	Exercise of employee stock options	None	
	0.0462			272,500	US$272.5			
	0.17			197,500	US$197.5			
	0.308			111,200	US$111.2			
	0.462			4,985	US$4.985			
	0.17			73,968	US$73.968	exercise of shareholder stock options		
2013.5.14	0.17	1,122,514,160	US$1,122,514.16	222,500	US$222.5	Exercise of employee stock options	None	
				87,419	US$87.419	exercise of shareholder stock options		
2013.5.30	0.17	1,122,514,160	US$1,122,514.16	7,250,322	US$7,262.822	exercise of shareholder stock options	None	
	0.017			3,750,000	US$3,750	Exercise of employee stock options		
	0.0462			384,150	US$384.15			
	0.17			4,519,000	US$4,506.5			
	0.308			222,350	US$222.35			
	0.462			1,213,804	US$1,213.804			
2013.8.30	0.17	1,122,514,160	US$1,122,514.16	22,456,834	US$22,456.834	exercise of shareholder stock options	None	
2014.1.16	NT$50	1,122,514,160	US$1,122,514.16	22,000,000	US$22,000	Cash capital increase to issue new shares	None	註 4
2014.2	0.308	1,122,514,160	US$1,122,514.16	153,000	US$153	Exercise of	None	

Month, year	Issue price (US$)	Authorized capital		Paid-in capital		Notes		
		Shares	Amount	Shares	Amount	Capital source	Using property other than cash to offset the share capital	Other
	0.462			137,220	US$137.22	employee stock options		
	0.17			180,000	US$180			
2014.4.3	0.462	1,122,514,160	US$1,122,514.16	1,010	US$1.01	Exercise of employee stock options	None	
	0.17			3,750	US$3.75			
2015.7.7	0.17	1,122,514,160	US$1,122,514.16	15,000	US$15	Exercise of employee stock options	None	
2016.2.24	NT$24.01	1,122,514,160	US$1,122,514.16	20,000,000	US$20,000	Cash capital increase to issue new shares	None	註 5
2019.1.10	0.462	1,122,514,160	US$1,122,514.16	37,500	US$37.5	Exercise of employee stock options	None	
2019.10.25	0.462	1,122,514,160	US$1,122,514.16	42,500	US$42.5	Exercise of employee stock options	None	
2020.7.21	0.17	1,122,514,160	US$1,122,514.16	3,750	US$3.75	Exercise of employee stock options	None	
2023.12.13	0	1,122,514,160	US$1,122,514.16	1,000,000	US$1,000	Issued of restricted employee shares	None	
2024.11.15	0	1,122,514,160	US$1,122,514.16	(2,700)	(US$2.7)	Cancellation of restricted employee shares	None	
2025.11.20	0	1,122,514,160	US$1,122,514.16	(6,007,000)	(US$6,007)	retirement of repurchased treasury shares	None	
	0	1,122,514,160	US$1,122,514.16	(900)	(US$0.9)	Cancellation of restricted employee shares	None	
Total				711,833,575	US$711,833.58			

Note1：Our company conducted a stock swap with TaiGen Taiwan shareholders, with a 1:1 exchange ratio for both common shares and preferred shares. The stock swap was completed on April 8, 2008, with a total of 1,000,000 common shares, 143,855,000 A-series preferred shares, and 83,446,627 B-series preferred shares. Due to the redemption rights attached to the preferred shares, they are accounted for as financial liabilities rather than shareholder equity in the financial statements, in accordance with accounting principles

Note2：Due to the redemption rights attached to the C-series preferred shares, they are accounted for as financial liabilities rather than shareholder equity in the financial statements, in accordance with accounting principles.

1. Capital sources

March 30, 2026；Unit：Share

Capital source	Authorized capital		
	Issued shares	Un-issued shares	Total
Common shares	711,833,575	410,680,585	1,122,514,160

3.Information about the shelf registration: None

(II)Major shareholders：List of shareholders with a shareholding ratio of more than 5% or the top 10 shareholders

March 30, 2026

shares / Main shareholder name	Number of shares held (share)	Shareholding ratio (%)
National Development Fund, Executive Yuan	103,007,259	14.47%
YFY Investment Holding Co., Ltd.	97,502,590	13.70%
Taiwan Sugar Corporation	35,911,058	5.04%
Chung Hwa Pulp Corporation	17,829,132	2.50%
YFY Paradigm Investment Co., Ltd.	17,654,353	2.48%
Ming-Chu Hsu	16,624,325	2.34%
SinoPac Venture Capital Co., Ltd.	14,289,154	2.01%
Hsin-Yi Enterprise Co., Ltd.	12,993,083	1.83%
Yaohua Glass Co., Ltd. Management Committee	9,858,529	1.38%
Shen-ming Tzeng	5,524,000	0.77%

(III) Dividend policy and implementation status

1、Dividend Policy as set out in the Articles of Incorporation

According to Article 111 of our company's articles of association, when distributing annual profits, the company may allocate the surplus after payment of taxes, donations, and offsetting accumulated losses. The company may also set aside reserves and distribute the remaining balance as distributable profits. The distribution of profits shall be prepared by the Board of Directors based on the audited or reviewed financial statements by a certified public accountant and shall be submitted to the shareholders' meeting for approval. The distribution ratio is as follows:

Because the Company is still at the growth stage, the dividends distribution will take into account the future and current economic overview, the Company’s then working capital requirement and financial structure, and the remaining profits for the relevant financial year and previous financial years to the Members as Dividends. No less than ten percent (10%) of the remaining profits after the reserves for the relevant financial year shall be declared and may be paid in the form of cash and/or bonus Shares, and cash Dividends shall be no less than ten percent (10%) of the total amount of cash Dividends and stock Dividends which may be subject to adjustment by taking into consideration the Company's cash flow, revenue and future operation needs.

In addition, according to Article 113 of the company's articles of association, dividends may be declared and paid out of profits of the Company, realised or unrealised, or from any reserve set aside from profits which the Board determines is no longer needed, or not in the same amount. Subject to the requirement of these Articles, Dividends may also be declared and paid out of Share Premium Account or any other fund or account which can

be authorised for this purpose in accordance with the Statute.

In response to the amendment to Article 235-1 of the R.O.C. Company Law, the distribution of dividends and bonuses is limited to shareholders, and employees are not the object of profit distribution. In line with the above regulations, the company has amended the Articles of Association on March 24, 2016, and passed the resolution of the shareholders' general meeting held on June 17, 2016.

2、Proposed Distribution of Dividend：

As our company is still in the research and development stage and requires working capital investment, there will be no dividend distribution this year. This was approved by the Board of Directors on March 9, 2026, and will be submitted to the Annual General Meeting of Shareholders on May 28, 2026 for approval.

(IV) Impact on business performance and EPS of the stock dividend distribution proposed at the 2025 shareholder meeting：N/A

(V) Remuneration of employees (including managers) and directors

1、The percentage or range of remuneration for employees (including managers) and directors as stated in the company's articles of association

According to Article 112 of the company's current articles of association,”Unless otherwise provided in the Applicable Law, where the Company makes profits before tax for the annual financial year, the Company shall allocate (1) no less than one percent (1%) of such annual profits before tax for the purpose of employees' remunerations (including employees(managers) of the Company and/or any Subsidiaries of the Company satisfying such conditions to be prescribed by the Board) (the "Employees' Remunerations"); and (2) up to two percent (2%) of such annual profits before tax for the purpose of Directors’ remunerations (the "Directors' Remunerations"). Notwithstanding the foregoing paragraph, if the Company has accumulated losses of the previous years for the annual financial year, the Company shall set aside the amount of such accumulated losses prior to the allocation of Employees(managers)' Remunerations and Directors’ Remunerations.”Besides considering the company's overall operational performance (including the achievement of important projects, occurrences of moral hazards by directors and managers or other events that negatively impact the company's image and reputation, improper internal management, personnel misconduct, and other risk events), industry future operational risks and development trends, reasonable compensation will also be based on individual performance achievement rate and contribution to the company's performance. Related performance evaluations and compensation fairness are subject to review by the Salary and Compensation Committee and the Board of Directors. The remuneration system will be periodically reviewed in accordance with the actual business situation and relevant laws and regulations to strike a balance between sustainable business operation and risk management.

2、The basis for estimating employee and director compensation, for calculating the number of shares to be distributed as employee compensation, and the accounting treatment of the discrepancy, if any, between the actual distributed amount and the estimated figure, for the current period：

If there are differences between the estimated and actual amounts for this period, the difference will be treated as an accounting estimate change and included in the income statement for the next period.

3、Distribution of compensation approved by the Board of Directors：

The Company's Board of Directors resolved on March 9, 2026, to distribute NT$ 580,209 in employee compensation for 2025. Furthermore, as the Company is in the new drug development stage and considering future funding needs, it is proposed not to allocate any compensation to directors this year.

4、The actual distribution of employee and director compensation for 2020 (including the number of shares, monetary amount, and stock price of the shares distributed) and any discrepancy between the actual distribution and the recognized employee, or director compensation, and the reason and handling thereof：No difference.

(VI)Buyback of treasury stock：

Share Repurchase Tranche	First
Date of Resolution by the Board of Directors	August 19, 2025
Purpose of Share Repurchase	Maintain corporate credit and protect shareholders' interests
Share Repurchase Period	August 22, 2025 to October 13, 2025
Share Repurchase Price Range (NT$)	6.50~13.00
Type and Number of Shares Repurchased	6,007,000 ordinary shares
Total Amount of Share Repurchase	NTD$57,301,130
Ratio of Shares Repurchased to the Planned Repurchase Quantity(%)	60.07%
Average Repurchase Price per Share	NTD$9.54
Number of Shares Cancelled	6,007,000 shares
Total Number of Shares Held by the Company	0 shares
Percentage of Total Issued Shares Held by the Company（%）	0%
Results of Share Repurchase Execution	Not Fully Executed
Reasons for Uncompleted Execution Upon Expiry of the Repurchase Period	The Company adopted a phased repurchase strategy based on share price movements and trading volume to protect shareholders' interests and maintain orderly market trading; therefore, the repurchase program was not fully executed.

II、Information on corporate bonds：None.

III、Information on Special Shares：None.

IV、Information on Global Depositary Receipts：None.

V、Issuance of employee stock warrants and stockholders stock warrants

(I) Status of employee stock options prior to their vesting period and their impact on shareholders' equity

March 31, 2026

Types of employee stock options	2023 First employee stock options		
Approval date/Total Unit	April 7, 2023 / 10,000 units		
Issue date	Style I：April 12, 2023	Style II：April 12, 2023	Style I：April 4, 2025
Units Issued	6,000 Units	3,000 Units	180 Units
Number of units still available	0	0	0
Ratio of shares granted to total outstanding shares	0.84%	0.42%	0.03%
Duration	Valid for 5 years from date of issue	Valid for 5 years from date of issue	Valid for 5 years from date of issue
Exercise	Issuance of new shares	Issuance of new shares	Issuance of new shares
Vesting schedule and quota（%）(Note 1)	Employee stock options can be exercised in accordance with the following periods and proportions from the date of commencement of the vested period： Period / Exercisable ratio After 2 full years 50% After 3 full years 25% After 4 full years 25%	Employee stock options can be exercised in accordance with the following periods and proportions from the date of commencement of the vested period： Period / Exercisable ratio After 32 full months 50% After 44 full months 25% After 56 full months 25%	Employee stock options can be exercised in accordance with the following periods and proportions from the date of commencement of the vested period： Period / Exercisable ratio After 2 full years 50% After 3 full years 25% After 4 full years 25%
Units exercised(shares)	0	0	0
Amount exercised	0	0	0
Units unexercised(units)	2,303,000	1,073,000	180,000
Exercise price for unexercised units	15.35 元	15.35 元	11.25 元
Units unexercised to total outstanding shares (%) (Note)	0.324%	0.151%	0.025%
Impact on shareholders' equity	Effect on dilution of shareholders' equity is not material.	Effect on dilution of shareholders' equity is not material.	Effect on dilution of shareholders' equity is not material.

Note: Declare the issuance of 10,000 units of employee stock options, with each unit entitling the holder to subscribe for 1,000 shares, totaling 10,000,000 shares, effective from April 7, 2023.

(II) Names of executive officers receiving warrants and names of Top 10 employees in entitlement, and status of exercise and subscription

1. The first employee stock option certificate in 2020

March 31, 2026；Share；NT$

	Title	Name	Obtain the number of subscriptions	The ratio of the number of subscriptions obtained to the total number of issued shares	Exercised				Unexercised			
					Subscription units	Subscription price	Subscription amount	The ratio of the number of subscriptions obtained to the total number of issued shares	Subscription units	Subscription price	Subscription amount	The ratio of the number of subscriptions obtained to the total number of issued shares
Mamager	Chairman & CEO	Kuo-Lung Huang	3,201,000	0.45%	-	-	-	-	3,201,000	23.55	75,383,550	0.45%
	Vice president	Richard Lu										
	Vice president	Li-Wen Chang										
	Vice president	Cheng-Yu an Tsai										
Employee	Supervisor	Chiayn Chiang	1,933,000	0.27%	-	-	-	-	1,933,000	23.55 19.1	43,266,00	0.27%
	Senior director	Jin Hong										
	Director	Tracy Wang										
	Chief Research	Patty Huang										
	Deputy supervisor	Charlie Cheng										
	Manager	Yan-Yu Liao										
	Deputy supervisor	W.C Chen										
	Researcher	Vivian Tien (Note 2)										
	Senior manager	Belen Huang										
	Director	Sandy Xie										

Note1: resigned on 2025/2

Note2: The first employee stock option certificate in 2020 expired on March 3, 2026.

2. The first employee stock option certificate in 2023

March 31, 2026；Share；NT$

	Title	Name	Obtain the number of subscriptions	The ratio of the number of subscriptions obtained to the total number of issued shares	Exercised				Unexercised			
					Subscription units	Subscription price	Subscription amount	The ratio of the number of subscriptions obtained to the total number of issued shares	Subscription units	Subscription price	Subscription amount	The ratio of the number of subscriptions obtained to the total number of issued shares
Mamager	Chairman & CEO	Kuo-Lung Huang	1,754,500	0.24%	-	-	-	-	1,754,500	15.35	26,931,575	0.24%
	Vice president	Richard Lu										
	Vice president	Li-Wen Chang										
	Vice president	Cheng-Yuan Tsai										
	Accounting Department Director	Mark Kao										
Employee	Supervisor	Chiayn Chiang	2,840,000	0.40%	-	-	-	-	2,840,000	15.35	43,594,00	0.40%
	Chief Research	Wen-chang Chen										
	Researcher	Yu-an Hunag										
	Manager	James Ting										
	Deputy supervisor	Belen Huang										
	Director	I-fen Chen										
	Director	Tracy Wang										
	Manager	Yan-Yu Liao										
	Researcher	Calvin Chen										
	Manager	Chin Lo										

VI、 Issuance situation of new employee restricted shares：

(I) Status of Restricted Employee Shares Not Yet Fully Vested: None

(II) Name of managerial staff and top 10 employees who have acquired new restricted employee shares, and the state of acquisition

	職稱（註 1）	姓 名	New restricted employee shares acquired	Proportion of new restricted Employee shares issued as part of total equities issued（Note 3）	Restrictions lifted				Restrictions not lifted			
					Quantum of shares no longer restricted	Issue price	Issue amout	Proportion of shares no longer restricted as part of total equities issued（Note 4）	Quantum of shares still restricted	Issue price	Issue amout	Proportion of shares remaining restricted as part of total equities issued（Note 4）
Managers	Chairman & CEO	Kuo-Lung Huang	758,000	0.11%	758,000	0	0	0.11%	0	NA	NA	0.00%
	Vice president	Richard Lu										
	Vice president	Li-Wen Chang										
	Vice president	Cheng-Yuan Tsai										
	Accounting Department Director	Mark Kao										
Employees	Senior Manager	Wen-chang Chen	173,000	0.02%	171,200	0	0	0.02%	1,800 (Note 4)	NA	NA	0.007
	Supervisor	Chiayn Chiang										
	Director	Tracy Wang										
	Senior Chief Research	Hang Pei Shu (註 6)										
	Chief Research	Yu-an Hunag										
	Assistant Manager	James Ting										
	Chief Research	Chung-Shu Hung										
	Senior director	Jin Hong										
	Manager	Yen-Yu Liao										
	Manager	Ya-Ching Hu (Note5)										
	Director	Hsiao-Shan Hsieh										

Note 1：Including managers and employees (those who have resigned or died should be indicated), individual names and titles should be disclosed, but their allocation or subscription information may be disclosed in an aggregated manner.

Note 2：Employees refer to employees other than managers.

Note 3：The total number of issued shares refers to the number of shares listed in the change registration information of the Ministry of Economic Affairs.

Noe 4：The shares that expire when an employee resigns.

Note 5：Resigned on 2024/2.

Note 6：resigned on 2025/3.

VII、 Issuance of new shares in connection with mergers or acquisitions or with acquisitions of shares of other companies：None

VIII、 Implementation of funds utilization plan：

For the period as of the quarter preceding the date of publication of the annual report, there has not uncompleted public issue or private placement of securities, or to such issues and placements that were completed in the most recent 3 years but have not yet fully yielded the planned benefits, so it is not applicable.

Chapter 5、Operations Profile

I、Descriptions of Business

(I) Business Scope

1、Main Business Activities

I199990 Other Consulting Service (pharmaceutical production technology consultant)

IZ99990 Other Industrial and Commercial Services (pharmaceutical R&D)

F601010 Intellectual Property

F107120 Wholesale of Precision Chemical Material

F207120 Retail sale of Precision Chemical Material

IG01010 Biotechnology Services

F108021 Wholesale of Drugs and Medicin

F208021 Retail sale of Drugs and Medicines

ZZ99999 All business items that are not prohibited or restricted by law, except those that are subject to special approval

2、Proportion of operating business (fiscal year 2025)

Our company is mainly engaged in the development of new drugs, and at present, its main sources of income are the licensing fees、royalties at the stage of product licensing, as well as product sales income.

Unit：NT$ thousand

Item	Operating revenue for fiscal year 2025	Proportion
External licensing	223,368	86.08%
Sales Revenue	36,106	13.92%
Total	259,474	100.00%

3、Products/Pipeline

TaiGen currently has three new drugs projects with global patent protection in progress:

① **Nemonoxacin (trade name: Taigexyn®), a new antibiotic for bacterial infections**, with both oral and intravenous infusion formulations already marketed in Mainland China and Taiwan. Currently, the Health Insurance reimbursement (NHI) price in Taiwan is NTD 156 per capsule for the oral formulation and NTD 2,071 per bag for the intravenous infusion formulation. As of January 2026, 125 hospitals (23 medical centers + 102 non-medical centers) and 15 pharmacies/clinics have purchased Taigexyn® capsules, while 72 hospitals (20 medical centers + 52 non-medical centers) have purchase Taigexyn® infusion solution. In December 2024, through TaiGen's partner, the New Drug Application (NDA) for Taigexyn® (Nemonoxacin) capsules was officially submitted to the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. In addition, Taigexyn® (Nemonoxacin) has been authorized in 36 countries globally, including its latest expansion into Vietnam in October 2025—a strategic move following Singapore and Malaysia to further penetrate the Southeast Asian market, with 5 drug approvals obtained in Taiwan, China, and Russia. Experts have

recognized TaiGen's capability from early drug development to multi-center clinical trials execution, positioning it as a benchmark for new drug development in Taiwan

② **Burixafor**, **a stem cell mobilizer**, has been transferred its global rights to GPCR Therapeutics Inc., a South Korean biotechnology company, for further clinical and market development in November 2020.

③ **Pixavir marboxil**, a novel anti-influenza drug available in both capsule and granule formulations, is the TaiGen's latest project. TG-1000 and JKN2301 are the internal R&D codes for the capsule and pediatric granule formulations, respectively.

TG-1000 Capsule (Adults and Adolescents)

In March 2023, TaiGen granted the rights for development, manufacturing, and commercialization within the licensed territory (Mainland China, Hong Kong, and Macau; excluding Taiwan) to our partner in Mainland China, Joincare Pharmaceutical Group Industry. The Phase III clinical trial initiated by the partner- Joincare in October 2023 successfully met its primary endpoint. Trial data demonstrated that the TG-1000 group was significantly superior to the placebo group in the median time to alleviation of all influenza symptoms, showing statistical significance. Furthermore, the drug exhibited an excellent safety profile with no drug-related serious adverse events (SAEs) reported.

In accordance with the agreement, TaiGen received milestone payments for "Successful Phase III Clinical Results" in May 2024 and "Successful New Drug Application (NDA) Approval in China" in December 2025. Following its successful market launch in China (under the brand name 壹立康®), TG-1000 was officially licensed to an Indian partner in October 2025 to actively expand its footprint in the Indian market. To date, TG-1000 has been licensed in two countries globally.

JKN2301 Granule (Pediatric)

In March 2025, Joincare submitted the Investigational New Drug (IND) application for the pediatric granule formulation to the NMPA (formerly CFDA). The application was approved in June of the same year, and the Phase III clinical trial for pediatric patients (under 12 years of age) was officially initiated in October 2025.

Moreover, TaiGen has implemented a robust global patent strategy for TG-1000. The substance patent applications have been granted in 24 countries, including China, Taiwan and the United States, with protection lasting until 2039. Furthermore, 12 patents regarding manufacturing processes and formulation have been granted. Under the current patent strategy, patent protection for TG-1000 is expected to extend through 2043.

④ **Non-cystic fibrosis bronchiectasis (NCFBE) new drug TG-4318** is a novel small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), independently developed by TaiGen Biotechnology. Its intended indication is non-cystic fibrosis bronchiectasis (NCFBE). In December 2025, TaiGen granted the development and commercialization rights of TG-4318 in Mainland China and the Hong Kong and Macau regions to the Joincare Pharmaceutical Group, which will conduct subsequent preclinical development activities. Preclinical studies had demonstrated that TG-4318 possesses excellent biochemical activity and high selectivity, highlighting its potential to become a best-in-class therapy within its category.

⑤ **ISM4808**, a novel therapy for anemia associated with chronic kidney disease (CKD), is a small-molecule prolyl hydroxylase (PHD) inhibitor licensed in by TaiGen Biotechnology. Its indicated use is for the treatment of CKD-related anemia. Preclinical studies had demonstrated that ISM4808 had the potential to become a best-in-class PHD inhibitor. By activating the HIF-α signaling pathway, it enhanceed erythropoietin (EPO) production and improved iron utilization, thereby promoting red blood cell regeneration for the treatment of CKD anemia. In December 2025, TaiGen entered into a licensing agreement with Insilico Medicine

(Shanghai) Co., Ltd., obtaining the exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). TaiGen will be responsible for subsequent clinical development planning.

4、**New Product (Services) Development Plan**

Name	New Product (Services) Development Plan	
New antibiotic for bacterial infections, Nemonoxacin (Taigexyn®)	Capsule form	• **Taiwan:** Continue to implement the post-marketing risk management plan and expand hospital procurement of Taigexyn® capsules. The target for 2025-2026 is to have 140 hospitals capable of purchasing the product. • **Malaysia**: Assisting the partner in obtaining NDA approval. • **Vietnam:** Assisting the partner in obtaining NDA approval.
	Infusion solution form	• **Taiwan:** Continue to implement the post-marketing risk management plan and expand hospital procurement of Taigexyn ® infusion solution. • **Malaysia:** Assisting the partner in submitting the NDA application. • **Vietnam:** Assisting the partner in obtaining NDA approval.
	Overseas authorization	• **Other unauthorized countries/regions:** Currently 36 countries around the world have been authorized (including Mainland China, Russia, the CIS and Turkey region, Latin America, South Korea, Singapore, Malaysia and Vietnam etc.). For other unauthorized countries/regions, continuous efforts will be made for out-licensing and promotion.
New antiviral drug for influenza, Pixavir marboxil (Trade name of the capsule dosage form in Mainland China: 壹立康®)	Capsule form	**Mainland China:** • **Post-Marketing Sales Promotion:** TaiGen will assist Joincare Pharmaceutical Group, in post-marketing sales promotion and will be entitled to receive post-marketing royalties. **Taiwan:** • **NDA Submission:** Upon receipt of feedback from Taiwan CDE regarding the Pre-NDA consultation, TaiGen will plan the NDA submission accordingly, ensuring that Taiwanese patients will also have the opportunity to access this locally developed antiviral influenza drug.
	Granule form	**Mainland China:** • **Completion of Pediatric Phase III Clinical Trials and NDA Submission:** TaiGen will assist Joincare Pharmaceutical Group, in completing Phase III clinical trials for pediatric patients (<12 years old) and the subsequent New Drug

Name	New Product (Services) Development Plan	
		Application (NDA) submission.
	Overseas authorization	• **India:** Collaborate with Indian partner to implement the localized production of APIs (Active Pharmaceutical Ingredients) and finished formulations to expand presence in the Indian pharmaceutical market. • **Other unauthorized countries/regions:** For other unauthorized countries/regions, continuous efforts will be made for out-licensing and promotion.
Non-cystic fibrosis bronchiectasis (NCFBE) TG-4318	Overseas authorization	• **Mainland China:** In December 2025, a Patent License and Commercialization Collaboration Agreement was signed with Joincare Pharmaceutical Group Co., Ltd., granting Joincare the rights to develop, manufacture, and commercialize the product within the licensed territory, which includes Mainland China, Hong Kong, and Macau, but excludes Taiwan. • **Other unauthorized countries/regions:** For other unauthorized countries/regions, continuous efforts will be made for out-licensing and promotion.
Anemia in Chronic Kidney Disease (CKD) ISM 4808	Clinical development	• **Phase I Clinical Trial:** Xiangya Hospital of Central South University has been selected as the Phase I clinical trial site. The first subject will be enrolled and dosed in Q1 2026, with completion of the Phase I trial planned for Q4 2026. The study aims will be evaluated the safety, tolerability, and pharmacokinetic profile of oral ISM4808 in healthy Chinese adults, while also exploring its pharmacodynamic characteristics.
New Drug Development (In-house discovery & In-licensing)	• Continuously expand the product pipeline through 'external licensing,' focusing on fields including, but not limited to, 'anti-infectives,' 'autoimmune diseases,' and 'chronic respiratory diseases.	

(II) Industry Overview

1、Current status and development of the industry

(1) Status and development of the global pharmaceutical industry

The global pharmaceutical industry continues to expand, driven by an aging population, the rising burden of chronic diseases, and sustained innovation in specialty therapies. According to the IQVIA Institute's latest outlook, the global medicine market (at invoice price levels) is projected to grow at a 5–8% CAGR through 2029, reaching approximately US$2.4 trillion, including estimates for COVID-19 vaccines and therapeutics.

Despite ongoing macroeconomic pressure and policy reforms aimed at controlling drug budgets, demand for medicines remains resilient. The post-pandemic period is characterized by a normalization of consumption patterns (especially respiratory and infectious disease medicines), while innovation continues to shift the market toward higher-value specialty products.



Source: IQVIA Market Prognosis, May 2025; IQVIA Institute, May 2025.

North America is expected to remain the largest contributor to absolute spending growth, with forecast spending growth of 6–9% through 2029. Western Europe is forecast at 4.5–7.5%, while China is projected to grow more moderately at 1–4% as pandemic-era volatility recedes.

Losses of exclusivity (LOE) will be a critical offset to spending growth in many developed markets, particularly as a surge in small-molecule patent expiries occurs over 2025–2029. This creates an environment where payers seek savings through generics and biosimilars while continuing to adopt innovative therapies in high-need areas.



Source: IQVIA Market Prognosis, May 2025.

Figure 2. Spending growth globally and by region, 2019–2029 excluding COVID vaccines/therapeutics

3. Outlook for the use of medicines (volume)

Measured in defined daily doses (DDD), global medicine use has been relatively flat since 2021 and is expected to grow on average 0.8% annually through 2029. Total global use is forecast to rise from 3.56 trillion DDDs in 2025 to 3.71 trillion in 2029.

Regional volume growth is expected to be highest in Latin America (2.2% CAGR) and China (1.6% CAGR), reflecting continued expansion of access and healthcare coverage. Developed regions such as North America, Western Europe, and Japan are expected to show slower volume growth, consistent with mature healthcare systems and stable access levels.



Source: IQVIA Institute, Jun 2025.

Figure 3. Historic and projected use of medicines by region, 2019–2029 (DDD, billions)



Source: IQVIA Institute, Jun 2025.

Figure 4. Trends in DDD across regions indexed to 2019 values

4. Per-capita access patterns and health equity

Per-capita medicine use differs markedly across regions and correlates broadly with income levels. Higher-income regions generally exhibit higher medicine use, reflecting better diagnosis rates, treatment availability, and healthcare coverage.

Notably, North America has lower per-capita DDD volumes than other developed regions, which may reflect higher patient out-of-pocket costs in the U.S. and differences in healthcare delivery models.

When adjusted for population, IQVIA estimates that global per-capita medicine use growth will be flat (0.0% CAGR) through 2029, implying that projected global volume increases are primarily driven by population growth rather than increased intensity of use.



Source: The World Bank, Dec 2024; International Monetary Fund, Apr 2025; IQVIA Institute, Jun 2025.

Figure 5. DDD per capita vs. GDP per capita (PPP), 2024



Source: The World Bank, Dec 2024; IQVIA Institute, Jun 2025.

Figure 6. Historical and projected per capita use of medicines by region, 2014–2029

5. Vaccination recovery and preparedness

Vaccination programs remain a key public health pillar, particularly in respiratory infectious diseases. IQVIA data indicate that adult vaccination doses peaked in 2020 (435 million doses) but have subsequently fallen below pre-pandemic trends in many countries.

The Institute estimates that approximately 150 million fewer adult vaccine doses were administered in 2024 compared with a continuation of pre-pandemic trends, leaving populations less protected from preventable diseases and potentially increasing demand for downstream medical management.



Source: IQVIA MIDAS, Dec 2024; UN Human Development Report, May 2025; IQVIA Institute, Jun 2025.

Figure 7. Global adult vaccinations, 2015–2024

6. Structural shift toward specialty medicines

Specialty medicines—often used for chronic, complex, or rare diseases—continue to represent an increasing share of total spending. By 2029, specialty medicines are projected to account for ~46% of global spending and ~54% of spending in the 10 largest developed markets. In contrast, pharmerging markets are projected to reach ~18% specialty share by 2029, reflecting affordability constraints and access gaps. This divergence underscores the importance of differentiated market access strategies by geography.



Source: IQVIA Institute, May 2025.

Figure 8. Specialty medicines share of spending, 2014–2029

7. Key therapy areas through 2029

Across major therapy areas, oncology is expected to remain the largest contributor to spending growth through 2029, followed by diabetes and obesity-related medicines. Immunology and diabetes growth are expected to slow, partly driven by biosimilar competition and maturing product classes.

Infectious diseases and respiratory medicines remain important categories, though their spending growth is expected to be more moderate compared with high-growth specialty segments.



Source: IQVIA Forecast Link, May 2025; IQVIA Institute, May 2025.

Figure 9. Global historic and forecast growth for top 20 therapy areas



Source: Global Oncology Trends 2025: Adopting New Therapies as Modadlities Shift and Expenditures Rise: May 2025. Report by the IQVIA Institute for Human Data Science.

Figure 10. Global oncology spending, 2015–2029

8. Antibiotics Market Analysis

Infectious disease management remains essential to health system resilience. Medicine-use patterns were disrupted during the COVID-19 pandemic due to reduced transmission of seasonal infections and changes in healthcare-seeking behavior.

IQVIA reports that the use of antibacterial rebounded as the pandemic eased and was up 6% in 2024 relative to pre-pandemic levels. Regional differences persist: Eastern Europe shows the highest per-capita antibacterial use (more than 50% higher than the global average), while several regions remain near flat growth on a per-capita basis.

Progress toward responsible antibacterial prescribing (as measured by the WHO AWaRe classification targets) is mixed across regions. While some regions meet the WHO 2023 target for access antibiotics, further stewardship improvement is required globally to balance access, appropriate use, and antimicrobial resistance risk.



Source: IQVIA MIDAS, Dec 2024; IQVIA Institute, Jun 2025.

Figure 11. Antibacterial volume (DDDs) and DDD per capita by region, 2015–2024



Source: IQVIA MIDAS, Dec 2024; WHO Access, Watch, Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, Jul 2023; IQVIA Institute, Jun 2025.

Figure 12. Share of antibacterial DDDs by WHO AWaRe classification, 2024

9. Anti-Influenza Drugs Market Analysis in China

Market scale (definition matters)

Published market reports estimate the broader influenza vaccines & therapeutics market at roughly USD ~9–10B in 2025, while narrower "influenza drug/antiviral" market definitions can be as low as ~USD 1.1B in 2025.

Therapeutic mix

Neuraminidase inhibitors (NAIs) remain the backbone in most countries (oseltamivir, zanamivir, peramivir), while polymerase inhibitors—especially the cap-dependent endonuclease inhibitor baloxavir marboxil—continue to gain share where reimbursed due to single-dose convenience and differentiated clinical positioning.

Table 1. Key marketed anti-influenza antivirals (2025)

Drug	Class / target	Typical dosing	2025 commercial note
Oseltamivir (Tamiflu; generics)	NAI (neuraminidase inhibitor)	BID x 5 days	Large generic base; pediatric use; high volume in seasonal peaks

Zanamivir (Relenza)	NAI	Inhaled	Limited by inhalation route
Peramivir (Rapivab)	NAI	IV single dose	Used in hospital/ED settings
Baloxavir marboxil (Xofluza)	PA endonuclease inhibitor	Oral single dose	Rapid uptake in high-activity seasons; China highlighted as growth driver in Roche disclosures

Notes: market sizing varies by definition/source; this summary focuses on therapeutics (not vaccines).

China highlight

Oseltamivir remains the anchor class in China's influenza antiviral market due to long-standing clinical familiarity, broad applicability across age groups, and extensive domestic generic supply. In 2025, the competitive structure continued to evolve as polymerase inhibitors—particularly PA- and PB2-targeting agents—expanded adoption and heightened channel attention. As a result, market performance is increasingly shaped by access and execution: reimbursement positioning, hospital formulary inclusion, procurement outcomes, peak-season supply stability, and clearly differentiated clinical use cases. Publicly cited audit data indicate that oseltamivir achieved RMB 5.9 billion in 2024 within the commonly referenced 'three terminals, six markets' framework, ranking first among systemic antivirals. Public reports citing the same audit framework further indicate that oseltamivir posted a year-on-year sales growth rate of 11.43% in 2025 Q1. For full-year 2025, this report provides an evidence-aligned estimate range (RMB 5.6–7.0 billion; base case RMB 6.3 billion) as a planning view, pending consistent public disclosure of national audited totals.



Figure 13. China oseltamivir market: 2024 actual (public) versus 2025 estimate range (annual report planning view).



Figure 14. 2025 estimated oseltamivir sales by segment (base case).

Baloxavir (originator brand "速福达", Xofluza) launched in China in 2021 and entered national reimbursement shortly thereafter. Public reporting using industry terminal-tracking databases indicates terminal sales growth from ~RMB 0.07B (2022) → ~RMB 0.63B (2023) → >RMB 0.70B (2024) → >RMB 2.0B (2025, +180% YoY), supported by strong seasonal demand and expansion across hospital, retail pharmacy, and e-commerce channels.

Table 2. Baloxavir (China) – Reported Terminal Sales Snapshot

Year	Reported terminal sales (RMB)	YoY growth	Notes / interpretation
2022	≈ 0.07B	—	Early post-launch year (industry tracking).
2023	≈ 0.63B	+758.78% (vs 2022)	Rapid expansion; reimbursement and awareness effects.
2024	> 0.70B	+38.84% (vs 2023)	Continued growth; strong seasonality.
2025	> 2.0B	+180% (vs 2024)	Breakout year; strong seasonal demand and multi-channel expansion.

Note: Figures are reported/estimated from industry tracking and public disclosures; actuals may vary by channel mix and reporting scope.

China market outlook: multi-mechanism competition and access-driven growth

China's influenza antiviral market is transitioning from reliance on legacy neuraminidase inhibitors toward an environment where multiple novel mechanisms compete side by side. As PA-targeting and PB2-targeting antivirals expand clinical adoption, market growth will be determined less by a single brand's seasonal demand and more by access levers such as reimbursement positioning, hospital formulary inclusion, supply stability during peak seasons, and differentiated clinical use cases.

Where future value will concentrate: clinically meaningful differentiation

Over the next three to five years, premium pricing and sustained share are most defensible when a product can demonstrate value in specific, decision-relevant settings. Key differentiation pathways include stronger evidence in high-risk or hospitalized populations, clearer benefits on endpoints that matter to health systems (such as reduction of complications or faster recovery), a higher barrier to resistance, practical pediatric dosing and formulations, and stronger integration into

test-to-treat workflows. In markets like China, operational excellence in distribution and peak-season supply can be as important as clinical messaging.

10. Non–Cystic Fibrosis Bronchiectasis (NCFB) Drug Market Analysis

Market inflection	Why DPP1 matters	What experts should watch
After years of off-label management, 2025 introduced the first approved therapy for NCFB. Premium branded maintenance therapy is now a realistic revenue pool—especially in frequent exacerbations.	DPP1 inhibitors act upstream in neutrophil maturation to reduce activation of destructive proteases. This disease-modifying rationale aligns with neutrophilic phenotypes common in NCFB.	Access and pricing will be evidence-driven. Differentiation will depend on real-world reductions in exacerbations/hospitalizations, safety/tolerability, and positioning versus follow-on DPP1 inhibitors and inhaled anti-infective.

The NCFB market: moving from supportive care to branded maintenance therapy

NCFB is a chronic airway disease characterized by irreversible bronchial dilation, chronic infection risk, and recurrent pulmonary exacerbations. Historically, pharmacologic management was dominated by episodic antibiotics, long-term macrolides in selected patients, and inhaled antibiotics where chronic infection was a major driver. This created a fragmented revenue mix anchored in generics and procedure-like supportive care. The first approval of a targeted anti-inflammatory maintenance therapy in 2025 changes how stakeholders can define the market. From a commercial perspective, the most addressable segment for premium drugs is not the full prevalence pool but the treated, high-burden segment: patients with frequent exacerbations, chronic bacterial infection (often including Pseudomonas aeruginosa), prior hospitalizations, and persistent symptoms despite optimized airway clearance. This segment concentrates avoidable costs, making it the natural starting point for payer coverage and specialist adoption. In the medium term, the key economic question is how quickly branded anti-inflammatory maintenance penetrates the frequent-exacerbation segment and whether it can displace some antibiotic utilization by reducing exacerbation burden.

DPP1 inhibition: a new target with clinically meaningful evidence

DPP1 (also known as cathepsin C) activates neutrophil serine proteases during neutrophil maturation. In neutrophil-driven airway diseases, excessive protease activity contributes to airway damage and persistent inflammation. By inhibiting DPP1 upstream, the class aims to reduce downstream protease-mediated injury rather than treating infection alone. The clinical anchor for the class is brensocatib, supported by Phase 3 data in ASPEN. The attached source summarizes statistically significant reductions in annualized pulmonary exacerbations at both 10 mg and 25 mg once daily, with supportive signals in time to first exacerbation and the fraction of patients remaining exacerbation-free through 52 weeks.

ASPEN trial snapshot (as reported in the attached source)

Endpoint (vs placebo)	**10 mg QD**	**25 mg QD**
Annualized pulmonary exacerbations	21.1% reduction	19.4% reduction
Time to first exacerbation	18.7% delayed	17.5% delayed
Patients without exacerbation (Week 52)	41.2%	40.0%
FEV1 change at Week 52 (mL)	11 mL	38 mL
QoL-B respiratory domain (points)	2.0	3.8

Market size and growth outlook

Published market estimates differ materially depending on whether they include only branded NCFB-specific therapies, the broader spend on antibiotics and supportive care, and whether they model global vs selected major markets. A recent Transparency Market Research model estimates the global NCFB treatment market at US$ 1.9B in 2024, growing to US$ 3.5B by 2035 (CAGR ~5.8%). Other analyst models cite different baselines (e.g., ~US$ 1.46B in 2023) and steeper growth assumptions when premium branded penetration is modeled aggressively. The launch of first-in-class DPP1 inhibition is expected to shift the revenue mix from generic anti-infective toward branded anti-inflammatory maintenance therapy in the high-risk segment.

Pricing, reimbursement, and value assessment

US list pricing for brensocatib has been reported at US$ 88,000 annually (WAC), with expected net pricing 25–35% lower after rebates/discounts. ICER's published health benefit price benchmark (HBPB) for brensocatib is far lower (low-thousands per year), implying potential affordability and access concerns.

11. CKD anemia HIF-PHIs Market Analysis in China

CKD-related anemia is driven primarily by insufficient endogenous erythropoietin (EPO) production, impaired iron utilization, and inflammation-mediated hepcidin dysregulation. Commercially, the treated population is best segmented into dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients, because access, prescribing behavior, and treatment intensity differ markedly between the two settings. China carries a large CKD burden. Published epidemiology studies have reported a national CKD prevalence around 10% in adult populations (with estimates varying by survey year and methodology). Within CKD, anemia prevalence rises with disease stage, increasing the addressable population for pharmacologic intervention in stage 3–5 CKD and dialysis cohorts.

Treatment landscape in China

Historically, the CKD-anemia standard of care in China was centered on injectable ESAs (epoetin alfa/beta and longer-acting analogs) combined with intravenous iron. Oral HIF-PHIs represent a mechanistic shift: by stabilizing hypoxia-inducible factor (HIF), they increase endogenous EPO production within a physiologic range and improve iron mobilization. From a market structure perspective, HIF-PHIs compete not only on efficacy and safety perceptions but also on convenience (oral dosing), tender price, and the ability to gain hospital formulary depth across dialysis centers and tertiary hospitals.

Table 3. Mechanism and positioning overview

Therapy class	Mechanism	Typical administration	Key commercial notes
ESAs (epoetin, darbepoetin, CERA)	Exogenous EPO receptor agonism	Injection (IV/SC); frequency varies	Mature class; strong price pressure; procurement-driven. Long-acting options differentiate in dosing interval.
HIF-PHIs (roxadustat, enarodustat, etc.)	HIF stabilization -> endogenous EPO + improved iron utilization	Oral; usually 3x weekly or daily depending on molecule	Rapid uptake enabled by NRDL; subject to patent expiry and generic entry; safety perception and label breadth critical.
IV iron (e.g., iron sucrose, FCM)	Iron repletion / mobilization	IV infusion	Often used as adjunct; procurement dynamics differ from erythropoiesis agents.

China represents the most commercially mature market for oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in chronic kidney disease (CKD)-related anemia.

Roxadustat (EVRENZO, 爱瑞卓) pioneered the class and scaled rapidly after National Reimbursement Drug List (NRDL) inclusion, with strong uptake in grade hospitals. However, from 2024 onward, the market enters a structurally new phase shaped by (i) a patent cliff and generic entries, (ii) tender-driven price compression, and (iii) the emergence of a second HIF-PHI (Enarodustat, 恩那罗) and additional late-stage pipeline candidates. Commercially, two parallel 'truths' matter for annual reporting: (a) channel-based hospital sales capture on-the-ground utilization and mix shifts, while (b) manufacturer-level net sales disclosures reflect realized revenue after distribution terms and pricing mechanics. Across both lenses, roxadustat remains the category anchor through 2024, while ESA brands increasingly behave as a commoditized baseline.

Key highlights (China)

Metric	Observation
Roxadustat grade-hospital channel sales	RMB 2.261B in 2023; RMB 2.061B in 2024 Q1–Q3 (channel dataset).
Roxadustat China net sales (manufacturer disclosure)	US$281.4M in 2023; US$320–350M expected for full-year 2024.
ESA benchmark (epoetin alfa, EPIAO)	3SBio reported RMB 757.5M sales in 2024 (RMB 725.3M in 2023).
Enarodustat early commercialization signal	Company disclosures indicate net sales have not reached the US$100M milestone threshold over a 12-month period by the report's cut-off.
Market sizing anchor (public reports)	China renal-anemia drug market cited at ~RMB 5.9B in 2024; broader CKD-anemia treatment market frequently described as '>RMB 10B' in industry analyses.

Sales performance and competitive dynamics

Roxadustat (EVRENZO, 爱瑞卓) – the category anchor

Channel datasets for grade hospitals indicate strong and sustained uptake of roxadustat through 2024, with sales exceeding RMB 2B annually in recent periods. Separately, manufacturer-level disclosures indicate roxadustat China net sales of US$281.4M in 2023, with full-year 2024 net sales expected in the range of US$320–350M. Interpretation: hospital-channel sales tend to overstate manufacturer revenue because they reflect procurement value at the hospital level; manufacturer net sales are affected by distribution terms, discounts, and revenue recognition practices. Nevertheless, both views align on a clear conclusion: roxadustat remains the dominant commercial driver of the HIF-PHI class in China through 2024.

ESAs – commoditized baseline with pockets of differentiation

Injectable ESAs continue to represent a large treatment base in CKD anemia, particularly in dialysis settings. However, tender pricing and VBP pressures compress branded economics. As a public benchmark, 3SBio's epoetin alfa franchise (EPIAO) reported RMB 757.5M sales in 2024, following RMB 725.3M in 2023. Commercial implication: the ESA segment's slower growth contrasts with HIF-PHI expansion in tertiary hospitals. Long-acting ESA options (e.g., CERA) can differentiate on dosing interval, but reimbursement and tender positioning remain decisive for share retention.

Enarodustat (Ennaruo, 恩那罗) – early-stage intra-class competition

Enarodustat was approved in China in 2023 and entered NRDL via negotiation, creating the first meaningful intra-class competition in oral HIF-PHIs. Company disclosures suggest the product's net sales have not yet reached the US$100M milestone threshold over a 12-month period as of the latest public reporting, indicating that uptake remains at an early ramp stage relative to roxadustat. Near-term competitive levers include differentiated clinical messaging (e.g., dosing convenience, safety narratives), regional formulary expansion, and tender strategy in NDD settings.

Market share view (indicative)

NRDL dossier materials for the 2022 adjustment process cited roxadustat sales and an indicative market share figure for 2021. While methodology and market definition may differ from other datasets, the share estimate reinforces the product's leadership position during its growth phase.



Figure 15. Indicative market share (2021, NRDL dossier reference).

Forward outlook (2025–2028) and scenario view

Outlook for China's CKD-anemia therapeutics market is shaped by opposing forces: volume growth and earlier anemia treatment on one hand, versus rapid price erosion from generics and procurement reforms on the other. Base-case expectation: HIF-PHI unit volumes continue to expand in both DD and NDD settings, but value growth decelerates as competitive tendering compresses prices. ESAs remain a large baseline but face ongoing commoditization; share retention hinges on long-acting convenience and institutional contracts.

Table 4. Scenario framework (illustrative)

Scenario	Assumptions	Implication for HIF-PHIs	Implication for ESAs
A. Fast generic erosion	Rapid multi-winner tenders; steep price cuts; high switching tolerance	Class volume rises but branded value declines; leader must defend with access + evidence	Price pressure intensifies; hospital contracts dominate
B. Managed transition	Gradual tender rollout; differentiated labeling and real-world evidence rewarded	Leader retains premium in key centers; second-in-class gains via segmentation	Stabilizes in dialysis centers; long-acting products maintain niche
C. Safety-driven rebalancing	New safety signals or guideline shifts change prescribing	Potential class-level headwinds; demand shifts back to ESA + iron	Relative benefit as fallback standard; volume increases

Strategic watch points for 2025: (i) breadth and pricing of roxadustat generics in provincial tenders; (ii) NRDL renewal dynamics and potential label expansion (e.g., chemotherapy-induced anemia); (iii) whether enarodustat can build differentiated institutional access in NDD clinics; and (iv) adoption of long-acting ESA options in dialysis networks.

2、The relationship of the upstream, midstream and downstream of the industry

The relationship between the upstream, midstream and downstream of new drug development



The development of a new drug generally begins with the discovery of a chemical substance with pharmacological activity by an upstream early-stage drug research institution, and then undergoes chemical modification to synthesize derivatives and screening for pharmacological activity. A series of in vitro biochemical tests and in vivo animal experiments are carried out by midstream biotech pharmaceutical R&D companies for selected target compounds, including various preclinical toxicological tests, pharmacological tests and pharmacokinetic tests, etc., and then an investigational new drug

(IND) application can be submitted to health authorities and three-stage human clinical trials can be conducted. Phase I clinical trials are used to confirm the safety and dose-ranging of the drug in healthy volunteers; Phase II clinical trials are to confirm the efficacy of the drug and side effects in a small number of patients, and then to carry out Phase III clinical trials for a large number of patients to establish efficacy and monitor long-term use response; After the investigational drug has undergone the phase I, phase II and phase III clinical trials, if it achieves the expected results, a new drug application (NDA) can be submitted to the health authority. Once the new drug is approved and is considered to be successfully developed and qualified for marketing. The downstream is the healthy facilities or authorized pharmaceutical companies that sell the medicine.

3、Various development trends of products

(1) **Anti-bacterial infection new drug** Nemonoxacin (trade name: Taigexyn®)

Since the discovery of antibiotics in the 1940s, deaths caused by infections have remained one of the leading causes of death in countries worldwide. In the past, pharmaceutical companies focused on the treatment of chronic diseases and ignored the antibiotic market. In addition, the regulatory requirements for the approval of antibiotics tend to be stricter; as a result, few new antibiotics have appeared in the medical market in recent years.

The spread of drug-resistant strains through human-to-human or human-to-environmental contact in the healthcare system continues to accumulate a range of resistance and it has become a serious threat to life for the elderly, those with chronic conditions (such as diabetes) and children who are highly dependent on the healthcare system. The current multidrug-resistant bacteria are dominated by the following strains: *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa* and *Enterobacter* species including a variety of Gram-negative bacteria (abbreviated as ESKAPE). The aforementioned drug-resistant strains account for two-thirds of infections that occur in the healthcare system. In addition, *Streptococcus pneumoniae*, the most common pathogen of pneumonia, also has serious drug resistance problems.

Resistance of these multi-drug resistant strains to current marketed antibiotics is developing too quickly. In the absence of new drugs, some physicians have turned to use old antibiotics but are restricted with side effects problems. Therefore, whether new antibiotics can be successfully developed to solve the infection with these drug-resistant strains and at the same time have the characteristics of not easy induced drug resistance is the major research trend in the pharmaceutical industry, which is highly valued by the United States and the European Union..

(2) **Anti-influenza virus new drug Pixavir marboxil (Trade name of the capsule dosage form in Mainland China: 壹立康®)**

Influenza is an acute respiratory infectious disease caused by influenza viruses, which can be infected by droplets or direct contact with the secretions of patients, due to the strong transmission capacity, wide range, rapid progression of the disease course, and easy to lead to serious complications, which has caused a serious threat to global public health.

Influenza virus belongs to the orthomyxovirus. Depending on the different

nucleoproteins, they can be divided into A, B, and C types. The World Health Organization's data shows that every year across the globe, there are an estimated 1 billion cases, of which 3 to 5 million are severe cases, resulting in 290 000 to 650 000 influenza-related respiratory deaths. Since the genetic material of influenza viruses is RNA, the probability of mutation will be higher than that of DNA, mutations may be single-point mutations or RNA recombination, resulting in more lethal new strains. Although influenza can use vaccines to prevent annual seasonal influenza outbreaks, seasonal influenza vaccine protection is not only limited but also cannot provide proper protection in the case of a pandemic caused by deadly new strains. Therefore, it is necessary to develop new anti-influenza virus drugs, even though there are many anti-influenza virus drugs that are currently in clinical use, such as the neurological aminoidase inhibitors Oseltamivir (Tamiflu®) and Zanamivir, Relenza®, as well as the Japanese Shionogi Hat-dependent nucleic acid endonuclease (Baloxavir, Xofluza®); however, the problem of drug resistance that has emerged so far leads to the imperfection of these drugs, so it is extremely important to develop new anti-influenza drugs that are more effective and less likely to develop drug resistance.

(3)) Non-cystic fibrosis bronchiectasis (NCFBE)new drug TG-4318

Non–Cystic Fibrosis Bronchiectasis (NCFBE) is a chronic and progressive airway disease characterized by irreversible bronchial dilation, persistent bacterial infection, and recurrent acute exacerbations, which over time lead to a decline in lung function and a significant reduction in quality of life. Although current treatment strategies—including intermittent or long-term antibiotic therapy, inhaled antibiotics, and macrolide agents—primarily focus on infection control and symptom relief, there are no therapies that directly target the core neutrophil-driven inflammatory mechanisms underlying the disease.

Studies have been shown that excessive activation of neutrophil elastase (NE) is a key driver of airway tissue damage and the vicious cycle of chronic inflammation, with its activation dependent on the upstream enzyme dipeptidyl peptidase 1 (DPP1). Although the first DPP1 inhibitor was approved in 2025, marking the beginning of mechanism-targeted therapy, it still faces clinical challenges such as differences in efficacy populations, long-term safety observations, and continued increase in antibiotic resistance, indicating that there is still a significant unmet medical need in this field..

Accordingly, the development of a next-generation DPP1 inhibitor with high selectivity and a favorable safety profile is warranted. By inhibiting NE activation at its source, such an agent could reduce the frequency of acute exacerbations and slow structural lung damage. This approach holds the potential to become a disease-modifying therapy for NCFBE, addressing the current treatment gap where management remains largely supportive and infection-focused.

(4)) Anemia in Chronic Kidney Disease (CKD) new drug ISM4808

Anemia associated with chronic kidney disease (CKD) is a major global public health concern, causing over 1.5 million deaths annually, with more than one-seventh of CKD patients affected by anemia. Current treatments primarily rely on exogenous erythropoiesis-stimulating agents (ESAs), iron supplementation, and blood transfusions.

While these interventions can improve hemoglobin levels, they are associated with several clinical limitations, including cardiovascular safety concerns, hemoglobin variability, inconvenience of intravenous administration, suboptimal iron utilization, and challenges with long-term treatment adherence.

Moreover, CKD patients often exhibit chronic inflammation and elevated hepcidin levels, leading to functional iron deficiency, which limits the effectiveness of iron supplementation alone. Some patients respond poorly to ESAs or require high doses to maintain hemoglobin levels, increasing potential risks and healthcare burden.

Therefore, there is an urgent clinical need for a novel therapy that can simultaneously stimulate physiological endogenous EPO production, improve iron metabolism and utilization, reduce cardiovascular risks, and offer the convenience of oral administration. Such a treatment would better address the underlying pathophysiology of CKD-related anemia and improve long-term clinical outcomes.

4、Competitive advantages

Name	Product Features and Competitive Advantages
New antibiotic for bacterial infections, Nemonoxacin (Taigexyn®)	• Novel non-fluoroquinolone antibiotic • Available in both oral and intravenous infusion formulations, requiring only one dose per day • Broad-spectrum antimicrobial activity: excellent clinical efficacy and good antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, and atypical pathogens • Compared to other fluoroquinolones, its advantages include: ① Less likely to develop resistance ② Lower side effects ③ Effective against multiple drug-resistant bacteria ④ Not delay the diagnosis and treatment of tuberculosis
New antiviral drug for influenza, Pixavir marboxil (Trade name of the capsule dosage form in Mainland China: 壹立康®)	• Single-dose treatment for influenza: A single dose of Pixavir marboxil is sufficient to cure influenza, significantly improving patient compliance compared to Tamiflu® (Oseltamivir), which requires twice-daily dosing for five consecutive days. • Effective against both Influenza A and B: Clinical trials have demonstrated that Pixavir marboxil effectively reduces the time to symptom relief for both Influenza A and Influenza B infections. • Superior efficacy in adolescent patients*:* In clinical trials, adolescent patients experienced faster symptom relief and more pronounced therapeutic benefits, highlighting its greater treatment advantage for younger patients. • Lower risk of antiviral resistance: Pixavir marboxil exhibits a lower frequency of resistance mutations

Name	Product Features and Competitive Advantages
	compared to other drugs with similar mechanisms, making it a key advantage in combating antiviral resistance. • Minimal impact from food intake: The absorption of Pixavir marboxil is less affected by food, reducing potential dietary interference with its effectiveness. • Outstanding safety profile: Pixavir marboxil has demonstrated excellent safety across various patient groups, providing a stable and reliable treatment option. • Extended patent protection: The patent protection for Pixavir marboxil extends until 2043, significantly longer than Xofluza® (expires in 2036) and Tamiflu® (already off-patent), offering long-term market competitiveness.
Non-cystic fibrosis bronchiectasis (NCFBE) TG-4318	• **Targeting a high unmet medical need market:** Non–Cystic Fibrosis Bronchiectasis (NCFBE) currently lacks innovative therapies with disease-modifying potential, with treatment primarily limited to antibiotics and supportive care, representing a clear gap for novel interventions. • **Best-in-class potential:** Preclinical data for TG-4318 demonstrated excellent biochemical activity and high selectivity, offering the opportunity to establish a differentiated advantage in the DPP1 inhibitor field. • **Differentiated mechanism with disease-modifying potential:** Directly inhibits neutrophil serine protease (NE) activation, targeting inflammation at its source to reduce the frequency of acute exacerbations and improve long-term outcomes, rather than merely controlling symptoms. • **Regional licensing reduces development risk:** Rights in Mainland China, Hong Kong, and Macau have been licensed to Joincare Pharmaceutical Group Co., Ltd., accelerating clinical advancement and sharing development risk, while retaining flexibility for commercialization and sublicensing in other regions. • **Global patent strategy underway:** A U.S. provisional patent has been filed, with plans to complete PCT, China (CN), and Taiwan (TW) filings, strengthening long-term asset value and positioning for international licensing negotiations.
Anemia in Chronic Kidney Disease (CKD) ISM4808	• **Nobel Prize–recognized mechanism:** By modulating the HIF-α signaling pathway, it simultaneously addressed both core issues of anemia—insufficient EPO production and impaired iron utilization—providing a mechanism

Name	Product Features and Competitive Advantages
	with a clear scientific foundation. • **Best-in-class potential:** Preclinical data demonstrated excellent biochemical activity and high selectivity, supporting its potential to become a best-in-class HIF-PHI. • **Outstanding drug properties:** Preclinical data confirmed that ISM-4808 exhibits good oral absorption, minimal off-target risk, strong biological activity, and stability, supporting an improved balance of efficacy and safety. • **Oral administration advantage:** Compared with conventional ESA injection therapy, oral dosing offers greater convenience, potentially improving long-term treatment adherence and accessibility. • **Regional exclusivity:** Secured development and commercialization rights in Greater China, providing strategic market value and flexibility for future sublicensing. • **Clear development milestones:** Phase I clinical trial will be initiated shortly, providing a defined timeline for milestones and value creation.

(III) Overview of technology and R&D

1、Research and development expense for the current fiscal year up to the date of the publication of the report

Unit: NT$ thousand

Fiscal year	2025	Until March 31,2026
Research and development expenses	96,884	23,156
Operating revenue	259,474	10,340
Research and development expense as a percentage of operating revenue	37%	224%

2、Successfully developed technology or product

Name	Successfully developed technology or product	
New antibiotic for bacterial infections, Nemonoxacin (Taigexyn®)	Capsule form	• **Taiwan:** In January 2015, it received a drug approval certificate from the TFDA for the treatment of community-acquired pneumonia. It was included in the Taiwan National Health Insurance list in January 2018. • **Mainland China:** In June 2016, it obtained a Class 1.1 new drug approval certificate from the CFDA for the treatment of community-acquired pneumonia. On November 28, 2019, it was successfully included in the supplementary medical insurance catalog of mainland China and began implementation in January 2020. • **United States:** In December 2013, it received QIDP (Qualified Infectious Disease Product) certification and Fast Track designation from the US FDA for two indications, "community-acquired pneumonia" and "acute bacterial skin and skin structure infections". After its launch in the United States, nemonoxacin will have 10 years of market exclusivity.
	Infusion solution form	• **Taiwan:** In October 2020, it obtained a drug approval certificate from the TFDA, and in March 2022, it was included in the Taiwan National Health Insurance list. • **Mainland China:** In June 2021, it obtained a drug approval certificate from NMPA and transferred the rights of Nemonoxacin (both capsule and intravenous infusion formulations) in mainland China to Zhejiang Medicine for a total amount of US$45 -50 millions.
	Oversea authorization	• **Mainland China:** In March 2021, TaiGen signed a contract with Zhejiang Medicine to transfer the rights of Nemonoxacin in mainland China, with a total contract value of US$45 -50 millions. • **Russia, Commonwealth of Independent States (CIS), and Turkey Region:** In January 2014, TaiGen signed a licensing agreement with Russian company R-Pharm. In April 2018, R-Pharm's Phase III clinical trial in the Russian region was successful. In December 2020, R-Pharm submitted the NDA for the intravenous infusion formulation, obtained the GMP certificate in November 2021, and then obtained the drug approval certificate in August 2022. • **Latin America Region:** In August 2016, TaiGen signed a licensing agreement with Mexican pharmaceutical group Productos Científicos in order to develop and

Name	Successfully developed technology or product	
		commercialize Nemonoxacin within the licensed territory. • **Korea Market:** In November 2020, TaiGen signed a licensing agreement with South Korean biotech company GPCR Therapeutics Inc. in order to develop and commercialize Nemonoxacin within the licensed territory. • **Singapore & Malaysia Region:** In October 2023, a commercialization licensing agreement was signed with a partner for the new drug in Singapore and Malaysia, marking TaiGen's official entry into the Southeast Asian pharmaceutical market. • **Vietnam Region:** In October 2025, a licensing agreement was signed with Vietnamese pharmaceutical companies Fideschem Inc. and Newsun Pharmaceutical JSC to further expand TaiGen's presence in the Southeast Asian pharmaceutical market.
New antiviral drug for HCV, Furaprevir	Clinical development	• **Taiwan:** In February 2017, the phase II clinical trial (Furaprevir combined with interferon alfa-2b and ribavirin) was completed, successfully increasing efficacy to over 90% and shortening the treatment duration to 12 weeks. • **Mainland China:** ① In April 2016, CFDA granted Furaprevir the priority review, and approved the clinical trial to begin. ② In April 2019, the phase II clinical trial (Furaprevir combined with Yimitasvir) was completed, successfully increasing efficacy to 97.4%, with treatment duration shortened to 12 weeks, and the phase III clinical trial achieved early completion of enrollment goal. ③ In August 2021, the clinical study report of the phase III clinical trial was completed.
New antiviral drug for HCV, Furaprevir	Overseas authorization	• **Mainland China：** ① In 2017, TaiGen and HEC Pharm established a joint venture company to jointly develop an all-oral new drug for HCV treatment, TaiGen obtained a $20 million USD in cash revenue and generating over 1 billion NTD in revenue. ② In 2019, TaiGen obtained a $5 million USD in cash revenue. ③ In 2023, disposed of equity in the joint venture company and TaiGe obtained a $9.98 million USD in cash revenue

Name	Successfully developed technology or product	
New antiviral drug for influenza, Pixavir marboxil	Clinical Development	• **China IND approved:** TaiGen submitted China IND application in Feburary 2020, and China NMPA approved clinical trials in May of the same year. • **US IND approved:** TaiGen submitted US IND application in September 2020, and US FDA approved clinical trials in October of the same year. • **Phase I clinical trial in adults:** TaiGen initiated Phase I clinical trial in China in July 2020, with all subjects enrolled by November of the same year. Trial results were positive, supporting the initiation of Phase II clinical trial. • **Phase II clinical trial in adults:** TaiGen submitted Phase II clinical protocol to both China NMPA and US FDA in September 2020 and November 2020, respectively (dual submission). The Phase II clinical trial was initiated in December 2020 after approval, with all subjects enrolled in February 2022. Trial results were positive and announced in August 2022, supporting the initiation of Phase III clinical trial. • **Phase III clinical trial in adults and adolescents:** In October 2023, Joincare Pharmaceutical Group initiated the Phase III clinical trial for adults and adolescents, successfully enrolling all participants by January 2024. In April 2024, the trial was unblinded successfully, achieveing the primary endpoint and supporting the following NDA application. • **NDA Approval:** In August 2024, Joincare Pharmaceutical Group submitted the New Drug Application (NDA) to the NMPA (National Medical Products Administration) for the treatment of acute uncomplicated Influenza A and B infections in patients aged 12 years and older. In December 2025, the product successfully received Marketing Authorization in Mainland China under the trade name 壹立康®. • **Pediatric Phase III Clinical Trial:** Joincare Pharmaceutical Group submitted an Investigational New Drug (IND) application for the pediatric granules formulation to the NMPA in March 2025 and received approval in June. A Phase III clinical trial for pediatric patients (under 12 years of age) was subsequently initiated in Mainland China in October 2025. • **Taiwan NDA Application:** In 2025, TaiGen initiated the Pre-NDA consultations with

Name	Successfully developed technology or product	
		the Taiwan CDE, ensuring that Taiwanese patients will also have the opportunity to access this locally developed antiviral influenza drug.
	Oversea Authorization	• **Mainland China** ① In March 2023, TaiGen signed a licensing agreement with Joincare, granting them the rights to develop, manufacture, and commercialize TG-1000 within the licensed territory (including China, Hong Kong and Macao but excluding Taiwan). Subsequent clinical trial development costs for TG-1000 will be covered by Joincare. ② In May 2023, TaiGen obtained a ¥20 million RMB in cash revenue. ③ In May 2024, the milestone payment for the successful completion of the Phase III clinical trial was received. ④ In December 2025, the milestone payment for the NDA approval of was received. • **India** In October 2025, TaiGen signed a licensing agreement with an Indian partner to actively expand its footprint in the Indian market.
Non-cystic fibrosis bronchiectasis (NCFBE) TG-4318	Oversea Authorization	• **Mainland China** In December 2025, a licensing agreement was signed with Joincare Pharmaceutical Group, granting rights to develop, manufacture, and commercialize TG-4318 within the licensed territory (including Mainland China, Hong Kong, and Macau, but excluding Taiwan). Subsequent preclinical research and clinical trial development costs for TG-4318 will be covered by Joincare.
Dietary Supplements	• TaiGen BioTech entered the dietary supplements field in 2022 and successfully launched 太甘澄, a dietary supplements with liver function protection (Metabolic Dysfunction-Associated Fatty Liver) and blood lipid regulation functions in March 2024. In September 2025, TaiGen further strengthened its product portfolio with the introduction of 太甘澄 PLUS, an upgraded formulation enriched with Coenzyme Q10, alongside 太捷唐, a health supplement designed to promote glucose metabolism	
Patent	• **Nemonoxacin:** TaiGen holds a total of 62 patents worldwide realted to Nemonoxacin, covering substance, composition, manufacturing processes and medical use. These patents provide comprehensive protection across major pharmaceutical markets,	

Name	Successfully developed technology or product
	including the United States, Russia, South Korea, Latin America, Taiwan and Singapore. The main patents for Nemonoxacin provide protection until 2029. • **Novel Antiviral drug for influenza, TG-1000:** TaiGen has implemented a robust global patent strategy for TG-1000. The substance patent applications have been granted in 24 countries, including China, Taiwan and the United States, with protection lasting until 2039. Furthermore, 12 patents regarding manufacturing processes and formulation have been granted. Under the current patent strategy, patent protection for TG-1000 is expected to extend through 2043. • **Novel drug for treating of Bronchiectasis, TG-4318:** In 2025, TaiGen filed a U.S. provisional patent application covering the substance of TG-4318. A PCT application is scheduled for filing in 2026 to support a global patent strategy.
Awards/Government Grants	• **TaiGen Biotechnology Co., Ltd.** ① Awarded "Outstanding Bio Industry Golden Award" by the Taiwan Bio Industry Organization in 2018 ② Awarded "Taiwan Gold Award" by the China Cross-Strait Cultural and Economic Exchange Association in 2018 • **Nemonoxacin：** ① Received a subsidy of NT$98.32 million from Ministry of Economic Affairs for Phase II clinical trial ② Received a subsidy of NT$8.8 million from the Ministry of Economic Affairs for phase III clinical trial ③ Awarded "Excellent R&D Achievement Award" from the Ministry of Economic Affairs in 2010 ④ Awarded "National Innovation Award" in 2013 ⑤ Awarded "Taipei Bio Golden Award-Technology Transfer Award" in 2013 ⑥ Awarded "Innovation of the Year" by Taiwan Bio Industry Organization in 2015 ⑦ Awarded "Golden Quality Award" for New Drug Research and Development Awards by the Ministry of Health and Welfare and Ministry of Economic Affairs in 2015 ⑧ Awarded "Advanced National Innovation Award" by Institute for Biotechnology and Medicine Industry in 2020 ⑨ Awarded "National Biotechnology and Medicine Care Quality Award- Bronze Award" by Institute for Biotechnology and Medicine Industry in 2020 ⑩ Awarded "Symbol of National Quality (SNQ) Award" by Institute for Biotechnology and Medicine Industry in 2021 ⑪ Awarded"The Most Prestigious Sustainability Awards" by Institute for Biotechnology and Medicine Industry in 2022

Name	Successfully developed technology or product
	• **Furaprevir:** ① Received a subsidy of NT$29.52 million from Ministry of Economic Affairs for preclinical development projects ② Received a subsidy of NT$57.06 million from Ministry of Economic Affairs for conducting Phase I clinical trials ③ Awarded "National Innovation Award in Enterprise/ R&D technology Category Gold Award" by Institute for Biotechnology and Medicine Industry in 2015 ④ Award "Bronze Quality Award" for New Drug Research and Development Awards by the Ministry of Health and Welfare and Ministry of Economic Affairs in 2015 ⑤ Awarded "Annual Chemical Technology Award" by Chemical Society in 2016 ⑥ Awarded "Innovation of the Year" by Taiwan Bio Industry Organization in 2017 ⑦ Awarded "Bronze Quality Award" for New Drug Research and Development Awards by the Ministry of Health and Welfare and Ministry of Economic Affairs in 2017 ⑧ Awarded "The 2nd APASL Award" by The Asian Pacific Association for the Study of the Liver [APASL] in 2018 ⑨ Awarded "Advanced National Innovation Award" by Institute for Biotechnology and Medicine Industry in 2020 • **Burixafor:** ① Received a subsidy of NT$18.34 million from Ministry of Economic Affairs for preclinical development projects ② Received a subsidy of NT$20.97 million from Ministry of Economic Affairs for conducting Phase I clinical trials ③ Received a subsidy of NT$11.38 million from Ministry of Economic Affairs for conducting Phase II clinical trials ④ Awarded "National Innovation Award in Enterprise/ R&D technology Category Gold Award" by Institute for Biotechnology and Medicine Industry in 2008 ⑤ Awarded "Chemical Technology Award" by Chemical Society in 2008 ⑥ Awarded "Silver Quality Award" for New Drug Research and Development Awards by the Ministry of Health and Welfare and Ministry of Economic Affairs in 2015 • **Anti-influenza virus new drug Pixavir marboxil (TG-1000):** ① Awarded "National Innovation Award" by Institute for Biotechnology and Medicine Industry in 2021 ② Awarded "Advanced National Innovation Award" by Institute for Biotechnology and Medicine Industry in 2023 ③ Awarded "Outstanding Biotechnology Industry Award – Annual Industry Innovation Award" by Institute for Biotechnology and Medicine Industry in 2024

(IV) Long-term and short-term business development plans

1、Short-term business development plans

（1）**Global Licensing Expansion：**

- ✓ **Taigexyn® (Nemonoxacin)** has been licensed in 36 countries/regions worldwide, including Mainland China, Russia, the Commonwealth of Independent States (CIS) and Turkey, Latin America, South Korea, Singapore-Malaysia and the Vietnam market. Efforts will continue to expand market licensing opportunities in unlicensed countries/regions.
- ✓ **Pixavir marboxil** has been licensed in 2 countries/regions (including Mainland China and India) currently. In 2025, the capsule dosage form received marketing authorization in Mainland China. In the same year, TaiGen successfully entered into a licensing agreement with an Indian partner, and will assist in the localized production of APIs and finished formulations to expand into the Indian pharmaceutical market. TaiGen continues to actively strategically position itself in both domestic and international markets; in addition to ongoing licensing negotiations in the US, Europe, Japan, and South Korea, the company is also seeking partners in Taiwan to further promote licensing opportunities outside of China.
- ✓ In December 2025, **TG-4318**'s development and commercialization rights in Mainland China, Hong Kong, and Macau were licensed to Joincare Pharmaceutical Group, which will be responsible for subsequent preclinical studies and advancement. Efforts to license the product in markets outside China are also ongoing.

(2) **Accelerating Sales Strategy：**

- ✓ In the Taiwan market, Taigexyn® continues to undergo post-marketing risk management planning, with active efforts to expand hospital procurement. The target for 2026 is to achieve：Taigexyn® capsules procured by 140 hospitals; Taigexyn® injections procured by 100 hospitals.
- ✓ At the same time, regional and domestic sales partners are collaborating on sales strategies, integrating market promotion, customer relationship management, and existing licensing achievements to accelerate Taigexyn®'s growth toward peak sales performance in Taiwan and Russia.
- ✓ As of December 2025, Pixavir Marboxil has successfully received approval for new drug marketing in Mainland China under the brand name **壹立康®**. Efforts are currently underway to support sales partners in expanding hospital procurement, with a target of inclusion in 500 hospital formularies during 2026 and to secure listing in the national health insurance program within the same year.
- ✓

(3) **New Drug Collaboration and Expansion：**

- ✓ Mainland China:
  - Our partner has obtained NDA approval for the Pixavir marboxil capsule dosage form in 2025. TaiGen has also received the corresponding NDA approval milestone payments, while simultaneously targeting the influenza drug market, which is valued at up to RMB 10 billion.
  - Pediatric Development: Meanwhile, our partner has completed the development of the Pixavir marboxil pediatric formulation. Clinical trial enrollment was initiated in 2025, with the goal of completing the pediatric clinical trials and NDA submission in 2026.
- ✓ India: TaiGen will assist in the localized production of Pixavir marboxil APIs and finished formulations to expand into the Indian pharmaceutical market.
- ✓ Taiwan: An application for Pre-NDA consultation for the Pixavir marboxil capsule dosage form has been submitted to the Taiwan CDE. Upon receiving the CDE's feedback on the Pre-NDA consultation, we will plan the Taiwan NDA accordingly, ensuring that Taiwanese patients will also have the opportunity to access this locally developed antiviral influenza drug.
- ✓ Malaysia: Actively assisting our partner in obtaining NDA approval for the Taigexyn® capsules and injections.
- ✓ Vietnam: Actively assisting our partner in expanding the Southeast Asian pharmaceutical market for Taigexyn® capsules and injections.

(4) **Advancing Both In-House R&D and External in-licensing evaluations：**

- ✓ **Regarding the NCFBE novel therapy TG-4318:** TaiGen will support its Chinese partner in completing preclinical studies, including GLP toxicology and pharmacology, while also advancing the global patent strategy.
- ✓ **Regarding the CKD anemia novel therapy ISM4808:** TaiGen will be completed the Phase I clinical trial by Q4 2026.
- ✓ **Other new drug in-licensing plans:** TaiGen will actively evaluate and in-license novel therapies that align with the company’s strategy and core technologies, further strengthening its product pipeline and market competitiveness.

2、Long-term business development plans

(1) **Global Partnerships and Intellectual Property Commercialization:** Actively seeking and establishing global partnerships, leveraging the company’s strong R&D capabilities and dual-engine strategy (in-house development and external acquisitions) to commercialize intellectual property of pipeline drugs. This will ensure stable financial returns and further expand the company’s global market presence.

(2) **International Licensing and Revenue Stability:** Gradually licensing successfully developed new drugs to international pharmaceutical companies, generating royalty income as a key pillar for stable revenue generation. This strategy will continuously support new drug development and market expansion, further scaling up operations, reducing costs, and diversifying market risks.

(3) **Ongoing Expansion into Overseas Markets:** For Taigexyn®, Pixavir marboxil

(TG-1000), and other new products, TaiGen will continue expanding global licensing efforts, actively entering emerging markets, strengthening collaborations with international partners, and consolidating and enhancing market share.

(4) **Talent Development and Technological Advancement:** Actively training and recruiting top-tier R&D talent to enhance new drug development technologies and clinical trial capabilities. Ensuring the TaiGen maintains a competitive edge in the highly competitive global pharmaceutical industry, driving long-term sustainable growth..

II、Market and Sales Overview

(I) Market analysis

1、Major commodities (service) sales areas

Our company is principally engaged in the development of new drugs and currently its main source of revenue is the sales of Nemonoxacin products and the income from milestone payments. In Taiwan, HOLDING DISP. CO., LTD., which has rich experience in anti-infective drug sales, was selected as our distribution partner of Nemonoxacin in Taiwan. The drug was first marketed and sold at out-of-pocket expenses basis in December 2015, and the oral dosage form was granted drug pricing under Taiwan's National Health Insurance in December 2017, and the injection dosage form was also granted drug pricing under Taiwan's National Health Insurance in February 2022, which is expected to help Nemonoxacin become a bellwether commodity in the market and boost revenue.

.

2、Market share

Nemonoxacin (Taigexyn®) capsule has been launched in Taiwan and obtained reimbursement pricing from the Taiwan National Health Insurance in December 2017. The intravenous infusion formulation also received drug approval license in Taiwan in October 2020, with pricing approved by the Taiwan National Health Insurance in February 2022. Our Russian partner, R-Pharm, officially passed the NDA review and approval process of the Russian Ministry of Health in August 2022, positioning it to potentially become a market-leading product. Other projects/products under ongoing R&D activities cannot be publicly sold on the market according to regulations, and therefore, their market share cannot be analyzed currently.

3、Future market supply and demand situation and its growth

(1) **Nemonoxacin (Taigexyn®), a New Antibiotic for Bacterial Infections**

- **Future Market Supply and Demand:**
  a. Stable Expansion in the Domestic Market: In the Taiwan market, the post-marketing risk management plan is ongoing, along with active efforts to expand hospital procurement. The target for 2026 is to achieve: 140 hospitals procuring the oral formulation; 100 hospitals procuring the injectable formulation. This demonstrates stable demand and confidence in Taigexyn® among domestic healthcare institutions.
  b. Diversified Expansion in the International Market: Taigexyn® has been licensed in 36 countries/regions, including Mainland China, Russia, the Commonwealth of

Independent States (CIS), Turkey, Latin America, South Korea, Singapore, Malaysia and Vietnam. In Malaysia, ongoing NDA approval and application support is being provided to partners. In Vietnam, actively assisting our partner in expanding the Southeast Asian pharmaceutical market for Taigexyn ® capsules and injections. This global licensing and partnership strategy helps to expand the market supply network, diversify risks, and establish a stable supply-demand relationship across multiple regions.

- **Growth Potential Outlook**

a. Clinical Advantages Driving Demand Growth: Taigexyn® is a novel, non-fluoroquinolone antibacterial drug with broad-spectrum antibacterial activity, low resistance development, and minimal side effects. Its once-daily dosing offers a clinical advantage, making it a preferred choice for healthcare providers and driving increased market demand.

b. Multi-Dosage Strategy Enhancing Market Competitiveness: The availability of both oral and intravenous infusion formulations allows for flexible clinical applications, catering to various patient needs and ensuring wider adoption across different infection scenarios. This versatility strengthens market penetration and accelerates growth in market share.

c. Global Licensing and Market Expansion Effects: Through international licensing agreements and close collaboration with global partners, Taigexyn® is positioned to enter more emerging markets. This strategy not only enhances brand recognition globally but also supports continuous market expansion, ensuring a sustainable and long-term revenue stream.

d. Long-Term Growth and Ongoing R&D Support: Leveraging the dual-engine strategy of in-house R&D and external in-licensing acquisitions, the product pipeline is expected to expand, further strengthening technological competitiveness and product value. This approach not only drives the growth of Taigexyn® itself but also provides technical and market support for future new drug development, ensuring long-term, stable growth.

- Comprehensive Outlook: With its clinical advantages, diverse formulations, and global market strategy, Taigexyn® holds strong supply-demand potential in both domestic and international markets. As global demand for antibacterial drugs continues to rise and product competitiveness increases, Taigexyn® is expected to achieve sustained growth, establishing itself as a key player in the antibacterial drug market.

(2) **Pixavir marboxil/TG-1000 (PA Endonuclease Inhibitor), a New Antiviral Drug for Influenza**

- **Future Market Supply and Demand:**

a. Global Influenza Surge Driving Market Demand: Multiple countries in the Northern Hemisphere (including the U.S., UK, Japan, South Korea, and Taiwan) are experiencing severe influenza outbreaks, with a surge in infections placing significant pressure on healthcare systems. Existing antiviral treatments are limited by efficacy windows, resistance concerns, and complex dosing regimens, failing to fully meet clinical needs.

b. Urgent Demand for Innovative Antiviral Therapies: Beyond vaccination, there is an urgent clinical need for a treatment that rapidly alleviates influenza symptoms while minimizing resistance development. Pixavir marboxil was developed to address these gaps, with clinical trial data demonstrating significant reductions in symptom relief time, filling the void left by existing therapies.

c. Stable Supply and International Licensing Strategy: Pixavir marboxil has obtained NDA marketing approval in China and has been successfully licensed to an Indian partner to expand into the Indian pharmaceutical market. TaiGen Biotech is actively seeking local and global partners—including those in the US, Europe, Japan, and South Korea—to rapidly enter key markets. This strategy ensures a stable post-launch supply chain and addresses urgent unmet market needs.

- **Growth Potential Outlook**

a. Clinical Advantages Driving Market Penetration：

✓ Single-Dose Treatment: Pixavir marboxil requires only a single dose, significantly improving patient adherence compared to traditional multi-dose regimens and reducing medication errors.

✓ Significant Symptom Reduction: Clinical data shows that Pixavir marboxil shortens influenza symptom relief time from 87.9 hours to 60.9 hours, demonstrating strong efficacy against both Influenza A and B, with notably superior results in adolescents.

✓ Enhanced Resistance Protection: Compared to existing antiviral treatments, Pixavir marboxil offers superior resistance prevention, addressing growing concerns over antiviral resistance mutations.

b. International Market Expansion Driving Growth

✓ Multi-Market Licensing and Partnerships: TaiGen Biotech is actively engaged in licensing negotiations to expand into the U.S., Europe, Japan, and South Korea.

✓ Global Pandemic Trends Boosting Demand: With influenza cases surging worldwide, the market for innovative antiviral drugs continues to expand, positioning Pixavir marboxil as a preferred choice for healthcare providers and government procurement programs.

c. Policy Support and Long-Term Market Protection

✓ Governments and public health organizations are increasing investments in influenza prevention and treatment, including higher vaccine procurement and

expanded treatment resources. Regulatory support for innovative antiviral drugs will provide policy and financial backing, facilitating Pixavir marboxil's market entry and long-term growth.

- **Comprehensive Outlook**

In the context of rising global influenza cases and the limitations of existing treatments, Pixavir marboxil stands out with its single-dose treatment, superior symptom reduction, enhanced resistance protection, and broad efficacy against various influenza strains. With TaiGen Biotech actively driving global licensing and local partnerships, Pixavir marboxil is poised to quickly meet the massive global demand for influenza treatment, becoming a key driver of sustained market growth.

(3) **Dietary Supplements**

- **Global Market: Steady Growth and Key Drives**

The global dietary supplement market reached USD 136.4 billion in 2024 and is projected to grow to USD 166.5 billion by 2028. This growth is primarily driven by five key factors:

- Demographic Shifts: Heightened health consciousness within an aging global population.
- Technological Innovation: Continuous breakthroughs in functional ingredients and formulation science.
- Industry Trends: The advancement of personalized nutrition and sustained focus on gut health.
- Economic Expansion: The rising purchasing power of the global middle class.

- **Taiwan Market: Dynamics, Challenges, and Regulations**

Market Scale and Economic Headwinds

In 2023, Taiwan's health food market (including traditional formats and dietary supplements) reached NTD 175.6 billion, representing a growth rate of 3.1%. However, the momentum slowed in 2024 due to global macroeconomic uncertainties and safety concerns sparked by the "Red Yeast Rice" incident in Japan. Consequently, the 2024 market scale is estimated at approximately NTD 180.6 billion, reflecting more cautious consumer sentiment.

Regulatory Landscape and Certifications

On the regulatory front, the Ministry of Health and Welfare (MOHW) officially added "Joint Health" as the 14th recognized functional claim in July 2025. By the end of 2024, a total of 455 products had obtained "Health Food" certification. The top five certified claims—regulating blood lipids, improving gastrointestinal function, liver protection, immune modulation, and body fat reduction—have remained consistent over the past five years, representing the core pillars of the local market.

- **Efficacy Demands: Current Leaders and Emerging Potentials**

Based on ITIS research and market observations, the demand for health benefits is categorized as follows:

Category	Functional Claims
Leading Segments	Gastrointestinal health, blood lipid regulation, immune modulation, eye care, and nutritional supplements.
High-Growth Potential	Weight management, eye care, anti-aging, and nerve soothing/sleep quality improvement.
Market Shift	Consumer focus is gradually shifting from general "immune support" toward targeted categories such as "blood lipid regulation," "eye care," and "joint health."

Strategic Insight: While gastrointestinal health and eye care remain the dominant market drivers, there is significant untapped potential in stress relief/sleep aids and anti-aging solutions. Furthermore, the inclusion of "Joint Health" in the regulatory framework is expected to catalyze new product development in the senior wellness sector.

4、Competitive niche

(1) The R&D team has extensive experience and technology in the research and development of new drugs.
(2) The company has a series of unique and excellent new chemical entity (NCE) product line, which can commercialize the intellectual property rights in the new drug development stage and obtain maximum economic benefits.
(3) Complete global patent layout.
(4) Has ability to perform clinical trials and apply for market authorizations for Novel Class 1 in China.
(5) Comply with the ICH guidelines for new drug development and meet international standards. In particular, high-quality clinical trials are TaiGen's competitive advantages.
(6) Establish good partnerships, including: Chinese market, Taiwan market, Korean market, Russia, Commonwealth of Independent States and Turkey market, Latin American market.

5、Advantages and disadvantages of the development prospects and countermeasures

(1) Favorable Factors：

A. **Talent Advantage:** The management team has recruited senior operators from multi-national biotechnology and pharmaceutical industries, which is a unique advantage that improves the efficiency of drug research and development and reduces the risk of drug development.
B. **Team advantages:** The core members of the team have different professional backgrounds and experience and have extensive experience in the field of new drug research and development. The advantage of the team is that the professional field is refined and wide, including organic synthesis, compound screening, process research, scale-up production, preclinical research, clinical research design and implementation, regulations, GMP production and other fields, covering the entire field of new drugs from research and development to production and marketing.

C. **Technical advantages:** The new drugs developed by the excellent R & D team have the industry's best and latest product advantages in the protection of global intellectual property rights, and can successfully commercialize intellectual property rights and obtain the maximum economic benefits.

D. **Advantages of clinical experience:** TaiGen**'s** clinical team performs high-quality clinical trials in accordance with ICH guidelines and has successfully completed more than 30 Phase I, II and III trials in the United States, mainland China, and Taiwan.

E. **Advantages in Greater China:** has the ability to conduct new drug clinical trials and apply for market authorizations in mainland China and Taiwan. China has become the world's second largest pharmaceutical market after the United States, which makes new drug development more profitable to invest.

F. **Global commercial licensing and marketing advantages:** TaiGen has established good partnerships in mainland China, Taiwan, South Korea, Southeast Asia, Russia, the Commonwealth of Independent States (CIS), Turkey, and Latin, which enabling faster drug market entry and enhanced sales growth.

(2) Unfavorable factors and countermeasures

A. **Costly R&D expense and long development time**

Countermeasures:

(A) Long-term support from strategic corporate shareholders.

(B) Make the best use of limited resources and cooperate with outsourced cooperation to make up for the shortage of its own manpower.

(C) Commercialize R&D results in a timely manner and balance risk and reward.

(D) Make good use of external resources: make good use of the "Principle of special review in the biotechnology field" of government and industry, apply for subsidies for clinical trial funds, obtain financing from financial institutions and capital market financing, and other channels

(E) By cooperating with external partners, commercializes the research and development results, creates new business models, and enhances the company's profitability.

(F) By cooperating with external partners, TaiGen provides talent and/or technology, and partners pay for clinical development costs to reduce costly financial expenditures.

B. **The efficacy of drugs in the earlier stage of research and development has yet to be confirmed by clinical trials**

Countermeasures:

(A) The R&D team has extensive international experience to ensure that new drug candidates in the preclinical stage are first-in-class or fast-in-class before entering the clinical stage to reduce the risk of failure.

(B) Find partners to work together on clinical development to reduce risk and accelerate the clinical development.

C. **Need to rely on big pharmaceutical companies to open up the international market**

Countermeasures:

(A) The Company's strategy is to license markets outside Greater China to international pharmaceutical companies or pharmaceutical companies with strong

sales capabilities/high market penetration in the region after completing the proof-of-concept trials of new drugs, so as to accelerate subsequent clinical trials, drug registration and marketing, and strengthen overseas licensing to open up international markets through partners.

(B) Utilize the established platform for the R& D and launch of Novel Class 1 in China to accelerate the launch of new drugs on both sides of the Taiwan Strait, and combine with external sales professional teams to maximize the market value of new drugs.

D. **The domestic new drug research and development industry is still in its infancy, and whether it is regulations, reviews, and enforcement, it is still immature, and there is still room for improvement**

Countermeasures:

After the direction of new drug research and development is determined, the actual research and development still requires the participation of a variety of experts, including technical backgrounds such as design, synthesis, pharmacology, pharmacokinetics, medicinal chemistry, toxicology, etc., as well as experts in patents, regulations and markets. During the development of new drugs and implementation of clinical trials, the company has accumulated a lot of relevant knowledge, promoted the new drug plan, and also integrated the resources of all parties, entrusted the most suitable academic or medical circles to cooperate, recruited relevant talents, and established a sound team required for new drug research and development.

(II) Important uses and manufacturing processes of main products

1、Important uses of main products

Product	Potential Clinical Indications
Nemonoxacin	Nosocomial pneumonia infection, diabetic foot infection, urinary tract infection and complex skin infection
Pixavir marboxil	Type A, Type B Influenza and Avian Influenza
TG-4318	Non-cystic fibrosis bronchiectasis (NCFBE)
ISM4808	Chronic kidney disease–associated anemia (CKD)

2、The manufacturing process of our main products

The production process of our main products is outsourced, and the current scale of the outsourced factories is sufficient to supply clinical phase II/III trials conducted in multiple countries and centers worldwide

(III) Supply status of main raw materials

Our company's new drug is still in the development stage, and the supply of raw materials for various products under development is currently relatively stable. We are also actively seeking high-quality secondary suppliers of raw materials to ensure a secure supply in the future.

(IV) The names of clients with more than 10% of total purchase (sales) and the amount and proportion of purchase (sales) in any of the last two years, and the reasons for the increase or decrease

1. The names of suppliers who have accounted for more than 10% of total purchase and the amount and proportion of their shipments in any of the last two years, together with the

reasons for the increase or decrease

As of the printing date of the annual report, our company's principal business is new drug development, and the main sources of revenue is from license-out of drug, which have not yet generated significant commercial activities of purchase and are therefore not applicable.

2. The names of customers who have accounted for more than 10% of the total sales and the amount and proportion of their sales in any of the last two years, together with the reasons for the increase or decrease

Unit：NT$ thousand

	2024				2025			
Item	name	amount	Percentage of net sales for the full fiscal year (%)	Relationship with the issuer	name	amount	Percentage of net sales for the full fiscal year (%)	Relationship with the issuer
1	A	111,876	74.26	-	A	190,068	73.25	-
2	B	-	-	-	B	31,560	12.16	-
3	C	30,460	20.22		C	25,539	9.84	-
4	Others	8,315	5.52	-	Others	12,307	4.75	-
	Net sales	150,651	100.00		Net sales	259,474	100.00	

In March 2015, we entered into an exclusive distribution agreement for the new antibiotic drug Nemonoxacin in Taiwan (the agreement expires five years from the date the first health insurance price of Nemonoxacin injection is applied and will be automatically renewed for three years without written notice of non-renewal, and the same shall apply thereafter) with HOLDING DISP. CO., LTD.. And the licensing revenue was recognized continuously in 2024 and 2025.

In 2023, we signed a patent implementation license and commercialization cooperation contract for the new influenza antiviral drug, Pixavir marboxil/TG-1000 with Joincare Pharmaceutical Group Industry Co., Ltd., and recognizing the upfront and licensing income in 2024 and 2025.

In 2025，TG-4318 (New Drug for Bronchiectasis) , we signed a licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd. for the R&D, commercialization, and manufacturing rights of TG-4318. The associated licensing revenue was recognized in the 2025 fiscal year.

In 2025, we signed licensing agreements with Fideschem Inc. and Newsun Pharmaceutical JSC. for the drug registration application and marketing rights of Nemonoxacin. The licensing revenue was recognized in the 2025 fiscal year.

In 2025, we signed a licensing agreement with an international Indian pharmaceutical company for the development, manufacturing, drug registration application, and marketing rights of Pixavir marboxil (TG-1000). The licensing revenue was recognized in the 2025 fiscal year.

III、The number of employees employed for the 2 most recent fiscal years, and during the current fiscal year up to the date of publication of the annual report, their average years of service, average age, and education levels

Year		2024	2025	2026/3/31
Number of Employees	14	14	13	13
	-	-	-	-
	38	17	18	16
	52	31	31	29
Average Age		43	48	49
Average Years of Service		8.46	11.46	11.65
Education	Ph.D.	19%	21%	15%
	Masters	52%	52%	59%
	Bachelor's Degree	29%	27%	23%
	Senior High School	0%	0%	3%
	Below Senior High School	-	-	-

IV、Environmental Expenditure Information

In the current fiscal year up to the date of the publication of the report, losses suffered due to environmental pollution (including compensation and environmental protection audit results violating environmental protection laws and regulations, the date of punishment, name of punishment, violation of laws and regulations, content of violations of laws and regulations, content of punishment should be listed), and the current and future estimates of possible occurrences should be disclosed Amount and Countermeasures:：In the current fiscal year up to the date of the publication of the report, the company has not suffered any loss due to environmental pollution.

V、Labor Relations

(I) Employee Welfare, Training, Retirement System and Implementation, Labor-Management Agreements, and Measures to Protect Employee Rights and Interests:

1、Employee welfare：

The Company has established an Employee Welfare Committee, allocating 0.1% of annual revenue to plan and provide high-quality welfare benefits for employees, including recreational activities, transportation subsidies, birthday cash gifts, childbirth subsidies, and funeral allowances. Additionally, the Company offers employees a free health checkup program during public holidays, complimentary coffee, parking spaces, and other welfare benefits.

Regarding the leave system, in addition to fixed weekends, employees with two months of service are entitled to one day of special leave, with a maximum of five days of special leave for employees with less than one year of service. To accommodate individual needs, the Company provides three days of paid sick leave annually, which employees may use for illness or vaccination. For employees requiring extended leave due to parental care, serious illness, or major personal circumstances, they may apply for unpaid leave to balance personal and family responsibilities.

Furthermore, the Company's Articles of Incorporation stipulate that, in the event of

pre-tax profits in any given year, no less than 1% of pre-tax profits shall be allocated as employee remuneration (including employees of the Company and/or its affiliates), which may be distributed in cash and/or stock.

2、Employee Training and Development:

New employee:

Upon joining, the Group arranges for relevant personnel to explain personnel regulations, provide an introduction to the Company, work rules, workplace environment, and introductions to supervisors and colleagues. Senior management also introduces departmental functions and development plans to help employees understand the organization.

Current Employees:

To enhance professional knowledge, skills, and personal development, thereby improving service quality and performance, full-time employees may participate in approved on-the-job education and training programs.

3、Retirement System and Its Implementation：

Taigen Taiwan:

In compliance with legal requirements, for employees hired on or after July 1, 2005, and those opting for the new pension system, the Company contributes 6% of monthly wages to individual pension accounts managed by the Bureau of Labor Insurance. For employees opting for the old pension system and those under the new system with retained years of service under the old system, the Company continues to allocate sufficient pension reserves to a designated account at the Bank of Taiwan, calculated based on the retirement payment standards of the old system. As of the end of 2023, the balance of the old pension system meets regulatory requirements and is sufficient to cover the retirement benefits of employees eligible for the old system by the end of 2024.

Taigen Beijing:

In accordance with the Social Insurance Law of the People's Republic of China, the Company contributes to social insurance for employees (including pension, unemployment, medical, maternity, and work-related injury insurance) to protect their rights and interests.

4、Labor-Management Agreements and Measures to Protect Employee Rights and Interests：

The Company values employee feedback and opinions. Employees may express their views through meetings or email, ensuring open communication channels between labor and management. The labor-management relationship is harmonious, and no significant labor disputes have occurred to date.

5、Employee Work Environment and Personal Safety Protection Measures：

The Company is committed to employee care, striving to fulfill its social responsibilities while pursuing sustainable business growth.

Employees are provided with regular health checkups, and the office environment is regularly cleaned and disinfected. To prevent occupational hazards, the Company has established a "Biosafety Committee" in accordance with regulations, holding annual biosafety meetings, conducting internal on-site inspections, and performing biosafety incident simulation drills. Annual environmental and equipment inspections are conducted, including radiation protection checks for laboratory surroundings and equipment, annual

inspections of the first-class pressure vessels in the animal facility, and quarterly environmental monitoring of the animal facility. Waste disposal is managed through contracts with professional external vendors, with weekly collection of laboratory waste. Toxic chemicals and precursor chemicals are registered and monitored, with regular reporting to the competent authorities to ensure a safe work environment. Additionally, access control systems are in place, and the Company has contracted with a security firm to maintain office safety.

(II) Any losses suffered by the company in the most recent fiscal year and up to the annual report publication date due to labor disputes (including any violations of the Labor Standards Act found in labor inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, the substance of the legal violations, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided：

Date	Describe	Document No.	Impact on the Company's Financial Operations
2024/11/04	The Taipei City Government's Labor Bureau discovered that TaiGen Biotechtechnology Co., Ltd., a major subsidiary of our company, used hazardous chemicals such as ethyl acetate, but did not label the bottles in the format required by law. As a violation of Article 10, Paragraph 1 of the Occupational Safety and Health Act, a fine of NT$30,000 was imposed.	北市勞職字第11360987411 號	No significant impact

VI、Information Security Management：

（I）Describe the framework for managing information and communication technology security risks, information security policies, specific management plans, and resources invested in information and communication technology security management.

1. Security Risk Management Framework

The management representative of the company is the head of the Finance and Administration Department, while the head of the Information Department is responsible for executing information security related tasks and implementing the established information security management objectives and policies. The chief auditor regularly reviews the execution status of the information security management system and personal data management system.

2. Information and Communication Technology Security Policy

2.1 To ensure the security of information, systems, equipment, and network communications in the company, and to effectively reduce the risk of inappropriate use, disclosure, alteration, or destruction of information assets due to human error, intentional acts, or natural disasters, an information security policy should be developed to establish the direction for information security management.

2.2 Definition of Information Security

Information security is a series of planned and continuous control measures that ensure the

proper protection of information assets, including software and hardware equipment.

2.3 Objectives of Information Security

Ensure the confidentiality, integrity, and availability of the business information of our company.

A. Confidentiality: Ensure that only authorized personnel can access the information assets required for work-related purposes.

B. Integrity: Ensure that the information used is accurate and has not been tampered with.

C. Availability: Ensure that authorized personnel can access the required information assets immediately when needed for work.

2.4 Information Security Scope

Information security scope covers areas such as personnel management and information technology.

2.5 Information Security Policy Content

A. Information security regulations must comply with the provisions of relevant government laws and regulations, such as the Criminal Law, National Security Law, Patent Law, Trademark Law, Copyright Law, Personal Data Protection Law for Computer-Processed Personal Data, etc.

B. Establishing an information team responsible for the establishment and promotion of information security systems.

C. Regularly carry out information security education and training, and promote information security policies and related implementation regulations.

D. Establish a management mechanism for information hardware and software to coordinate the allocation and utilization of resources.

E. Information security factors should be incorporated into the design of new information systems before construction to prevent situations that may harm system security.

F. Establish physical and environmental security measures for computer rooms and regularly maintain them.

G. Clearly define the usage permissions for information systems and network services to prevent unauthorized access.

H. Develop an internal audit plan for information security and regularly review individual computer usage.

I. Develop an information security disaster recovery plan and conduct practical exercises to ensure the continuity of business operations.

3. Concrete Management Plan

3.1 Multi-layered Cybersecurity Protection

A. Internet Security: Strengthen network firewall and network control to prevent malicious attacks and intrusions from the internet.

B. Device Security: Install endpoint protection software based on the type of computer, and cooperate with firewall protection in the area. Additionally, use cloud-based artificial intelligence and machine learning to predict malicious program intrusion behavior and block the risk of ransomware intrusion. Also, strengthen the backup for important core personal computers.

C. Server Security: Upgrade the operating system, complete server virtualization, and establish an off-site backup policy. Conduct periodic disaster recovery drills to ensure data

integrity and availability.

3.2 Education and Training: Strengthen employee awareness of social engineering attacks and implement phishing email defense and detection.

4. Allocation of Resources for Information Security Management.

4.1 All new employees have completed information security and protection education and training courses.

4.2 Deploying endpoint protection software and antivirus software for the entire company.

（II）Disclose the losses, potential impact, and response measures due to significant information security incidents during the current and previous fiscal years up to the date of report printing. If it is not possible to make a reasonable estimate, it should be stated that such estimation is not possible.

In the fiscal year 2025, our wholly-owned subsidiary, Tai Jing Biotechnology Co., Ltd., passed the information security-related audit without significant deficiencies and did not violate information security or cause significant information security incidents such as sensitive information leaks and fines

VII、Important contracts

Nature of contract	Parties	Beginning and end dates of contract	Major content	Restrictive clauses
Licensing Agreement and Amendment	Zhejiang Medicine Company, Limited("ZMC")	June 21, 2012 to June 21, 2032	TaiGen Taiwan and TaiGen Beijing entered into an Agreement to give rights to ZMC for development, manufacturing and commercialization of Nemonoxacin in China (excluding Hong Kong, Macau and Taiwan). On March 30, 2021, Parties entered into an Amendment to transfer the patent right and the right of patent application to ZMC in the consideration between USD 45 million to 50 million depending on the conclusion for the application of the patent extending.	None
License Agreement	R-Pharm	From 2014.1.13 to the later of (i) the expiration of the patent; (ii) the fifteenth (15th) anniversary after the first commercial sale of the Product.	TaiGen Taiwan and R-Pharm signed an exclusive Agreement to grant rights to R-Pharm to develop and commercialize Nemonoxacin in the territories of Russian Federation and other members of the Commonwealth Independent States. Under the terms of the agreement, R-Pharm will be responsible for the development, registration and commercialization of Nemonoxacin in these territories and assume all associated costs. In exchange for the exclusive rights. TaiGen received from R-Pharm an upfront payment, and will be eligible for additional regulatory and commercial milestones as well as royalties on product sales in the future.	None
License Agreement	Productos Cientificos, SA. DE C.V.("Productos Cientificos")	From 2016.8.26 to the later of (i) the fifteenth (15th) anniversary after the first commercial sale of the Product; (ii) the expiration of the patent;	TaiGen signed an exclusive Agreement to give rights to Productos Cientificos to develop and commercialize Nemonoxacin in Mexico, Brazil, Columbia, Peru, Uruguay, Paraguay, Bolivia, Venezuela, Argentina, Chile, Costa Rica, Honduras, Nicaragua, Panama, Guatemala, El Salvador, Ecuador, and other regions. Productos Cientificos will be responsible for the development, registration and commercialization of Nemonoxacin in these territories and assume all associated costs. In exchange for the exclusive rights, TaiGen will receive an upfront payment, and will be eligible for additional	None

Nature of contract	Parties	Beginning and end dates of contract	Major content	Restrictive clauses
			regulatory and commercial milestones in the future.	
Distribution Agreement	Holding Disp., Co., Ltd.	5 years starting from the applicable date of the NHI drug price of intravenous formulation	TaiGen Taiwan signed an exclusive distribution agreement to give rights to Holding Disp., Co., Ltd. to distribur Nemonoxacin in Taiwan. The Agreement will be expired after 5 years starting from the applicable date of the NHI drug price of intravenous formulation. Upon the expiration, the Agreement can be e automatically renewed for three years unless any party notifies the other the will for termination in writing.	None
TECHNOLOGY TRANSFER AND COOPERATION AGREEMENT	GPCR Therapeutics ("GPCR")	20 years started from 2020.11.9	TaiGen Taiwan signed an exclusive Agreement with GPCR. Under the terms of the agreement, GPCR will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea. The ownership of Burixafor worldwide is also transferred to GPCR. TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments in return.	None
SUPPLY AGREEMENT	Nang Kuang Pharmaceutical Co., Ltd	10 years started from October 23, 2020. The Agreement can be automatically renew for successive two (2) years for once.	Nang Kuang shall manufacture and supply the Nemonoxacin injection for TaiGen in accordance with the terms and conditions of this SUPPLY AGREEMENT.	None
WAREHOUSE AND LOGISTICS SERVICE AGREEMENT	ORIENT EUROPHARMA	September 1,2017 to August 31, 2018. The Agreement can be automatically renew for one year unless any party refuses to do so.	ORIENT EUROPHARMA shall provide warehousing and logistic service in accordance with articles of the Agreement.	None
DRUG MANUFACTURING AGREEMENT	PEI LI PHARMACEUTICAL INDUSTRIAL CO., LTD	November 1, 2019 to October 30, 2026. The Agreement can be automatically renew for three year unless	PEI LI shall manufacture Taigexyn Capsule 250 mg for TaiGen Taiwan in accordance with articles of the Agreement.	None

Nature of contract	Parties	Beginning and end dates of contract	Major content	Restrictive clauses
		any party refuses to do so.		
Patent implementation license and commercialization cooperation contract	TaiGen Taiwan, TaiGen Beijing, Joincare Pharmaceutical Group Industry Co., Ltd	Effective from March 21, 2023, the contract period depends on the results of patent applications for pediatric dosage forms	The subsidiaries of the company grants the exclusive license of TG1000 products in China, Hong Kong and Macao to Joincare, to develop, manufacture and sell TG1000 products, and collects license fees and sales royalties from Joincare.	None
License Agreement	TaiGen Taiwan and YSP Industries(M).SDN. BHD.	From October 6, 2023.8.26 to the twentieth (20th) anniversary after the first commercial sale of the Product.	Authorize YSP to apply for drug licenses and market the product in Malaysia and Singapore.	None
License Agreement	TaiGen Taiwan and Company A	From October 3, 2025 until the expiaration of the patent of TG1000.	TaiGen Taiwan, the subsidiary of the company grants the exclusive license of TG1000 products in India to Company A, g to develop, manufacture and sell TG1000 products, and collects license fees and sales royalties from Company A.	None
License Agreement	TaiGen Taiwan, FIDESCHEM INC., NEWSUN PHARMACEUTICAL JOINT STOCK COMPANY	From October 1, 2025 to October, 2045.	TaiGen Taiwan, the subsidiary of the company grants the exclusive license of Nemonoxacin products in Vietnam to NEWSUN, grants it the authority to develop, and sell Nemonoxacin products, and collects license fees and sales royalties from NEWSUN. FIDESCHEM is responsible for the coordination of development and selling.	None
License Agreement	TaiGen Taiwan, TaiGen Beijing, INSILICO MEDICINE LTD., INSILICO MEDICINE IP LIMITED	From December 12, 2025 until 20 years after the first commercial sale of the product.	I INSILICO MEDICINE and INSILICO MEDICINE IP grant the exclusive license of ISM4808 products in China, Hong Kong Macao and Taiwan to TaiGen Taiwan, TaiGen Beijing to develop, manufacture and sell ISM4808 product.	None
Patent implementation license and commercialization cooperation contract	TaiGen Taiwan, TaiGen Beijing, Joincare Pharmaceutical Group Industry Co., Ltd	Effective from Nov. 26, 2025, the contract period depends on the outcome of the patent application.	The subsidiaries of the company granted exclusive license of TG4318 in China, Hong Kong and Macao to Joincare, to develop, manufacture and sell TG4318 products, and collects license fees and sales royalties from Joincare.	None

Chapter 6、Review of Financial Condition, Operation Results, and Risk Management

I、Financial status

Unit:NT$ thousand；%

Item \ Year	2024 年	2025	Difference	
			Amount	%
Current Assets	1,086,085	1,119,941	33,856	3.12%
Long-term investment	2,453	3,405	952	38.81%
Net property, plant and Equipment	9,969	3,537	(6,432)	-64.52%
Intangible Assets	12,054	22,447	10,393	86.22%
Other Assets	63,721	17,924	(45,797)	-71.87%
Total Assets	1,174,282	1,167,254	(7,028)	-0.60%
Current Liabilities	46,084	83,104	37,020	80.33%
Long-term liabilities	-	-	-	-
Other liabilities	45,872	9,273	(36,599)	-79.79%
Total liabilities	91,956	92,377	421	0.46%
Share capital	20,942	20,767	(175)	-0.84%
Capital collected in advance	-	-	-	-
Capital Surplus	466,295	451,167	(15,128)	-3.24%
Retained earnings	640,601	634,323	(6,278)	-0.98%
Other equity interests	(45,512)	(31,380)	14,132	-31.05%
Total equity	1,082,326	1,074,877	(7,449)	-0.69%

1.The main reasons of significant changes in assets, liabilities, and equity for the last two years and their effects: (amount changed by 10% or more, and amount reached 1% of total assets for the year)

Other Assets：Decreased by NT$45,797 thousand in 2025, primarily due to a reduction in right-of-use assets.

Current liabilities：Increased by NT$37,020 thousand in 2025, mainly due to a increase in short-term borrowings.

Other Liabilities：Decreased by NT$36,599 thousand in 2025, primarily due to the reduction in lease liabilities.

Other Equity：Increased by NT$14,132 thousand in 2025, mainly due to exchange gain recognized from the translation of financial statements of foreign operations.

2. If the impact is significant, the future response plan should be stated: No significant impact.

II、Financial performance

(I) The main reasons for significant changes in operating revenue, net operating income and income before tax for the last two years

Unit：NT$ thousand；%

Item \ Year	2024	2025	Changes by increase or decrease	
			Amount	
Operating revenue	150,651	259,474	108,823	72.24%
Deduct：sales returns and allowances	-	-	-	-
Net sales	150,651	259,474	108,823	72.24%
Operating costs	16,132	18,174	2,042	12.66%
Gross profit	134,519	241,300	106,781	79.38%

Item \ Year	2024	2025	Changes by increase or decrease	
			Amount	
Operating expenses	256,617	171,905	(84,712)	-33.01%
Operating income(loss)	(122,098)	69,395	191,493	-156.84%
Net operating income and gains	92,599	23,848	(68,751)	-74.25%
Non-Operating expenses an losses	3,386	35,802	32,416	957.35%
Net Income (Loss) for the Year	(38,583)	45,178	83,761	-217.09%
Other comprehensiveincome(loss)	(30,470)	16,278	46,748	-153.42%
Total comprehensive income(loss)	(69,053)	61,456	130,509	-189.00%

The main reasons of significant changes in operating revenue, net operating income, and income before tax for the last two years: (amount changed by 10% or more, and amount reached 1% of total assets of the year)

1. Operating Revenue: Increased by NT$108,823 thousand in 2025, primarily due to increase of the recognition of revenue from the licensing of the anti-influenza virus new drug TG-1000.
2. Operating Expenses: Decreased by NT$84,712 thousand in 2025, primarily due to a reduction in research and development expenses.
3. Operating Profit (Loss): Operating income increased by NT$191,493 thousand in 2025, mainly due to the recognition of increased revenue from the licensing of the anti-influenza virus new drug TG-1000 , as well as the reduction in operating expenses.
4. Non-operating Income and Gains: Decreased by NT$68,751 thousand in 2025, mainly due to the foreign exchange gain in 2024.
5. Non-operating Expenses and Losses: Increased by NT$32,416 thousand in 2025, primarily due to foreign exchange losses incurred in 2025.
6. Net Income (Loss) for the Year: The net profit in 2025 increase by NT$83,761 thousand mainly due to the higher revenue in 2025.
7. Other Comprehensive (Loss) Income: Increased by NT$46,748 thousand in 2025, primarily due to exchange gains recognized from the translation of financial statements of foreign operations in 2025.

(II) The expected sales volume and its basis and the possible impact on our company's future financial operations and the plan for response

We started to sell the oral dose of Nemonoxacin in the out-of-pocket healthcare market in Taiwan in mid-December 2015.

The oral dose was granted drug pricing under Taiwan's National Health Insurance in December 2017 and the injection dose was also granted drug pricing under Taiwan’s National Health Insurance in February 2022. Based on the overall market and our company's annual operation plan, we will generate supply revenue from the sales of new drugs in the future.

III、Cash flow

(I) Analysis of changes in cash flow for the most recent year (fiscal year 2023)

Unit：NT$ thousand；%

Item \ Year	2024	2025	Increase(decrease) amount	Increase(decrease) percentage(%)
Operating activities	(173,088)	20,929	194,017	(112.09%)
Investing activities	(110,872)	83,371	194,243	(175.20%)
Financing activities	(17,400)	(34,641)	(17,241)	99.09%

Analysis of changes：

1. Operating activities：The cash inflow from operating activities in 2025 increases from the the previous year by NT$202,993 thousand, mainly due to the increased milestone payment received in 2025 for the licensing-out of TG-1000.
2. Investing activities： The cash inflow from investing activities in 2025 differs from the cash outflow in the previous year by NT$185,267 thousand, primarily due to the proceeds from the disposal of Financial assets at fair value through other comprehensive income - current in 2025.
3. Financing activities：The cash outflow from financing activities in 2025 increased by NT$17,241 thousand, mainly due to the purchase of treasury stock in 2025.

(II) Cash liquidity shortage improvement plan: Our company has no cash shortage

(III) Analysis of cash liquidity for the coming year (fiscal year 2025)

Unit：NT$ thousand

Cash balance at beginning of year (1)	Estimated full-year net cash flow from operating activities (2)	Estimated full-year net cash flows from investing and financing activities (3)	Estimated surplus (shortfall) of cash (1)+(2)+(3)	Remedies for cash shortage	
				Investment plan	Financial plan
933,010	529	(56,017)	877,522	-	-

1.Analysis of changes in Cash flow scenarios for fiscal year 2026:

(1) Cash balances at the beginning of the period include time deposits with a deposit period of more than three months and money market funds, which are classified in the financial statements as financial assets at amortized cost and financial assets at fair value through profit or loss.

(2) Operating activities: The company expects to generate revenue from new drug licensing in 2026 while continuing to invest in new drug research and development, resulting in a net operating cash inflow of NT$529 thousand.

(3) Investing and financing activities: This is mainly due to estimated interest income, the planned acquisition of potential new drug patent technology, and capital expenditures for purchasing R&D equipment, totaling NT$56,017 thousand.

2. Remedial measures and flow analysis for projected cash shortfalls: None.

IV、The impact of significant capital expenditures on financial operations in the current fiscal year：

None.

V、Investment policy in the past year, profit/loss analysis, improvement plan, and investment

plan for the coming year.

(I) Reinvestment policy

Our company's recent change in investment policy involves focusing mainly on investments related to our core business development and refraining from investing in other industries. The relevant departments will follow internal control procedures such as the "Investment Cycle" and "Procedures for Acquisition or Disposal of Assets" to execute the new policy. These measures and procedures have been discussed and approved by the board of directors or shareholders' meeting.

(II) The main reason for the profit or loss of reinvestment in the most recent year, and the improvement plan：

Reinvest in business	Investment return in the most recent year (2025)	Illustratation
TaiGen Biotechnology Co., Ltd.	NTD 56,487 thousands	The company’s new drug development product, Nemonoxacin, has obtained marketing approvals in Mainland China, Taiwan, and Russia, contributing to the product's revenue. Additionally, the new anti-influenza virus drug TG-1000 has been licensed out in Mainland China, the Hong Kong and Macau Special Administrative Regions, as well as India, which is generating licensing income.
TaiGen Biotechnology Holdings Limited	NTD 76,571 thousands	As an investment holding company, the main source of its gains comes from recognizing the post-tax profits of TaiGen Beijing.
TaiGen Biopharmaceuticals Co. (Beijing), Ltd.	NTD 76,571 thousands	The company's primary activities currently involve conducting clinical trials for new drug development, resulting in research and development expenses. In the 2025 fiscal year, the company recognized licensing-out revenue from the out-licensing of the new anti-influenza virus drug TG-1000 in Mainland China, as well as the Hong Kong and Macau Special Administrative Regions.
Taigen Biomedical Corporation	NTD(843) thousands	The company's primary activity currently involves the research and development of health supplements. In the 2025 fiscal year, the company recognized sales revenue from health supplements.

Improvement plan：TaiGen Taiwan is currently in the drug research and development phase of new drug development. Once the drug development activities are completed and the drug is either licensed out or obtains regulatory approval, it will contribute to revenue growth and improve profitability.

(III) Investment plan for the next year：The company has no foreign investment plans in the next year.

VI、Analysis and assessment of risk issues as of the end of the fiscal year and the date of printing the annual report

(I) The impact of interest rate, exchange rate fluctuations, and inflation on the company's profits and future response measures：

1. The impact of interest rate changes on the company's profits and future response measures

The short-term borrowings of this group are bank revolving loans, and the amount accounts for 3.26% of the net worth ratio. The borrowing period is short, so the impact of interest rates on the liability side is minimal. Interest income is not the Group's main source of profits, so overall, interest rate changes are not expected to have a significant impact on the company. The Group maintains a good long-term relationship with banks and currently has reasonable borrowing terms. The Group also keeps track of recent interest rate changes and, when loan terms expire, assesses the various sources of funding and their terms and costs to secure the required funding in the most effective way.

2.The impact of exchange rate fluctuations on the company's profits and future response measures.

Exchange rate fluctuations may affect the Group's operations in the form of costs related to clinical trials conducted in other countries, royalties or license fees received for the licensing of new drugs to other countries, etc. In addition to closely monitoring exchange rate fluctuations, the Group may purchase foreign currency deposits when exchange rates are favorable to pay for foreign currency expenses. In addition, when signing license agreements, the Group also tries to negotiate exchange rate conditions that are favorable to the Group and allocates funds in the same currency as the expense to avoid exchange rate risk..

Exchange rate fluctuations are not expected to have a significant impact on the Group, and in the future, the Group will also pay attention to major currency movements in the foreign exchange market, maintain a good relationship with banks, and keep track of exchange rate trends to reduce exchange rate risk.

3. The impact of inflation on the company's profits and future response measures

The Group constantly monitors market price fluctuations and has a good relationship with long-term suppliers. There have been no significant impacts on the Group's profits due to inflation in recent years. The Group mainly engages in the research and development of new drugs, so the technology, costs, and future products are less affected by inflation.

(II) Policies, main reasons for profit or loss, and future response measures for high-risk, highly leveraged investments, lending funds to others, endorsement guarantees, and derivatives trading

1.The Group focuses on its core business and has a financial policy of stability and conservatism, and does not engage in high-risk, highly leveraged investments or derivatives trading.

2.The Group has shareholder resolutions in place for "Procedures for Acquisition or Disposal of Assets", "Procedures for Endorsement & Guarantees", "Procedures for Financial Derivatives Transactions", and "Procedures for Lending Funds to Other Parties", which have been modified to comply with relevant laws and regulations and passed by shareholder resolution. In the future, related transactions will be conducted in accordance with the above procedures and will be announced and reported in accordance with relevant laws and regulations.

(III) Future R&D plans and estimated R&D expenses

1. Future Research and Development Plans

(1) TaiGen will accelerate the introduction of licensed new drug candidates and advance them efficiently into IND application and clinical development, fully leveraging the TaiGen's core drug research and development capabilities to enable the candidates to realize their commercial value as soon as possible.

(2) By introducing licensed drug candidates, TaiGen will also expand into other therapeutic areas to enhance the scope and capabilities of its drug development.

(3) Based on the TaiGen's R&D technology platform, TaiGen will expand the scope of new product development to include dietary supplements/health foods, aiming to create products that truly support human health. TaiGen has currently developed two health supplements, one dual functions product (liver-protection and lipid-lowering) and another for blood-sugar regulation. These products are expected to enhance the TaiGen's operational momentum.

(4) Novel antibacterial agent_Taigexyn® (Nemonoxacin)
Taigexyn® has been licensed in 36 countries/regions worldwide (including Mainland China, Russia, the CIS and Turkey region, Latin America, South Korea, Singapore and Malaysia, and Vietnam), which will help partners expand local pharmaceutical markets. For other countries/regions without licenses, market authorization efforts will continue.

(5) New antiviral drug for influenza_Pixavir marboxil

A. Expand the pharmaceutical market in Mainland China
In December 2025, the NDA for Mainland China approval was successfully obtained. TaiGen has received the milestone payment for the NDA approval and will subsequently target the influenza drug market, with potential sales reaching tens of billions of RMB.
The pediatric formulation of Pixavir Marboxil has been developed, and the Phase III pediatric clinical trial began patient enrollment in 2025. Efforts are underway to complete the pediatric clinical trial and NDA submission in 2026.

B. Expand the pharmaceutical market in India
TaiGen will assist its Indian partners in local production of Pixavir Marboxil's API and formulation to expand the pharmaceutical market in India.

C. Expand the pharmaceutical market in Taiwan
TaiGen has submitted a pre-NDA application for Pixavir Marboxil capsules to the Taiwan CDE. Upon receiving the CDE's recommendations for the pre-NDA, TaiGen will plan the Taiwan NDA accordingly, aiming to provide the public with access to this new anti-influenza drug developed by the Taiwan team.

D. Other overseas markets
TaiGen is actively expanding into overseas markets and is actively negotiating licensing agreements in Europe, the US, Japan, and South Korea.

(6) New drug of non-cystic fibrosis bronchiectasis (NCFBE)_TG-4318
TaiGen will assist its China partners in completing preclinical studies, including GLP toxicology and pharmacology, while simultaneously strengthening the global patent portfolio.

(7) New drug of Anemia in Chronic Kidney Disease (CKD)_ISM4808
TaiGen is expected to complete the Phase I clinical trial in Q4 2026.

2. Expected research and development costs

In order to support the above-mentioned research and development plan, our group will allocate research and development expenses on a yearly basis according to the progress of product development. For achieving the expected progress of research and development, it is estimated that the research and development expenses to be invested in 2025 will be

approximately NTD 212 million.

(IV)The impact of important domestic and foreign policy and legal changes on the company's financial operations and response measures.

1.Taiwan

To foster the development of the biotech and new drug industry, the government enacted the "Biotech and New Drug Development Act" in 2007, which was later superseded by the "Act for the Development of Biotech and Pharmaceutical Industry" in 2021. This updated legislation expanded the scope of eligibility for "biotech and pharmaceutical companies" and extended the period of tax incentives. TaiGen Taiwan, the Group's main operating entity, was officially recognized by the Ministry of Economic Affairs in 2024 as an eligible company under this Act. Furthermore, the "Regulations Governing Investment Tax Credits for Research and Development Expenditures of Biotech and Pharmaceutical Companies" also facilitate the Group's new drug development.

In December 2025, the Executive Yuan approved the "National Medicine Resilience Preparedness Plan." Through subsidies, investment incentives, and R&D support, the plan aims to promote the domestic production of critical medications and strengthen the nation's drug resilience and self-supply capabilities. The subsidy schemes offered under this plan are expected to significantly benefit the Group's R&D initiatives. Our management team continues to closely monitor the progress of subsequent legislative developments and subsidy implementation measures.

2.America

Starting October 1, 2025, the United States imposed a 100% tariff on all branded or patented pharmaceuticals, with exemptions granted only to pharmaceutical companies that have established manufacturing bases within the U.S. Subsequently, in January 2026, Taiwan and the U.S. signed a trade agreement under which generic drugs and Active Pharmaceutical Ingredients (APIs) exported from Taiwan to the U.S. are entitled to "zero tariffs." Although the Company, as a new drug development entity, does not anticipate these tariffs will directly impact our core operations, such policy shifts may lead to significant changes in the pharmaceutical market and global landscape. The Group will continue to monitor these developments closely and prudently assess their potential impact on both the Group and our strategic partners.

3.China

In 2011, the Chinese government implemented the Hospital Antibiotic Use Management Measures, which established strict and clear regulations and management for the use and item management of antibiotics in hospitals at all levels. With the implementation of this management method, the survival space of small manufacturers was restricted, leading to a stagnation in the overall growth of the antibiotic market. However, the sales of original drugs and leading brand generic drugs continued to grow, which should have a positive and healthy impact on long-term market development.

As the Company's primary operations are based in Taiwan, the Group remains committed to monitoring domestic and international policy trends and regulatory changes. In the event of such changes, we consult with local legal and accounting professionals to obtain

expert assessments and recommendations. Relevant information is gathered to provide reference for management decision-making, ensuring that appropriate measures are implemented promptly in response to regulatory updates.

(V) The impact of technological changes and industrial changes on the company's financial business and countermeasures

The impact of technological change and industry changes on the financial and business operations of the company and the measures taken in response. These changes may affect the terms and content of the current licensing negotiations of the group, and may affect the negotiation intentions of licensing partners due to the emergence of similar drug. The group closely monitors the research and development trends of its competitors in similar drugs and takes timely measures in response. The group's research and development of drugs also has a high threshold for entry, so it is unlikely to be affected by technological changes and industry changes in the short term in terms of licensing negotiations.

The group's R&D team regularly holds meetings with experts to discuss industry R&D trends and its own R&D strategy, quickly grasp the trends in drug development, and make adjustments to R&D plans in response to industry changes. Although this may affect the timing and amount of R&D investment by the group, the company's management level is able to keep track of budget and actual differences on a monthly basis, allocate resources optimally, and take necessary measures in response, so technological changes and industry changes should not have a significant impact on the company's financial operations.

The group places great importance on information security management and has established an IT department responsible for preventing computer viruses, cyberattacks, data breaches, ensuring legal compliance, and managing risks. The department is tasked with planning and implementing information security management, including: company network and email security control, information system access control, promoting information security awareness among employees, and improving technology and operational processes related to information to ensure the company's information security.

(VI) The impact of corporate image change on corporate crisis management and countermeasures

Since the group establishment, we have been dedicated to the development of new drugs, with the goal of developing "first in class" or "best in class" innovative compound new drugs in the same class to promote human welfare. For many years, the group has followed relevant laws and regulations, has won numerous awards in Taiwan, and has received economic specialties from the Ministry of Economic Affairs for various R&D projects. It is highly valued by the government, industry, and academia, has a good corporate image, has established a good reputation and word of mouth, and has not had any behavior that has caused a poor corporate image or a corporate crisis.

(VII) Expected benefits, possible risks and countermeasures of mergers and acquisitions

The group does not currently have any plans to acquire other companies in the recent fiscal year or as of the date of printing of the annual report.

(VIII) Expected benefits, possible risks and countermeasures of plant expansion

The group does not currently have any plans to expand its factories in the recent fiscal year or as of the date of printing of the annual report.

(IX) Risks and countermeasures faced by concentration of purchase or sales

The Group is engaged in the business of new drug research and development. Aside

from Nemonoxacin (oral and injectable formulations), which has received new drug approval from the Ministry of Health and Welfare (MOHW) and is produced and sold directly by the Group, both TG-1000 and Nemonoxacin follow an out-licensing model for overseas development, production, and sales via our partners. Under this model, the Company does not bear inventory or sales risks. As for our other drug candidates, they are primarily in the drug discovery or clinical trial stages; therefore, there is no risk of sales concentration. Furthermore, due to industry characteristics, while procurement activities may exhibit concentration, the Company maintains long-term contracts with suppliers to mitigate potential impacts, and thus no material risks are anticipated.

(X) Directors, supervisors or major shareholders holding more than 10% of the shares, the impact, risks and countermeasures of a large number of equity transfers or replacements on the company

In the recent fiscal year and as of the date of printing of the annual report, there have been no situations where the shares of directors or shareholders holding more than 10% of the shares have been significantly transferred or replaced.

(XI) The impact, risks and countermeasures of the change of management rights on the company

The main shareholders of the company are government shares and YFY INC. and its related companies, which have been long-term supporters of the company since its establishment, so there have been no changes in the election of directors or changes in management that have affected the company's operations. The company also has a comprehensive system of internal controls and related management measures in place, and any changes in management should be effectively controlled in terms of their impact and risk on the company's operations.

(XII) Litigation or non-litigation matters

1、Major ongoing lawsuits, non-lawsuits or administrative lawsuit: None

2、Major ongoing lawsuits, non-lawsuits or administrative lawsuits caused by directors, s pervisors or shareholders with over 10% shareholdings: None.

(XIII) Other important risks and countermeasures

1. Industry risk

A. A. The domestic new drug development industry is still in its infancy, with regulations, review processes, and implementation all not yet fully mature. TaiGen’s corresponding strategies are:
After confirming the development direction for new drug research, actual R&D process requires participation of experts from multiple disciplines, including those with technical backgrounds in design, synthesis, pharmacology, pharmacokinetics, pharmaceutical chemistry, and toxicology, as well as cross-functional specialists in patents, regulations, and market analysis. During the development of new drugs and the execution of clinical trials, TaiGen has accumulated extensive relevant knowledge, promoted new drug programs, and integrated various resources. TaiGen also collaborate with the most suitable academic and medical experts, recruit and train relevant talent, and establish a comprehensive new drug R&D team.

B. There may be other companies conducting similar drug development in the market, competing for the market share once the drug is launched. Additionally, depending on the nature of the drug, substantial marketing experience and resources may be required. TaiGen’s corresponding strategies are:
TaiGen’s strategy is to license the European, US, and Japanese markets to international

pharmaceutical companies after completing the proof-of-concept trials of new drug, in order to accelerate subsequent clinical trials, regulatory approval, and market launch. In China, TaiGen leverages its established Class 1.1 new drug R&D platform and fully utilizes the ECFA framework to accelerate cross-strait new drug approvals, while combining with external professional sales teams to maximize the market value of its new drugs.

2. Operational risk

A. Financial risk

The main problem facing the pharmaceutical research and development industry is the long development time for new drugs. On average, it takes at least ten years for a new drug to go from research and development to market, and the cost of this process is enormous. It is difficult for domestic pharmaceutical companies with limited financial resources to complete this massive project independently, unless they are large pharmaceutical companies or multinational groups with strong financial resources.

- The company's countermeasures：

(a) Long-term support of strategic institutional shareholders

(b) Optimal utilization of limited resources through outsourcing cooperation

(c) Timely licensing of research and development results to achieve a balance between risk and reward

(d) Utilizing external resources: applying for government and industry special "Principles for Special Review of Biotechnology Fields" to support clinical trial funding, obtaining financing from financial institutions, and listing on the stock exchange to increase funding channels.

(e) Collaborating with internationally renowned pharmaceutical companies to commercialize research and development results and create new business models to increase company profits.

B. Technical risk: the risk that a drug will not pass clinical trials or obtain market approval due to safety or effectiveness concerns

- The company's countermeasures：

The R&D team has extensive international experience and ensures that only "first in class" or "best in class" candidates for new drugs at the preclinical stage will enter the clinical stage. Currently, the new drugs in TaiGen R&D have all reached clinical proof of concept and have relatively low risk.

C. Technical risk: There is a risk that a drug may fail to pass clinical trials or obtain regulatory approval due to safety or efficacy issues. TaiGen’s corresponding strategies are:
Our R&D team has extensive international experience and ensures that only drug candidates that are “first in class” or “best in class” at the preclinical stage proceed to clinical development.

VII、Other important matters：None

Chapter 7、Special Disclosurs

I、Affiliated enterprise information：

(I) Affiliated business merger business report

1. Affiliated Enterprise Profile

(1) Affiliated Enterprise Chart



(2)According to Article 369 of the Company Law, it is presumed to be a controlling and subordinate company：None

2. Basic information of related enterprises

Unit：NT$ thousand

Name of enterprise	Date of Establishment	Address	Paid-in capital	Main business and products
TaiGen Biotechnology Co., Ltd.	2001.04.30	7F., No. 138, Xinming Rd., Neihu Dist., Taipei City	2,311,514	New drug development, Medical Technology, Consultant
TaiGen Biotechnology Holdings Limited (Cayman)	2001.04.26	PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands	711,833	Investment holding
TaiGen Biopharmaceuticals Co.（Beijing）, Ltd.	2004.08.31	A2502, No. 18, Chaoyangmenwai Street, Chaoyang District, Beijing, China	748,228	New drug development

Name of enterprise	Date of Establishment	Address	Paid-in capital	Main business and products
Taigen Biomedical Corporation	2023.11.03	4F., No. 51, Sec. 2, Chongqing S. Rd., Zhongzheng Dist., Taipei City, Taiwan (R.O.C.)	3,000	Food research

3. The same shareholder information for presumed to entities with control or subsidiary relationships.：None

4. The industries covered by the overall business operations of the related entities.：Research and development of new drugs.

5. Information on the directors, supervisors, and presidents of affiliated enterprises

Unit：thousand share

Company	Position	Name or representative	Shares held	
			Shares	%
TaiGen Biotechnology Co., Ltd.	Chairman Director Director Director Director Director Supervisor President	TaiGen Biopharmaceuticals Holdings Limited Representative：Kuo-Lung Huang Representative：Weng-Foung Huang Representative：Peter Wu Representative：Hong-Jen Chang Representative：Hsun-Yuan Tsou Representative：I-Jen Huang Representative：I Hsueh Tsai Li-Wen Chang	231,151	100%
TaiGen Biotechnology Holdings Limited (Cayman)	Director Director Director	Kuo-Lung Huang Show-Chung Ho I Hsueh Tsai	163,000	100%
Taigen Biomedical Corporation	Chairman	Kuo-Lung Huang	3,000	100%
TaiGen Biopharmaceuticals Co.(Beijing),Ltd.	Chairman Director Director Supervisor president	Kuo-Lung Huang I Hsueh Tsai Li Wen Chang Richard Lu Kuo-Lung Huang	(Note)	100%

Note：The limited company is represented by the amount of capital contribution, with a capital contribution of RMB 133,608,000.

6. Profiles of affiliated enterprises in 2025

Unit：NT$ thousand

Name of company	Book value by the end of the year	Profit and loss for the period(after tax)
TaiGen Biotechnology Co., Ltd	1,067,073	56,487
TAIGEN BIOMEDICAL FOOD CORPORATION	(321,944)	76,571
TaiGen Biotechnology Holdings Limited (Cayman)	2,509	(843)
TaiGen Biopharmaceuticals Co.(Beijing),Ltd.	(321,944)	76,571

(II) Consolidated financial statements of affiliated enterprises：Similar to the consolidated financial reports of TaiGen Biopharmaceuticals Holdings Limited and its affiliates.

(III) Affiliation report：As this company is not a subsidiary of any other company, it is not applicable.

II、In the current fiscal year up to the date of the publication of the report, the situation of private placement of securities：None.

III、In the current fiscal year up to the date of the publication of the report,the holding or disposition of the Company's shares by subsidiaries.：None

IV、Other necessary supplementary informations：

The company was listed on the OTC on January 17, 2014, the commitments and their handling：

Commitment made at the time of the application for OTC trading of stock	Progress on Commitments
The commitment is to add the following to the "Procedures for Acquisition or Disposal of Assets": "The company shall not waive the future capital increase of TaiGen Biotechnology Co., Ltd., TaiGen Biotechnology Co., Ltd. shall not waive the future capital increase of TaiGen Biotechnology Holdings Limited, and TaiGen Biotechnology Holdings Limited shall not waive the future capital increase of TaiGen Biopharmaceuticals Co. (Beijing), Ltd. In the future, if any of the aforementioned companies needs to waive the capital increase or dispose of the equity of the aforementioned companies due to strategic alliance considerations or other reasons approved by the OTC, it shall be resolved by a board resolution approved by more than two-thirds of the total number of directors of the company present, with the attendance of a majority of the directors." If there are any amendments to these procedures in the future, they should be disclosed as material information on the Public Information Observation System and reported to the OTC for record-keeping.	Our company's extraordinary shareholders' meeting passed the revised 'Procedures for Acquisition or Disposal of Assets' on December 27, 2013. The board of directors of each subsidiary also passed the revised 'Procedures for Acquisition or Disposal of Assets,' which included additional provisions related to OTC requesting the company's commitments ; In accordance with the government's legal amendment on December 30, 2013, the revised "Procedures for Acquisition or Disposal of Assets" was passed at the shareholders' meeting on June 9, 2014. The updated provisions of the "Procedures for Acquisition or Disposal of Assets" have been uploaded to the Public Information Observation System. In accordance with the amendment of our company's articles of association and the establishment of an Audit Committee, the revised provisions of the "Procedures for Acquisition or Disposal of Assets" were passed at the shareholders' meeting on June 17, 2016. The updated provisions have been uploaded to the Public Information Observation System.

V、Any event which has a material impact on the shareholders' equity or onprices of securities as specified in Article 36, Paragraph 2, Subparagraph 2 of the Securities and Exchange Act that have occurred in the past year up to the publication date of this report: None.

VI、Explanation of significant differences from our country's shareholder equity protection

Due to slight discrepancies between the laws of the Cayman Islands and those of the Republic

of China (Taiwan), the GreTai Securities Market (GTSM) has issued various letters on March 14, 2012 (Letter No. 1010100302), May 19, 2014 (Letter No. 10301006961), November 14, 2014 (Letter No. 10301018101), January 20, 2015 (Letter No. 10400000511), March 9, 2018 (Letter No. 10701002161), December 7, 2018 (Letter No. 10701102991), January 8, 2020 (Letter No. 10800681281), May 31, 2021 (Letter No. 11000579652), March 15, 2022 (Letter No. 11101004091), January 17, 2023 (Letter No. 11200504511), May 13, 2024 (Letter No. 11300607121), and February 10, 2026(Letter No. 11500531151) announcing amendments to the "Foreign Issuer Registration Jurisdiction Shareholder Rights Protection Checklist" (referred to as the "Shareholder Rights Protection Items"), which may not necessarily apply to our company. The following list illustrates the differences between our current Articles of Association (referred to as the "Articles of Association") due to provisions of Cayman Islands law and the Shareholder Rights Protection Items, as well as provisions of the Articles of Association.

Differences in the protection of shareholders' equity	**Cayman Islands Laws and Regulations**	**Company's Articles of Association Rules and Explanation**
The following matters involving significant shareholder rights require the attendance of shareholders representing two-thirds or more of the total issued shares, with a majority vote of the attending shareholders for approval. If the total shares represented at the meeting fall short of the prescribed quota, the matter may be approved with the attendance of shareholders representing more than half of the total issued shares and with the consent of two-thirds or more of the voting rights of the attending shareholders: 1. Entering into, amending, or terminating contracts related to the leasing of all business operations, entrusting operations to others, or engaging in joint ventures with others, which have a significant impact on the company's operations; 2. Amending the Articles of Association; 3. Amendments to the Articles of Association that prejudice the rights of preferred shareholders require a separate resolution of the	According to the compulsory provisions of the Cayman Islands Companies Law, concerning amendments to the company's articles of association (including revisions detrimental to the rights of preferred shareholders), dissolution (excluding instances where the company voluntarily dissolves due to inability to pay debts), and mergers, they must be passed by a "Special Resolution" (i.e., a resolution passed by at least two-thirds of the shareholders entitled to vote at a shareholders' meeting who are present in person or by proxy). Additionally, as per the provisions of the Cayman Islands Companies Law, if a company	1. Article 1 of our company's Articles of Association defines the voting method for matters related to shareholder equity protection as a "Supermajority Resolution," which requires the attendance of shareholders representing two-thirds or more of the total issued shares, with a majority of voting rights present at the shareholder meeting. If the total shares represented at the meeting fall short of this threshold, the resolution can still be passed by shareholders representing over half of the total issued shares, with at least two-thirds of the voting rights present at the meeting. This is either through direct attendance or proxy representation. 2. According to the guidance on shareholder equity protection, as per the Taiwan Stock Exchange Corporation's Foreign Securities Listing Review Guidelines Article 4, Section 1, Clause 13, significant matters concerning shareholder equity protection should be added to the company's Articles of Association or organizational documents, provided they do not violate the laws and regulations of the jurisdiction of incorporation. While the term "Special Resolution" is a statutory term defined in the Cayman Islands Companies Law, matters requiring "Special Resolution" under the law must be passed by shareholders as such, and the threshold for voting rights should not be lower than that required by the Cayman Islands Companies Law. As per Article 1 of our company's Articles of Association, a "Special Resolution" refers to a resolution passed by at least two-thirds of the voting

Differences in the protection of shareholders' equity	Cayman Islands Laws and Regulations	Company's Articles of Association Rules and Explanation
preferred shareholders' meeting; 4. Distributing dividends and bonuses in full or in part by issuing new shares; 5. Resolutions regarding dissolution, merger, or division; 6. Issuing restricted stock to employees. 7.	voluntarily dissolves due to inability to pay debts, it must be passed by an "Ordinary Resolution.	rights represented by shareholders entitled to vote at the meeting, either in person or by proxy (if permitted by the meeting notice). 3. Pursuant to the provisions of the Cayman Islands Companies Law, Article 131 of our company's Articles of Association stipulates that amendments to the articles of association must be passed by a "Special Resolution," aligning with the requirements outlined in the guidance on shareholder equity protection. 4. As per the provisions of shareholder equity protection, any amendment to the Articles of Association that prejudices the rights of preferred shareholders requires a resolution by the preferred shareholders. Pursuant to Section 24 of the Companies Act (as revised) of the Cayman Islands and Article 131 of our company's Articles of Association, any amendment or alteration of any article or in whole or in part shall require approval by Special Resolution. And per Article 14(a) of our company's Articles of Association, any change to the rights attached to different classes of shares shall also be approved f the authorization of a "Special Resolution" by the holders of such shares at a shareholder meeting. Pursuant to Section 24 of the Companies Act (as revised) of the Cayman Islands and Article 131 of the Articles of Association, any amendment to the Articles of Association shall require approval by Special Resolution of the shareholders at a general meeting. In addition, such amendment shall require the separate approval by Special Resolution of the holders of the affected class of preference shares in accordance with Article 14(a) of the Articles of Association. The quorum for any such general meeting shall be as prescribed under Article 35 of our company's Articles of Association, namely, shareholders holding in the aggregate more than one-half (1/2) of the total issued Share capital of the Company present in person or by proxy. 5. According to Section 116 of t Companies Act (as revised) of the Cayman Islands,

Differences in the protection of shareholders' equity	Cayman Islands Laws and Regulations	Company's Articles of Association Rules and Explanation
		voluntary dissolution of a company requires a "Special Resolution," while in cases of insolvency, it should be done by an "Ordinary Resolution." As dissolution falls directly under the provisions of the Cayman Islands Companies Law and has not been amended in our company's articles of Association, it complies with the guidance on shareholder equity protection. 6. Section 233(6) of the Companies Act (as revised) of the Cayman Islands mandates that mergers must be approved by a "Special Resolution." Any additional provisions in the company's Articles of Association must also comply with the requirements of the law. Accordingly, Article 47(e) of our company's Articles of Association stipulates that mergers require a "Supermajority Resolution" to pass. However, for mergers defined under the Cayman Islands Companies Law, they must also adhere to the requirements of the law, aligning with the guidance on shareholder equity protection.
When shareholders exercise their voting rights in writing or electronically, the method of exercise should be specified in the notice convening the shareholder meeting. Shareholders who exercise their voting rights in writing or electronically are considered to be present at the shareholder meeting. However, regarding ad hoc motions and amendments to original proposals at that meeting, they are considered to have abstained from voting.	Cayman Islands law does not have specific provisions regarding shareholder voting by communication. According to legal counsel familiar with Cayman Islands law, voting by written or electronic means does not constitute personal attendance under Cayman Islands law. In such cases, the chairman of the shareholder meeting should be authorized to vote on behalf of the shareholder.	Article 55 of our company's Articles of Association states: "When exercising voting rights by written or electronic means, the method of exercise shall be specified in the notice convening the shareholder meeting. For the purposes of this article and the Cayman Islands Companies Law, shareholders exercising their voting rights by the aforementioned written or electronic means shall be deemed to have appointed the chairman of the shareholder meeting as their proxy, to exercise their voting rights in the shareholder meeting as instructed in written or electronic documents. The chairman acting as proxy shall have no authority to exercise the voting rights of such shareholders on any matter not mentioned or specified in the written or electronic documents, nor shall he/she vote on any amendments to proposals at the shareholder meeting. Shareholders shall be deemed to have abstained from voting on any ad hoc motions or amendments to original proposals at the shareholder meeting." This

Differences in the protection of shareholders' equity	Cayman Islands Laws and Regulations	Company's Articles of Association Rules and Explanation
		provision complies with the requirements of the guidance on shareholder equity protection, note 1.
After a shareholder has exercised their voting rights by written or electronic means and wishes to attend the shareholder meeting in person, they should express their intention to revoke the prior exercise of their voting rights in the same manner as the original exercise, at least two days before the meeting. If the revocation is made after this deadline, the voting rights exercised by written or electronic means shall prevail.	According to the advice of our Cayman Islands legal counsel, under the principles of English common law, the act of a principal attending the meeting in person constitutes the revocation of their proxy. Since shareholders exercising their voting rights by written or electronic means are deemed to have entrusted the chairman of the shareholder meeting to represent them in exercising their voting rights based on the instructions in the written or electronic documents, the effectiveness of the content of this provision regarding shareholder equity protection needs to be determined based on the interpretation of common law.	This provision is in accordance with the requirements of the guidance on shareholder equity protection and is found in Article 56 of our company's Articles of Association.
After the delivery of the proxy to the company, if a shareholder wishes to attend the shareholder meeting in person or wishes to exercise their voting rights by written or electronic means, they must provide written notice to the company to revoke the	According to the explanation provided by our Cayman Islands legal counsel, the Cayman Islands Companies Law does not restrict the appointment of	This provision is in accordance with the requirements of the guidance on shareholder equity protection and is found in Article 53 of our company's Articles of Association.

Differences in the protection of shareholders' equity	Cayman Islands Laws and Regulations	Company's Articles of Association Rules and Explanation
proxy at least two days before the meeting. If the revocation is made after this deadline, the voting rights exercised by the appointed proxy shall prevail.	proxy voters, as this is governed by the provisions of the company's articles of association. Under the principles of English common law, a person may revoke their proxy by attending the meeting in person. Since shareholders exercising their voting rights by written or electronic means are considered to have entrusted the chairman of the shareholder meeting to represent them based on the instructions in the written or electronic documents, the effectiveness of the content of this provision regarding shareholder equity protection needs to be determined based on the interpretation of common law.	
1. Directors of the company are required to faithfully execute their duties and exercise the duty of care and diligence of a prudent manager. If there is a breach of these duties resulting in damages to the company, the director is liable for compensation. If the misconduct is committed for	Under common law, all directors owe fiduciary duties to the company. These duties include acting in good faith, avoiding conflicts of interest, and acting in the best interests of the	The provisions outlined in the shareholder equity protection checklist are in accordance with the requirements of our company's Articles of Association, specifically stated in Article 76. This ensures compliance with the standards for safeguarding shareholder rights and interests.

Differences in the protection of shareholders' equity	Cayman Islands Laws and Regulations	Company's Articles of Association Rules and Explanation
one's own benefit or that of another, the shareholders' meeting may resolve to treat the gains from such misconduct as gains of the company. 2. Directors of the company are jointly liable with the company for compensation if their actions in executing the company's business violate laws and cause harm to others. 3. Managers and supervisors of the company, within the scope of their duties, bear the same liability for compensation as directors of the company.	company. If a director breaches their fiduciary duties or specific provisions of Cayman Islands law, their individual liability would be determined based on the interpretation of common law.	

TaiGen Biopharmaceuticals Holdings Limited

Representative：Kuo-Lung Huang